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Abstract 
 
The P2Y14 receptor is the most recently identified member of the P2Y family 
of receptors for adenine and uridine nucleotides and nucleotide sugars. It is 
activated by UDP, UDP-glucose and its analogues, as well as the synthetic 
analogue MRS2690, which exhibits greater potency and selectivity at the 
P2Y14 receptor. The principle aim of this study was to investigate the 
functional expression of the P2Y14 receptor in porcine pancreatic arteries, 
and the signalling pathways underlying the vasoconstriction evoked by 
P2Y14 receptor agonists, together with an examination of the effects of 
UDP-glucose and MRS2690 on insulin secretion from the rat INS-1 823/13 
ǃ-cell line. 
Segments of porcine pancreatic arteries were prepared for isometric 
tension recordings in warmed oxygenated Krebs¶-Henseleit buffer. Agonists 
were applied after preconstriction with U46619, a thromboxane A2 mimetic. 
ATP induced vasoconstriction followed by a vasorelaxation in pancreatic 
arteries; the contraction was blocked by NF449 (a P2X1 receptor selective 
antagonist), while the relaxation to ATP was blocked by an adenosine 
receptor antagonist. Neither the contraction, nor the relaxation to ATP were 
affected by removal of the endothelium. ADP evoked vasorelaxation, which 
was inhibited in the presence of SCH58261 (a selective adenosine A2A 
receptor antagonist). UTP-induced vasoconstriction was attenuated 
significantly in endothelium-denuded arteries. UDP, UDP-glucose and 
MRS2690 induced concentration-dependent contractions in porcine 
pancreatic arteries with a rank order of potency of MRS2690 (10-fold) > 
UDP-glucose = UDP. The contractions evoked by UDP-glucose and 
MRS2690 were significantly attenuated in the presence of PPTN (a selective 
P2Y14 receptor antagonist), indicating actions at P2Y14 receptors. The 
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expression of P2Y14-like receptor was shown by immunohistochemical and 
contractile studies to be on the endothelium of the pancreatic arteries. 
UDP-glucose and MRS2690 inhibited forskolin-stimulated cAMP production. 
UDP-glucose and MRS2690 increased the level of MLC2 phosphorylation; 
this effect was blocked by PPTN, indicating the involvement of P2Y14 
receptors. UDP-glucose increased the level of ERK1/2 phosphorylation. 
UDP-glucose and MRS2690 inhibited glucose-induced insulin release from 
the rat INS-ǃ-cell line; this effect was blocked by PPTN, indicating 
actions through P2Y14 receptors. PPTN itself was able to elevate 
significantly basal insulin secretion from INS-1 823/13 ǃ-cells, which may 
suggest a constitutive release of UDP-glucose from these cells. 
These results suggest that, in porcine pancreatic arteries, ATP induces a 
vasoconstriction mediated by P2X1 receptors followed by a vasorelaxation 
evoked by adenosine receptors present on the vascular smooth muscle. 
ADP induced a relaxation mediated by adenosine A2A receptor. Moreover, 
my data indicate for the first time, an endothelium-dependent contraction 
evoked by UTP. A novel vasocontractile role of P2Y14 receptors in porcine 
pancreatic arteries was also documented. The contractile response was 
mediated largely by the endothelium. P2Y14-mediated contraction involves 
a cAMP-dependent mechanism, which is consistent with P2Y14 receptor 
coupling to Gi protein, and an elevation in phosphorylated MLC2 and 
ERK1/2. Activation of the P2Y14 receptor evoked a decrease in the level of 
insulin secreted from the rat pancreas. The current data have identified 
novel roles of the P2Y14 receptor as a mediator of pancreatic artery 
contractility and in regulation of insulin secretion. If its role within the 
vasculature is shown to be more widespread, the P2Y14 receptor may be a 
novel target for the treatment of cardiovascular disease. 
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MRS2211 Pyridoxal-5Ļ- phosphate-6-azo (2-chloro-5-
nitrophenyl)-2,4-disulfonate 
MRS2279  2-chloro-N6-methyl-(N)-methanocarba-Ļ-
deoxyadenosine-ĻĻ-bisphosphate 
MRS2365   (N)-methanocarba-2-MeSADP 
MRS2500  N6-methyl-(N)-methanocarba-2Ļ-
deoxyadenosine-3Ļ,5-bisphosphate 
xix 
 
MRS2578  N,Nļ-1,4-butanediyl bis(NĻ-[3-
isothiocynatophenyl)] thiourea 
MRS2690   2-thiouridine-5Ļ-diphosphoglucose 
MRS2698 [[(2R,3S,4R,5R)-4-amino-3-hydroxy-5-(4-oxo-
2-sulfanylidenepyrimidin-1-yl)oxolan-2-
yl]methoxy-hydroxyphosphoryl] phosphono 
hydrogen phosphate 
MRS2768   Uridine-Ļ-tetraphosphate į-phenyl ester 
MRS2802 [({[(2R,3R,4S)-5-(2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-1-yl)-3,4-
dihydroxyoxolan-2-
yl]methoxy}(hydroxy)phosphoryl)difluorometh
yl]phosphonic acid 
MRS4062   N4-phenylpropoxycytidine-5¶-triphosphate 
NDGA    Nordihydroguiaretic acid 
NF 340 4,4'-(Carbonylbis(imino-3,1-(4-methyl-
phenylene)carbonylimino))bis(naphthalene-
2,6-disulfonic acid) tetrasodium salt 
NF023 8,8Ļ-(carbonylbis[imino-3,1-phenylene 
carbonylimino])bis-1,3,5-naphthalenetrisulfonic 
acid 
NF279  8,8'-[Carbonylbis(imino-4,1-phenylen
ecarbonylimino-4,1-
phenylenecarbonylimino)]bis-1,3,5-
naphthalenetrisulfonic acid hexasodium salt 
NF449  4,4Ļ,4ļ,4Ļļ-(carbonylbis[imino-5,1,3-
benzenetriyl-bis{carbonylimino}]) 
tetrakisbenzene-1,3-disulfonic acid octasodium 
salt 
NF546  4,4Ļ-(carbonylbis(imino-3,1-phenylene-
carbonylimino-3,1-(4-methyl-phenylene)-
carbonylimino))-bis(1,3-xylene-a,aĻ-
diphosphonic acid); PPTN 4-(4-(piperidin-4-
yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-2-
naphthoic acid 
Nifedipine 1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-
3,5-pyridinedicarboxylic acid dimethyl ester 
PD98059 (2-(2-amino-3-methoxyphenyl)-4H-1-
be­nzopyran-4-one) 
PPADS pyridoxalphosphate-6-azophenyl-ĻĻ-
disulphonate 
xx 
 
PSB 0739  1-Amino-9,10-dihydro-9,10-dioxo-4-[[4-
(phenylamino)-3-sulfophenyl]amino]-2-
anthracenesulfonic acid sodium salt 
PSB1115  4-[2,3,6,7-tetrahydro-2,6-dioxo-1-propyl-1H-
purin-8-yl)benzenesulphonic acid 
PSB-36  1-butyl-8-(3-noradamantanyl)-3-(3-
hydroxypropyl)xanthine 
PSB603  8-[4-[4-(4-chlorophenzyl)piperazide-1-
sulfonyl)phenyl]]-1-propylxanthine 
PSB-716  1-amino-4-(2-methoxyphenyl)-2-
sulfoanthraquinone 
SCH4421416  2-(2-furanyl)-7-[3-(4-methoxyphenyl)propyl]-
7H-pyrazolo [4,3-e][1,2,4]triazolo[1,5-
c]pyrimidin-5-amine 
SCH58261 5-amino-2-(2-furyl)-7-
phenylethylpyrazolo[4,3-e]-1,2,4-
triazolo[1,5c]pyrimidine 
S-ENBA (2S)-N6-(2-endonorbanyl)adenosine; SLV320, 
trans-4-[(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-
4-yl)amino]cyclohexanol 
Thapsigargin (3S,3aR,4S,6S,6AR,7S,8S,9bS)-6- (Acetyloxy)-
2,3,3a,4,5,6,6a,7,8,9b-decahydro-3,3a-
dihydroxy-3,6,9-trimethyl-8-[[(2Z)-2-methyl-
1-oxo-2-butenyl]oxy]-2-oxo-4-(1-
oxobutoxy)azuleno[4,5-b]furan-7-yl octanoate 
TNP-ATP   ĻĻ-O-(2,4,6-trinitrophenyl)-ATP 
UK14304 5-Bromo-6-(2-imidazolin-2-
ylamino)quinoxaline) 
VUF5574  N-(2-methoxyphenyl)-N-(2-[3-
pyridyl]quinazolin-4-yl)urea 
XAC Xanthine amine congener 
Y-27632 Trans-4-[(1R)-1-Aminoethyl]-N-4-
pyridinylcyclohexanecarboxamide 
dihydrochloride 
Zafirlukast N-[3-[[2-Methoxy-4-[[[(2-methylphenyl)
sulfonyl]amino]carbonyl]phenyl]methyl]-1-
methyl-1H-indol-5-yl]carbamic acid cyclopentyl 
ester 
ZM241385 4-(2-[7-amino-2-{2-furyl}{1,2,4}triazolo{2,3-
a}{1,3,5}triazin-5-yl amino]ethyl)phenol 
  
Chapter 1 
General introduction 
 
1 
 
 
 
 
 
 
 
 
 
 
Chapter One 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
General introduction 
 
2 
 
General introduction 
 
This chapter will begin with a description of the structure of blood vessels 
and their layers, as well as the ways of controlling the blood flow into these 
vessels. This will then be followed by a review about purine receptors and 
their classification. This review will focus mainly on the most recently 
discovered member of the P2Y receptor family, the P2Y14 receptor and its 
ligands. Subsequently, the chapter will provide an overview about the 
pancreas; its structure, the arterial supply to the pancreas, as well as the 
hormones and enzymes released from it. Finally, the structure, 
biosynthesis, secretion and role of insulin will be considered. The general 
introduction will conclude with a description of the aims and the objectives 
of the project. 
 
1.1. Vascular system 
 
1.1.1. Blood vessel structure 
 
The structure of blood vessels varies according to the function, but in 
general they comprise of three distinctive layers (Figure 1.1). The 
innermost layer (tunica intima) which contains the endothelial cell layer. It 
consists of a single layer of endothelial cells and thus appears flattened and 
smooth. This layer is surrounded by the middle layer (tunica media) which 
is a thick wall containing the smooth muscle cells, this layer is innervated 
by motor nerves, most of which are part of the sympathetic nervous 
system (Rutishauser, 1994; Clancy & McVicar, 2009). The outer layer 
(tunica adventitia) contains an abundance of two types of connective 
tissues; collagen fibers and elastin fibers (Figure 1.1), which provide the 
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arterial walls with strength and flexibility. This layer is innervated by 
sensory neurones (Rutishauser, 1994; Sherwood, 1997). The main role of 
the vessels is to drive the blood from the heart to the tissues and then 
back to the heart, as well as passing the deoxygenated blood, by the 
pulmonary artery, to the lung to remove the carbon dioxide (CO2) and to 
reoxygenate it (Rutishauser, 1994). The capillaries are the simplest among 
the blood vessels, and they just contain a single layer of endothelial cells 
surrounded by a basement membrane (Rutishauser, 1994). 
 
Figure 1.1. A schematic representation of the structure of the blood 
vessels. Adapted from Clancy & McVicar (2009). 
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1.1.2. Control of arterial blood pressure 
 
Arterial blood pressure acts as the driving force for blood flow through the 
tissues of the body. The arterial blood pressure depends on two major 
factors, the cardiac output and the peripheral resistance (Rutishauser, 
1994; McGeown, 2002). The cardiac output is the amount of blood ejected 
from the heart per minute, and it is determined by the heart rate and the 
stroke volume. The peripheral resistance is regulated by the diameter of 
the blood vessels. The diameter of the blood vessels depends on the 
balance of a variety of factors (neural, hormonal and local) that exert an 
influence on the smooth muscles at any given time (Rutishauser, 1994). It 
has been shown that a change in the diameter of the arterioles has a 
greater effect on the blood flow than that in large arteries. Consequently, 
the arterioles offer the greatest peripheral resistance. The veins drive the 
flow of the blood back to the heart, this is significant in determining the 
cardiac output. The resistance to the blood flow through the veins is low 
comparing with that through the arteries. However, a change in diameter 
of the veins would alter the venous return of blood back to the heart, and 
that will affect the stroke volume. 
 
1.2. Purinergic signalling 
 
Purinergic signalling is one of the most ancient biological systems, and it is 
believed to be the most ubiquitous intracellular signalling system in living 
tissues (see review by Burnstock et al., 2010). Purine and pyrimidine 
receptors play a major role as signal transduction proteins in eukaryotes. 
These receptors consist of several subtypes with extracellular nucleotides 
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and nucleotide sugars as potent ligands. These receptors are found on the 
surface of almost all cells with widespread expression and effect. 
 
1.3. A brief historical perspective 
 
The role of purinergic signalling was first identified in 1929 by Drury & 
Szent-Gyorgyi, through investigation of the effects of sheep heart, brain 
and kidney extracts on guinea-pig, cat and dog heart. These extracts, 
when were injected intravenously, resulted in the slowing down of the 
heart rate and vasodilatation of the coronary arteries, hence causing 
hypotensive actions. The active component in the extracts were found to 
be the adenosine-¶-monophosphate (AMP) (Drury & Szent-Gyorgyi, 1929). 
These findings were confirmed by further experiments showing the ability 
of purine nucleotides to induce a heart block and to act as vasodilators of 
coronary arteries (Bennett & Drury, 1931; Lindner & Rigler, 1931; Wedd, 
1931; Wedd & Drury, 1934; Ralevic & Burnstock, 1998; Winbury et al., 
1953; Wolf & Berne, 1956), and other arteries (Gaddum & Holtz, 1933; 
Houck et al., 1948). Meanwhile, some reports showed that adenosine-5¶-
triphosphate (ATP) was more effective than adenosine (ado) at producing a 
heart block (Drury, 1936; Green & Stoner, 1950). It was also shown that 
extracellular nucleotides evoked non-cardiovascular responses, including 
ATP-induced contraction of the intestine (Gillespie, 1934) and uterus 
(Deuticke, 1932; Watts, 1953). In addition, the role of ATP in the nervous 
system has been investigated since 1947 (see review by Burnstock et al., 
2010). 
In the 1960s, the term '' non-adrenergic, non-cholinergic nerves¶¶ (NANC) 
was suggested to describe the nerves which were other than adrenergic 
and cholinergic (Burnstock et al., 1963). These nerves were determined 
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following the inhibition of the activities of adrenergic and cholinergic 
neurotransmission in the guinea-pig taenia coli using blocking agents. It 
was found that the electrical stimulation of guinea-pig taenia coli was still 
able to induce a hyperpolarisation and relaxation (Burnstock et al., 1963). 
The previous effect was blocked in the presence of a neurotoxin, indicating 
the involvement of some nerves which were distinct from adrenergic and 
cholinergic in that response (Bulbring & Tomita, 1967). Subsequently, in 
the 1970s, studies were conducted to identify the neurotransmitter utilised 
by the NANC nerves of the gastrointestinal tract and urinary bladder 
(Eccles, 1964; Burnstock, 1971). After investigating several substances as 
potential neurotransmitters, ATP was found to be the substance which 
acted as a co-transmitter with catecholamines in adrenergic nerves and 
with acetylcholine in a number of cholinergic nerves (see review by 
Burnstock et al., 2010). In 1972, the word '' purinergic¶¶ was introduced to 
describe the nerves which utilise ATP as a neurotransmitter (Burnstock, 
1972). 
In 1978, Burnstock introduced the first classification of the purinergic 
receptors (Burnstock, 1978). The nomenclature used by Burnstock divided 
these receptors into P1 and P2 purinoceptors. P1 receptors were reported 
to be much more responsive to the adenosine and AMP than to ATP and 
adenosine-5¶-diphosphate (ADP), while P2 receptors were proposed to be 
much more responsive to ATP and ADP than to AMP and adenosine 
(Burnstock, 1978). In 1985, a report suggested a pharmacological basis for 
discriminating two types of P2 receptors (P2X and P2Y receptors) 
(Burnstock & Kennedy, 1985). They showed that P2X receptors were most 
potently activated by DE-methylene-adenosine-5Ļ-triphosphate (DE-
meATP), while 2-methylthio-adenosine-5Ļ-triphosphate (2-MeSATP) was at 
that time the most potent agonist at P2Y receptors. Later in 1989, it was 
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observed that some P2Y receptors responded to pyrimidine nucleotides as 
well as to purine nucleotides (Seifert & Schultz, 1989). 
The current classification was first defined in 1994 on the basis of 
molecular structure and transduction mechanisms (Abbracchio & 
Burnstock, 1994; Abbracchio et al., 2003). It was proposed that purinergic 
receptors may be sub-divided into two major families: a P2X receptor 
family of ligand-gated ion channel receptors, which are activated by ATP 
and its analogues, in addition to a P2Y receptor family of G protein-coupled 
receptors (Abbracchio & Burnstock, 1994; Burnstock, 2007). P2Y receptors 
are activated by ATP, ADP, uridine-5¶-triphosphate (UTP), uridine-5¶-
diphosphate (UDP) and UDP-sugars and their analogues. In fact, both P1 
and P2 receptors may be responsive to ATP and ADP since adenosine can 
be produced from ATP or ADP in metabolic breakdown (section 1.7). 
It is believed that P1 and P2 receptors and their signalling are involved in 
many non-neuronal and neuronal mechanisms, including immune 
responses, inflammation, platelet aggregation, pain, modulation of cardiac 
functions, exocrine and endocrine secretion (Burnstock & Knight, 2004; 
Burnstock, 2006a). Purinergic signalling can mediate cell proliferation, cell 
death and cell differentiation (Abbracchio & Burnstock, 1998; Burnstock, 
2002). In addition, extracellular purine and pyrimidine nucleotides play a 
significant role in regulating the blood flow in a variety of tissues, via 
inducing vasoconstriction or vasorelaxation by activating purine or 
pyrimidine receptors (Burnstock et al., 2010). 
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1.4. Purine and pyrimidine receptors 
 
The diagram below shows the classification of the main families of 
adenosine, purine and pyrimidine receptors (P1 and P2 receptors), and 
their respective subtypes along with their signal transduction mechanisms 
(Figure 1.2). 
 
1.4.1. P1 receptors  
 
P1 receptors (adenosine receptors) can be sub-divided into four distinct 
subtypes; A1, A2A, A2B and A3 receptors (Figure 1.2, Table 1.1) (Olah & 
Stiles, 2000; Fredholm et al., 2001; Cobb & Clancy, 2003; Yaar et al., 
2005). Adenosine receptors are G protein-coupled receptors with a 
structure common with other G protein-coupled receptors. They consist of 
seven putative transmembrane (TM) domains of hydrophobic amino acids, 
each domain has an D-helix with approximately 21-28 amino acids, with an 
extracellular N-terminus and an intracellular C-terminus (see review by 
Ralevic & Burnstock, 1998) (Figure 1.3). The seven transmembrane 
domains are linked via three extracellular and three intracellular hydrophilic 
loops (Figure 1.3) (Ralevic & Burnstock, 1998). P1 receptors primarily 
couple to adenylyl cyclase, where A1 and A3 are negatively coupled to 
adenylyl cyclase through Gi/o protein, A2A and A2B receptors are positively 
coupled to adenylyl cyclase through Gs protein (Reshkin et al., 2000). 
Adenosine receptors have been reported to play a significant role in the 
cardiovascular system especially by regulating blood pressure and cell 
function, and mediating cardioprotection (see reviews by Ledent et al., 
1997; Peart & Headrick, 2007; Headrick et al., 2011). The main 
distribution and the signalling transduction mechanisms of adenosine 
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receptors, together with their selective agonists and antagonists are listed 
in Table 1.1. 
 
Figure 1.2. Diagrammatic representation of the subtypes of adenosine, 
purine and pyrimidine receptors along with their transduction mechanisms. 
Adenosine, 
purine and 
pyrimidine 
receptors 
Adenosine 
receptors 
A1 Gi/o 
A2A Gs 
A2B Gs 
A3 Gi/o 
P2X receptors  
P2X1 Ion channels 
P2X2 Ion channels 
P2X3 Ion channels 
P2X4 Ion channels 
P2X5 Ion channels 
P2X6 Ion channels 
P2X7 Ion channels 
P2Y receptors 
P2Y1 Gq/11 
P2Y2 Gq/11 
P2Y4 Gq/11 
P2Y6 Gq/11 
P2Y11 Gq/11, Gs 
P2Y12 Gi/o 
P2Y13 Gi/o 
P2Y14 Gi/o 
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Figure 1.3. A schematic representation of the adenosine receptor. In 
common with other G protein-coupled receptors, adenosine receptors have 
seven putative transmembrane domains (I-VII), each domain contains an 
D-helix. These domains are linked via three extracellular and three 
intracellular hydrophilic loops. The arrangement of the transmembrane 
regions forms a pocket for the ligand binding site. S-S denotes the 
presence of hypothetical disulfide bridges. Figure is based on data from 
Jacobson et al. 1993; Ralevic & Burnstock, 1998. 
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1.4.2. P2 receptors  
 
P2 receptors are membrane bound receptors responsive to the extracellular 
nucleotides and nucleotide sugars. These receptors are divided into two 
distinct families: P2X receptors which are ligand-gated ion channels and 
P2Y receptors, which are metabotropic G protein-coupled receptors.  
To date, the nomenclature subcommittee of the International Union of 
Basic and Clinical Pharmacology (IUPHAR) has recognised seven 
mammalian P2X receptor subunits: P2X1, P2X2, P2X3, P2X4, P2X5, P2X6 
and P2X7 receptors (Figure 1.2) (Khakh et al., 2001), while IUPHAR has 
recognised eight mammalian subtypes of P2Y receptors: P2Y1, P2Y2, P2Y4, 
P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14 receptors (Figure 1.2) (Abbracchio et 
al., 2006). The missing numbers among P2Y receptors (p2y3, p2y5, p2y7, 
p2y8, p2y9, p2y10 and p2y15) represent either receptors that have some 
sequence homology to the P2Y receptors but they are not responsive to 
nucleotides, or they are non-mammalian orthologues, or that are 
mammalian orphan receptors; in these cases a lower case (p2y) has been 
suggested to be used (Abbracchio et al., 2006). 
The ligands for P2 receptors are ATP, ADP, UTP, UDP and UDP-sugars 
(Kügelgen, 2008). A number of selective agonists and antagonists at P2 
receptors are shown in Table 1.1. Several compounds can be used as non-
selective antagonists at P2 receptors, including suramin, 
pyridoxalphosphate-6-azophenyl-ĻĻ-disulphonate (PPADS), Reactive 
blue-2 and some other antagonists (see reviews by Ralevic & Burnstock, 
1998; von Kügelgen, 2006). However, some P2 receptors are resistant to 
these antagonists. For example, it was shown that suramin and PPADS are 
weak/inactive at rat recombinant P2Y4 receptors (Bogdanov et al., 1998b; 
Wildman et al., 2003). To date, there is no report of the antagonist 
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sensitivity of P2Y14 receptors for suramin and PPADS. It should be noted 
that some P2 receptor antagonists, including suramin and PPADS, can 
inhibit the ecto-nucleotidase enzymes (section 1.7). That may reduce their 
efficacy as P2 receptor antagonists, which results in an increase in the 
responses to P2 receptor ligands via a decrease in their breakdown (Chen 
et al., 1996; Ralevic & Burnstock, 1998; Grobben et al., 1999; Vollmayer 
et al., 2003;  Munkonda et al., 2007). 
 
1.4.2.1. P2X receptors 
 
P2X receptors are ligand-gated ion channels. They comprise seven distinct 
homomeric subtypes P2X1-7 (Khakh et al., 2001). P2X receptor identities 
range between 26-47% and the length of each subtype is between 379 and 
595 amino acids (Khakh et al., 2001). The native ligand at all P2X 
receptors is ATP (Coddou et al., 2011). DE-meATP was initially shown to be 
an agonist only at homomeric P2X1 and P2X3 receptors. Subsequently, it 
was shown to be also an active agonist at P2X5, P2X6 and P2X4 receptors 
(Kennedy et al., 2013). The structure of P2X receptors is shown in Figure 
1.4. P2X subunits have two hydrophobic, transmembrane spanning regions 
which cross the plasma membrane, they are connected by an extracellular 
loop, with approximately 280±300 amino acids, the latter contains the ATP 
binding site (Jiang et al., 2000; Kawate et al., 2009; Kennedy et al., 
2013), in addition to a further site where the antagonist can bind (Garcia-
Guzman et al., 1997; Kawate et al., 2009). Since P2X subunits have only 
two transmembrane regions, a single subunit on its own is not able to form 
a functional receptor. Reports using a variety of experimental techniques 
showed that three subunits are required to form a functional P2X receptor, 
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and hence three agonist molecules are required to bind to a single receptor 
in order to activate it (see review by Burnstock & Kennedy, 2011). 
P2X receptors are multisubunit, as they may be homomeric (contain 
identical subunits) or heteromeric (contain different subunits). For 
example, it was reported that the heteromeric P2X2/3 receptor can be 
formed via the combination of P2X2 and P2X3 receptors (Lewis et al., 
1995). Similarly, the heteromeric P2X1/2, P2X1/4, P2X1/5, P2X2/6, 
P2X4/7 and P2X4/6 receptors have been characterised (see reviews by 
Coddou et al., 2011; Kennedy et al., 2013). P2X receptors are non-
selective cation-conducting, which mediate initially a rapid non-selective 
passage of cations (Na+, K+, Ca2+) through the cell membrane, resulting in 
depolarisation and thus Ca2+ influx via L-type voltage-dependent calcium 
channels (Bean, 1992; Dubyak & El-Moatassim, 1993; Kennedy et al., 
2013). P2X receptors have approximately equal permeability to Na+ and K+ 
cations with significant permeability to Ca2+ (Evans & Kennedy, 1994). 
Cations can also regulate ATP-activated currents in P2X receptors, since 
Ca2+ could inhibit P2X receptor currents via decreasing the affinity of P2X 
receptor ATP binding sites (Honore et al., 1989; Khakh et al., 2001). 
P2X receptors can be divided into two groups depending on whether they 
desensitise rapidly (within 100-300 ms) or not. P2X1 and P2X3 receptors 
were shown to be rapidly desensitised, while other P2X receptors (namely, 
P2X2, P2X4, P2X5, P2X6 and P2X7) are not desensitised rapidly or do not 
desensitise at all (Ralevic & Burnstock, 1998; Coddou et al., 2011). The 
mechanism by which the desensitisation is induced, requires an interaction 
between the two hydrophobic channels at P2X1 or P2X3 receptors, as well 
as an involvement of a number of amino acids of the intracellular terminus, 
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which are located just before the first transmembrane (TM1) domain of P2X 
receptors (Werner et al., 1996; Allsopp & Evans, 2011).  
P2X receptors are found throughout the body, and they are abundantly 
present in the nervous system, where they are involved in rapid purinergic 
synaptic transmission. Thus P2X receptors are involved in physiological 
regulation of the periphery and the central nervous system (CNS). Some of 
P2X receptors, including P2X1, P2X4 and P2X7, are functionally expressed 
in the cardiovascular system, and they have been proposed to be potential 
targets for treatment of some cardiovascular disorders (see review by 
Kennedy et al., 2013). A number of P2X receptor selective agonists and 
antagonists, in addition to the receptors main distribution and their signal 
transduction mechanisms, are listed in Table 1.1. 
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Figure 1.4. A schematic representation of P2X receptor, showing two 
hydrophobic transmembrane domains (TM1 and TM2) crossing the lipid 
bilayer of the plasma membrane, with intracellular N- and C-termini. The 
putative extracellular domain contains two disulfide-bonded loops (S-S) 
and three N-linked glycosyl chains (triangles). Figure is adapted from 
Ralevic & Burnstock, 1998. 
 
1.4.2.2. P2Y receptors 
 
P2Y receptors are G protein coupled receptors which are responsive to 
purine and pyrimidine nucleotides and nucleotide sugars (Ralevic & 
Burnstock, 1998; Abbracchio et al., 2006). P2Y receptors contain 308-377 
amino acids with a mass of 41-53 kDa after glycosylation (Ralevic & 
Burnstock, 1998). Their structure is common to that of other G protein-
coupled receptors (Figure 1.3). They contain seven D-helical 
transmembrane domains of hydrophobic amino acids, these domains are 
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connected via three extracellular and three intracellular loops, with an 
extracellular N-terminus and an intracellular C-terminus (Ralevic & 
Burnstock, 1998; Jacobson et al., 2012). It has been shown that four 
amino acid residues of TM6 and TM7 might be essential for agonist binding, 
potency and specificity (Erb et al., 1995; Jiang et al., 1997; Barnard & 
Simon, 2001). 
P2Y receptors can be divided on the basis of their endogenous ligands into 
adenine nucleotide-preferring (P2Y1, P2Y11, P2Y12 and P2Y13 receptors) and 
uracil nucleotide or UDP-sugar-preferring (P2Y2, P2Y4, P2Y6 and P2Y14 
receptors) (von Kugelgen, 2006). Alternatively, P2Y receptors can be 
distinguished as P2Y1-like family and P2Y12-like family based on their 
sequence alignments and effector coupling. The P2Y1-like family couples to 
Gq protein and involves an activation of the phospholipase C (PLC) 
signalling pathway (Costanzi et al., 2004). This sub-family contains P2Y1, 
P2Y2, P2Y4, P2Y6 and P2Y11, although P2Y11 receptor can couple to Gs 
protein too, leading to an activation of adenylyl cyclase (Communi et al., 
1997). The P2Y12-like family can couple to Gi protein leading to an 
inhibition of adenylyl cyclase (Jacobson et al., 2012). The sequence 
homology between the two sub-families is low, for instance, the sequence 
identity between P2Y1 and P2Y12 receptors is only 20%. While the sequence 
identity between the members within the same sub-family is higher, for 
instance, the sequence identity between P2Y12 and P2Y14 receptors is 45% 
(Jacobson et al., 2012). 
P2Y receptors have a wide distribution throughout the body and they 
mediate various responses in a variety of tissues (see reviews by 
Burnstock, 2007; Erlinge & Burnstock, 2008; Burnstock et al., 2010). They 
have been found to be present in the central nervous system (Ralevic et 
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al., 1999; Moore et al., 2000; Brown & Dale, 2002; Vasiljev et al., 2003), 
cardiovascular system (Patel et al., 1996; Bogdanov et al., 1998a; Muraki 
et al., 1998), stomach (Otsuguro et al., 1996), liver (Dixon et al., 2000, 
2003), placenta (Somers et al., 1999) and kidney (Takeda et al., 1996). It 
has been reported that P2Y receptors play significant roles in the exocrine 
and endocrine pancreas (Luo et al., 1999; Coutinho-Silva et al., 2001) and 
adipose tissue (Yegutkin & Burnstock, 1999). A number of P2Y receptor 
selective agonists and antagonists, in addition to the receptors main 
distribution and their signal transduction mechanisms, are listed in Table 
1.1. 
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Table 1.1. Characteristics of adenosine, purine and pyrimidine receptors 
Receptor Main 
distribution 
Selective 
agonists 
Selective 
antagonists 
Transduction 
mechanism 
P1 (adenosine) receptors 
A1 brain, spinal 
cord, heart, 
endothelial 
cells, adipose 
tissue 
CPA, CCPA, 
S-ENBA, 
GR79236 
PSB-36, 
DPCPX, 
SLV320, 
KW3902 
Gi/o 
 
A2A brain, heart, 
lungs, spleen, 
CGS21680,  
HE-NECA, 
ATL-146e 
SCH442416, 
ZM241385, 
SCH58261 
Gs 
A2B large 
intestine, 
bladder, 
endothelial 
cells 
Bay60-6583 
 
PSB-603, 
MRS1754, 
MRS1706, 
PSB1115 
Gs 
A3 lung, liver, 
brain testis 
heart 
Cl-IB-MECA,  
CP532,903 
MRS1220, 
VUF5574, 
MRS1523, 
MRS1191 
Gi/o 
 
P2X receptors 
P2X1 smooth 
muscle, 
platelets,  
L-ǃǄ-meATP, 
DE-meATP, 
BzATP 
TNP-ATP, 
NF449,        
NF023 
Intrinsic 
cation channel 
(Ca2+, Na+) 
P2X2 smooth 
muscle, CNS, 
autonomic 
and sensory 
ganglia 
- NF279 Intrinsic 
cation channel 
(particularly 
Ca2+) 
P2X3 sensory and 
some 
sympathetic 
neurons 
DE-meATP, 
BzATP, 
A317491 
TNP-ATP,  
A317491, 
AF353 
Intrinsic 
cation channel 
P2X4 CNS, colon, 
smooth 
muscle 
- BBG, 
5-BDBD 
Intrinsic 
cation channel 
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P2X5 proliferating 
cells in skin, 
gut, bladder 
DE-meATP - Intrinsic 
cation channel 
P2X6 CNS, motor 
neuron in 
spinal cord 
DE-meATP - Intrinsic 
cation channel 
P2X7 stomach, 
kidney, 
bladder 
BzATP KN62, 
A804598, 
A839977 
Intrinsic 
cation channel 
P2Y receptors 
P2Y1 epithelial and 
endothelial 
cells, platelets 
2-MeSADP, 
MRS2365 
MRS2500, 
MRS2279, 
MRS2179 
Gq/11 
P2Y2 epithelial and 
endothelial 
cells, immune 
cells, smooth 
muscle 
MRS2698, 
MRS2768, 
PSB1114 
PSB-716 Gq/11 
P2Y4 epithelial cells MRS4062, 
U73Ǆ6 
- Gq/11 
P2Y6 epithelial 
cells, placenta 
5-iodoUDP, 
PSB-0474 
MRS2578 Gq/11 
P2Y11 spleen, 
intestine 
ARC67085, 
NF546 
NF340 Gq/11, Gs 
P2Y12 platelets, glial 
cells 
2-MeSADP ARL66096, 
AZ11931285 
Gi/o 
P2Y13 spleen, brain, 
bone marrow 
- MRS2211 Gi/o 
P2Y14 placenta, 
adipose 
tissue, 
stomach 
MRS2690, 
MRS2802 
PPTN Gi/o 
Adapted from Burnstock, (2007); Burnstock et al. (2010); Jacobson et al. 
(2012); Barrett et al. (2013); Kennedy et al. (2013); Burnstock & Ralevic 
(2014). 
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1.4.2.2.1. P2Y14 receptor 
 
The P2Y14 receptor (also known as GPR105), which was identified in 2000 
as the eighth member of the P2Y receptor family, is responsive to uridine-
5'-diphosphate-glucose (UDP-glucose) and other sugar nucleotides 
(Chambers et al., 2000; Abbracchio et al., 2003). It was originally cloned 
from immature human myeloid cells (KIAA0001) (GenBankTM accession 
number D13626) (Nomura et al., 1994). The rat and mouse orthologues of 
P2Y14 receptor showed 80% and 83% amino acid identities respectively, to 
the human GPR105 protein. In addition, the human P2Y14 receptor shares 
45% amino acid identity with human P2Y12 and P2Y13 receptors and 22% 
with the P2Y1 receptor (Freeman et al., 2001; Abbracchio et al., 2003; 
Moore et al., 2003). 
P2Y14 receptor is activated by UDP-glucose (Figure 1.5B) and other 
nucleotide sugars, with a rank order of potency of P2Y14 receptor ligands as 
follows: UDP-JOXFRVH  8'3-glucuronic acid > UDP-galactose > UDP-N-
acetylglucosamine (Chambers et al., 2000; Ko et al., 2007). The structure 
activity relationship (SAR) of synthetic nucleotides for activation of the 
human P2Y14 receptor resulted in development of a compound with a 2-
thiouracil modification, MRS2690 (2-thiouridine-5Ļ-diphosphoglucose) 
(Figure 1.5C), with 7-fold greater potency than UDP-glucose at P2Y14 
receptors (Ko et al., 2009). P2Y14 receptor-dependent inhibition of cyclic 
adenosine-¶-monophosphate (cAMP) accumulation in C6 glioma cells 
expressing P2Y14 receptor, human embryonic kidney 293 (HEK-293) cells 
and Chinese hamster ovary (CHO) cells was shown in the presence of UDP-
glucose, as well as in the presence of UDP with similar efficacies, indicating 
that UDP (Figure 1.5A) is a potent agonist at P2Y14 receptor (Carter et al., 
2009). In contrast, other nucleotides (CDP, GDP and ADP) exhibited 100-
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fold less potency than that of UDP or UDP-glucose in activating the human 
P2Y14 receptors (Carter et al., 2009). 
 
 
 
Figure 1.5. Chemical structure of UDP (A), UDP-glucose (B) and MRS2690 
(C), the agonists at P2Y14 receptor. 
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Recently, a novel high affinity competitive antagonist at P2Y14 receptors 
was identified, this antagonist, named 4-(4-(piperidin-4-yl)phenyl)-7-(4-
(trifluoromethyl)phenyl)-2-naphthoic acid (PPTN) (Figure 1.6). It was 
synthesised, as a naphthoic acid derivative, as described by Gauthier et al. 
(2011) and Barrett et al. (2013). PPTN was initially characterised in P2Y14 
receptor-expressing HEK cells through its ability to inhibit UDP-glucose-
stimulated Ca2+ mobilisation (Robichaud et al., 2011). It showed good 
affinity for the P2Y14 receptor (Ki = 1.9 nM in a chimpanzee P2Y14 binding 
assay) (Robichaud et al., 2011). When it was examined in human C6 
glioma cells, PPTN at a concentration as low as 1 nM abolished the ability of 
UDP-glucose to inhibit forskolin-stimulated cAMP accumulation (Barrett et 
al., 2013). Similarly, the activity of UDP at P2Y14 receptors were blocked by 
PPTN (Barrett et al., 2013). PPTN showed selectivity for P2Y14 receptors 
since it did not exhibit agonist or antagonist affinity at P2Y1, P2Y2, P2Y4, 
P2Y6, P2Y11, P2Y12 or P2Y13 receptors with a range of concentrations up to 
10 µM (Barrett et al., 2013). 
 
Figure 1.6. Chemical structure of 4-(4-(piperidin-4-yl)phenyl)-7-(4-
(trifluoromethyl)phenyl)-2-naphthoic acid (PPTN), a selective antagonist at 
the P2Y14 receptor. 
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The P2Y14 receptor is involved in heterotrimeric Gi protein mediated 
signalling, which induces an interaction of the GiD subunit with adenylyl 
cyclase and subsequent inhibition of cAMP, and hence pertussis toxin (PTX) 
was able to completely abolish the P2Y14 receptor agonist responses in C6 
glioma cells and HEK-293 cells expressing P2Y14 receptors (Carter et al., 
2009; Fricks et al., 2009). In addition, Gi protein derived GǃǄ-dimers are 
also involved in the signalling pathways of P2Y14 receptor leading to the 
activation of phospholipase &ǃ signalling pathway which results in 
activation of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) 
(Rebecchi & Pentyala, 2000; Schulte & Fredholm, 2003). The P2Y14 
receptor was reported to activate ras homolog gene family member (Rho) 
Rho-associated protein kinase (ROCK) signalling in human neutrophils, this 
effect was abolished following incubation with PTX (Sesma et al., 2012). 
UDP-glucose-evoked extracellular signal-regulated kinase (ERK1/2) 
phosphorylation was also shown in HEK-293 cells (Fricks et al., 2009). 
The widespread distribution of P2Y14 receptor was observed in human and 
mouse tissues including adipose tissue, placenta, liver, kidney, spleen, 
stomach and intestine, in which the P2Y14 receptor is expressed at high 
level (Charlton et al., 1997; Chambers et al., 2000; Freeman et al., 2001). 
In addition P2Y14 receptor is expressed in the immune system including 
primary neutrophils and primary lymphocytes (Charlton et al., 1997; Moore 
et al., 2003). The P2Y14 receptor is present at a moderate level in brain, 
heart and lung (Chambers et al., 2000; Freeman et al., 2001; Moore et al., 
2003). A moderate level of P2Y14 receptor was also detected in the HEK-
293 cell line, while P2Y14 mRNA was not detected in cell lines derived from 
human brain including glial and neuronal origin (Moore et al., 2003). 
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P2Y receptor desensitisation is a regulatory phenomenon that terminates 
receptor signalling following prolonged exposure of the receptor to the 
agonist, leading to down-regulation of surface receptors (Galas & Harden, 
1995). It was shown previously that P2Y2 receptors desensitised following 
constant application of UTP (Sanabria et al., 2008; Rodriguez-Rodriguez et 
al., 2009). Studies on UTP and UDP activated human P2Y4 and P2Y6 
receptors revealed that UTP induced a rapid desensitisation of the IP3 
response and a 50% loss of cell surface receptors. Subsequently, the 
removal of the agonist (UTP) results in a rapid recovery of the surface 
receptors. On the other hand, UDP did not induce a rapid desensitisation 
but it also did not result in a rapid recovery after removal of the agonist 
(Brinson & Harden, 2001). Regarding the P2Y1 and P2Y12 receptors, it has 
been shown that P2Y1 and P2Y12-mediated platelet responses desensitise 
quickly (Hardy et al., 2005). There appears to be no report which has 
investigated whether P2Y14 receptor may exhibit desensitisation. 
 
1.5. Mechanism of nucleotides release 
 
The existence of ATP in the extracellular milieu has been identified a long 
time ago (see reviews by Ralevic & Burnstock, 1998; Burnstock et al., 
2010). The release of ATP to the extracellular milieu may occur from 
excitatory/secretory tissues or from nonexcitatory tissues (see review by 
Lazarowski et al., 2003a). The exocytotic release of ATP by excitatory cells 
(neurons, platelets and secretory cells) features the release of ATP as a co-
transmitter from terminal nerves. The storage and the release of ATP from 
these cells are controlled by electrochemical force generated by the activity 
of ATPase (Evans et al., 1992). Furthermore, ATP can be released from 
nonexcitatory cells, including endothelial and epithelial cells, smooth 
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muscle, circulating lymphocytes, erythrocytes, monocytes and hepatocytes 
(see reviews by Lazarowski et al., 2003a; Lazarowski et al., 2011). The 
nonexocytotic release of ATP is believed to occur in three different 
contexts: 1) ATP may be released due to the mechanical stimulation of 
epithelial, endothelial cells and some other cells; 2) A number of agonists 
may promote the release of ATP; 3) ATP could be released by resting cells 
in the absence of any external stimulus (Lazarowski et al., 2003a). 
1) The mechanism by which ATP can be mechanically released from the 
nonexcitatory cells (endothelial cells) is by subjecting these cells to shear 
stress, following an increase in flow rate (Bodin & Burnstock, 2001). 
Likewise, ATP can be generated from 1321N1 cell line during a medium 
change (Lazarowski et al., 2003a). Both cases resulted in approximately 50 
times elevation of the level of ATP released from these cells (Lazarowski et 
al., 2003a). 
2) The release of ATP to extracellular side can also be triggered in the 
presence of some pharmacological stimuli (Lazarowski et al., 2003a), 
including thrombin which has been shown to promote the release of ATP 
from aortic endothelial and smooth muscle cells (Yang et al., 1994). ADP 
and UTP induced an increase within the level of extracellular ATP in 
endothelial cell culture, COS-7 and HEK-293 cells (Yang et al., 1994; 
Ostrom et al., 2000). 3) ATP was found to be continuously released from 
many resting (nonsecretory) cells, including 1321N1, C6 rat glioma and 
airway epithelial cells (Lazarowski et al., 2000), since the level of ATP in 
the extracellular milieu persists at low nanomolar (1-10 nM) concentrations 
in the presence of ecto-ATPase enzymes (Lazarowski et al., 2000). 
Following release of ATP to the extracellular medium, it may be broken 
down to ADP with an inorganic phosphate (Pi) as well as to AMP with 
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inorganic pyrophosphate (PPi), and subsequently to adenosine by activities 
of ecto-nucleotidase enzymes (Joseph et al., 2004) (section 1.7). Other 
nucleotides namely UTP, ADP and UDP-glucose are also released by resting 
and mechanically stimulated tissues with similar mechanisms as described 
for ATP (see reviews by Lazarowski et al., 1997; Lazarowski et al., 2003b; 
Simon et al., 2008). 
 
1.6. UDP-glucose 
 
UDP-glucose is a nucleotide sugar which is biosynthesised in the cytosol 
and transported into the lumen of the endoplasmic reticulum (ER) and 
Golgi apparatus (ER/Golgi), and serves as a sugar donor involve in 
glycosyltransferase-catalysed reactions (Sesma et al., 2009). This 
nucleotide sugar can be biosynthesised from UTP by the activity of a UDP-
glucose pyrophosphorylase enzyme in the presence of glucose-1-
phosphate. The latter results from glucose by the activity of glucokinase, 
before being converted to glycogen as the activity of glycogen synthase 
(Seoane et al., 1996). UDP-glucose pyrophosphorylase catalyses a 
reversible production of UDP-glucose and pyrophosphate (PPi) (Kleczkowski 
et al., 2004). 
UTP + glucose-1-phosphate               UDP-glucose + pyrophosphate (PPi) 
 
 
 
UDP-glucose pyrophosphorylase 
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The transport of UDP-glucose from the cytosol into the lumen of the 
endoplasmic reticulum and Golgi apparatus occurs by means of ER/Golgi 
nucleotide sugar transporters (identified as SLC35 nucleotide sugar 
transporters). These transport the cytosolic UDP-sugars to ER/Golgi 
apparatus using uridine-5'-monophosphate (UMP) as an antiporter 
substrate (Hirschberg et al., 1998; Ishida & Kawakita, 2004). It has been 
shown that the nucleotide sugar concentrations in ER/Golgi are 20-fold 
higher than those in the cytosol (Hirschberg et al., 1998). In addition, 
brefeldin A which blocks the traffic between ER and the Golgi, has been 
shown to decrease UDP-sugars release from astrocytoma cells and yeast 
(Esther et al., 2008; Kreda et al., 2008). Overexpression of SLC35 
transporters in mucosal and basolateral compartments resulted in an 
enhancement of the cellular release of UDP-glucose, and displayed a 3.3-
fold increase in the rate of UDP-glucose release compared with that in cells 
that do not express SLC35 (Sesma et al., 2009). 
The concentration of intracellular cardiac UDP-glucose was estimated at 
100 mM (Laughlin et al., 1988). UDP-glucose has been shown to be 
released constitutively from a number of cells, including differentiated 
human airway epithelial cells, COS-7, CHO-K1, yeast, 1321N1 and C6 
glioma cells, to the extracellular milieu in two different ways: exocytosis 
from vesicles or cytosolic release through plasma membrane transporters 
or channels. Subsequently, UDP-glucose can act as an extracellular 
signalling molecule (Abbracchio et al., 2003; Lazarowski et al., 2003a; 
Lazarowski et al., 2003b; Sabirov & Okada, 2005; Sesma et al., 2009), as 
the concentration of extracellular UDP-glucose may reach effective levels 
ranging between 1-20 nM (Arase et al., 2009). On the other hand, the 
concentration of extracellular UDP-glucose may reach effective levels 
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ranging between 10 nM- 1 mM during cell damage and/or injury (Arase et 
al., 2009). 
Mechanical stimulation, induced by medium change, promoted ATP and 
UDP-glucose release from 1321N1 cells, the extracellular UDP-glucose 
concentration ranged within 10- 20 nM and was constant over 2-3 h, 
whereas the extracellular concentration of ATP reached a maximum 
concentration of 100 nM within 10-20 min, but it was followed by a 
substantial decrease of the extracellular concentration to a resting steady-
state level (3 nM). These findings suggest that the UDP-glucose rate of 
metabolism was much lower than that of ATP or the hydrolysis of UDP-
glucose induced by ecto-nucleotidase enzymes is balanced by its 
constitutive release (Lazarowski et al., 2003b).  
 
1.7. Ecto-nucleotidases 
 
Following released to the extracellular compartments (section 1.5), the 
biological activities of ATP, ADP, UDP, UTP and UDP-glucose are controlled 
by the activity of membrane-bound enzymes regulating nucleotide 
hydrolysis and phosphorylation (Zimmermann, 2000). Four major families 
of ecto-nucleotidases have been described by Zimmermann (2000): the 
ecto-nucleotide triphosphate diphosphohydrolase family (eNTPDase), the 
ecto-nucleotide pyrophosphatases (eNNPs), the 
glycosylphosphatidylinositol (GPI)-anchored ecto-¶-nucleotidase, and GPI-
anchored alkaline phosphatases (APs) (Zimmermann, 2000). In addition, 
an ecto-nucleotide diphosphokinases (eNDPKs) family was identified in 
2001 (Yegutkin et al., 2001). 
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The ENTPDase family can hydrolyse nucleoside-¶-triphosphates (NTP) and 
nucleoside-¶-diphosphate (NDP). This family contains eight members: 
eNTPDase1-8 (Zimmermann, 2000; Kukulski et al., 2005). They can 
degrade NTP to NDP with Pi as well as NDP to NMP with PPi (Joseph et al., 
2004). The, eNPP family contains three subtypes (eNPP1-3), and they can 
hydrolyse ATP directly to AMP, as well as hydrolysing the pyrophosphate 
linkages of UDP-glucose resulting in glucose-1-phosphate + UMP (Figure 
1.7) (Zimmermann, 2000; Lazarowski et al., 2003b). GPI-anchored ecto-
¶-nucleotidase and APs are the enzymes which degrade extracellular AMP 
to adenosine with Pi (Lazarowski et al., 2003a,b; Joseph et al., 2004). The 
eNDPKs facilitate the synthesis of ATP via catalysing the phosphorylation of 
extracellular ADP to ATP using nucleotide triphosphates, such as UTP or 
guanosine-5'-triphosphate (GTP), as substrates (Figure 1.7) (Yegutkin et 
al., 2001, 2002). 
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Figure 1.7. A schematic representation of the effect of ecto-nucleotidase 
enzymes on the extracellular nucleotides and nucleotide sugars (ATP, UDP 
and ADP, UDP-glucose). Following extracellular release ATP, UDP and UDP-
glucose are broken down by ecto-nucleotide triphosphate 
diphosphohydrolase family (eNTPDase) or ecto-nucleotide 
pyrophosphatases (eNNPs). AMP is broken down to adenosine (Ado) by 
GPI-anchored alkaline phosphatases (APs). ATP is re-synthesised by the 
activity of ecto-nucleotide diphosphokinases (eNDPKs) mediated by de 
novo ATP synthesis. ǃǄ-meATP, suramin and PPADS are inhibitors of 
eNTPDase and eNNPs. Arrows represent positive influences, while dotted 
arrows represent the negative influence. Figure is based on data from 
Zimmermann (2000) and Joseph et al. (2004). 
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1.8. Functional expression of P1 and P2 
receptors in the vasculature 
 
The expression of P2Y1, P2Y2, P2Y6 and P2X4 receptors on the vascular 
endothelial cells and P2Y2, P2Y4, P2Y12, P2X1 and P2X7 receptors on 
vascular smooth muscle has been documented (Figure 1.8) (see review by 
Erlinge & Burnstock, 2008). ATP can induce vasoconstriction or 
vasorelaxation, following activating purine or pyrimidine receptors 
expressed on the vascular smooth muscle or on the vascular endothelial 
cells (Burnstock, 1988). The vasoconstriction induced by ATP was shown to 
be mediated mainly by P2X1 receptors as seen in mesenteric arteries (Vial 
& Evans, 2002), rabbit saphenous arteries (Ramme et al., 1987) and renal 
vasculature (Chan et al., 1998; Inscho et al., 2004). Likewise, other 
nucleotides are able to elicit a vasoconstriction in a variety of arteries, 
including UTP and UDP activating P2Y2 and P2Y6 receptors respectively, 
expressed on the vascular smooth muscle cells (VSMCs) (Figure 1.8) 
(Malmsjo et al., 2000). Besides, ADP was reported to induce a contraction 
of human mammary arteries via activating P2Y12 receptors present on the 
VSMCs (Wihlborg et al., 2004). 
The vasorelaxation induced by ATP was shown to be mediated by 
endothelial P2Y1, P2Y2 and P2X4 receptors (Figure 1.8) (Wang et al., 
2002). In addition, other nucleotides were able to induce a relaxation, 
including UTP, UDP and ADP via acting at endothelial P2Y2, P2Y6, P2Y4 or 
P2Y1 receptors (Figure 1.8) (Ralevic et al., 1991b; Wang et al., 2002; 
Wihlborg et al., 2003). The mechanism by which the nucleotides induce 
vasorelaxation involve the release of endothelial derived relaxing factors 
(EDRFs) or prostacyclin (PGI2). Alternatively, vasorelaxation can be 
triggered by the release of endothelium-derived hyperpolarising factors 
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(EDHFs), which relax the smooth muscles by activating potassium channels 
followed by a hyperpolarisation (Malmsjo et al., 1998; Mistry et al., 2003). 
P1 receptors are expressed throughout the vasculature with the adenosine 
as an endogenous ligand (Burnstock, 1978). A2A or A2B receptors can be 
found on the vascular endothelial cells or smooth muscle (Schulte & 
Fredholm, 2003), the activation of these receptors results in vasodilatation 
in a number of vessels (Figure 1.8) (Belardinelli et al., 1996; Ongini et al., 
1996; Conti et al., 1997; Feoktistov & Biaggioni, 1997; Kemp et al., 1999; 
Olanrewaju et al., 2000). Activation of A1 adenosine receptors leads to an 
elevation in intracellular calcium in airway smooth muscle cells resulting in 
airway constriction (Figure 1.8) (Zhou et al., 2013). Activation of A3 
receptors in mice aorta induced an endothelium-dependent contraction 
involving an increase in the level of cyclooxygenase (Ansari et al., 2007). 
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Figure 1.8. A schematic representation of P1 and P2 receptor-mediated 
regulation of the circulation. Extracellular ATP, UDP, ADP and UTP can act 
at P2 receptors expressed on the endothelial cells (ECs) or vascular smooth 
muscle cells (VSMCs) to elicit a vasorelaxation or a vasoconstriction 
respectively. Similarly, adenosine (Ado) can act on P1 receptors expressed 
on the EC or VSMC to elicit a vasorelaxation or a vasoconstriction 
respectively. Arrows represent positive influences. Figure is based on data 
from Erlinge & Burnstock, 2008. 
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1.9. The pancreas (overview) 
 
The pancreas is a glandular organ (endocrine and exocrine gland) which 
lies below the stomach, above the first loop of the duodenum, between the 
spleen on the left and the duodenum on the right (Sherwood, 1997). The 
length of the human pancreas is approximately 12-15 cm and its weight is 
approximately 60-100 g (Schaefer, 1926), while the porcine pancreas 
weight is 190-698 g (Ferrer et al., 2008). The pancreas consists of four 
parts: the head, the uncinate process, the neck and the tail (Figure 1.6, 
inset) (see review by Woodburne & Olsen, 1951). The pancreas is 
composed of exocrine and endocrine cells; the exocrine cells surround the 
endocrine cells. Its bulk varies depending on the species, and in rodents, it 
comprises 70-90% of acinar cells plus 5-25% of duct cells (Naya et al., 
1997). Exocrine cells secrete a pancreatic juice consisting of the enzymatic 
secretion which includes lipase, D-amylase, colipase, carboxyl ester lipase, 
DNAse and RNAse and some other proteins including trypsin inhibitor, 
which play a significant role in digestion. These enzymes are secreted from 
the acinar cells. In addition, exocrine cells secrete an aqueous alkaline 
solution, which is secreted by the pancreatic ducts, and allows optimal 
functioning of the pancreatic enzymes (Sherwood, 1997). 
The islet endocrine cells constitute only 1-2% of the pancreas bulk (Naya 
et al., 1997; Novak, 2008), these cells consist of isolated islands of 
endocrine tissues which are called the islets of Langerhans. These tissues 
are clusters of cells scattered throughout the pancreas and composed of D, 
ǃ, įand F cells. In rat and mouse, E-cells constitute 60-80% of the bulk of 
the islet and they are located in the islet core, while the remaining 
endocrine cells are dispersed at the periphery of the islet (Naya et al., 
1997). In human, the D- and į-islets are not confined to the islet 
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periphery, rather they are dispersed throughout the islets (Dubois et al., 
2000). Islet cells secrete several hormones: glucagon is secreted from D-
cells, and insulin and amylin are secreted from ǃ-cells (more details about 
insulin are provided in section 1.12). The effects of insulin and glucagon 
are opposing, while an elevation in glucose concentration suppresses 
glucagon secretion, it promotes insulin secretion (Ohneda et al., 1969). 
Somatostatin is released from į-cells; its role is to regulate the secretion of 
both insulin and glucagon, since į-cell somatostatin was shown to evoke a 
tonic inhibitory effect on glucagon and insulin secretion (Hauge-Evans et 
al., 2009). In addition, somatostatin exerts its effect by inhibiting the 
digestion of nutrients and decreasing nutrient absorption (Sherwood, 
1997). Pancreatic polypeptide is secreted from endocrine F-cells (Ekblad & 
Sundler, 2002), it has been reported to have an influence on hunger, and 
energy balance, since it slows down the gastrointestinal motion of chyme 
and reduces further food intake, hence pancreatic polypeptide can modify 
metabolic and energy homeostasis (Holzer et al., 2012). In addition, there 
is some evidence for the expression of ܭ-cells in the islet which are ghrelin-
producing (see review by Gittes, 2009). 
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Figure 1.9: Gross structure of the pancreas (inset), General pattern of arterial supply of the pancreas (main), 
hand drawn figure, information is based on data from Woodburne & Olsen, 1951. 
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1.10. The arterial blood supply of the pancreas  
 
The pancreas is supplied by the blood mainly via three sources: the 
splenic, hepatic and superior mesenteric arteries (Figure 1.9, main), and 
drains into the portal vein (see reviews by Bonner-Weir, 1993; Bertelli et 
al., 1998). Two double arterial branches (posterior superior and anterior 
superior pancreaticoduodenal arteries) provide the head of the pancreas 
and the uncinate process with the blood supply (see review by Woodburne 
& Olsen, 1951), in addition to two inferior pancreaticoduodenal arteries 
(posterior and anterior) (Figure 1.9, main). The superior and inferior 
pancreaticoduodenal arteries branch originally from the gastroduodenal 
artery and the superior mesenteric artery respectively (Figure 1.9, main) 
(Woodburne & Olsen, 1951).  
One of the major arteries among the pancreatic arteries designated as the 
dorsal pancreatic artery, is also called the superior pancreatic artery 
(Bertelli et al., 1998). The dorsal pancreatic artery supplies the neck and 
the body of the pancreas with blood. It branches originally from the splenic 
artery and it is considered as one of the largest vessels leaving the splenic 
artery (Figure 1.9, main) (Vandamme & Bonte, 1986). It descends to the 
lower border of the pancreas and it is divided into two branches (right and 
left branches). The right branch of the dorsal artery appears on the surface 
of the pancreas close to the neck and to the uncinate process; this branch 
provides the head of the pancreas with blood (Figure 1.9, main), as well as 
forming an anastomosis with the little left branch of the anterior superior 
pancreaticoduodenal artery. The left branch of the dorsal pancreatic artery 
forms the inferior pancreatic artery which runs through the inferior border 
of the body of the pancreas and anastomoses with the caudal pancreatic 
artery and with the pancreatica magna artery (Figure 1.9, main) 
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(Woodburne & Olsen, 1951). This latter artery (pancreatica magna artery) 
is a branch of splenic artery, and it accesses the pancreas at approximately 
the junction of the middle and left thirds of the gland. Then it sends 
branches to right and left sides of the pancreas which are oriented along 
the main pancreatic duct (Figure 1.9, main) (Woodburne & Olsen, 1951). 
The tail of the pancreas is provided with its blood supply by means of the 
caudal pancreatic artery which is also a branch of the splenic artery (Figure 
1.9, main). It anastomoses with the dorsal pancreatic artery and 
pancreatica magna artery (Bertelli et al., 1998). 
The microvasculature of the pancreas is supplied from anastomosing 
arteries derived from the hepatic and superior mesenteric arteries. These 
arteries form arcades within the glands from which smaller branches are 
produced as interlobular arteries (Bockman, 1992). Then the interlobular 
arteries branch further to form the intralobular arterioles, which supply the 
lobules of exocrine and endocrine tissues with blood. It has been found 
that the proportion of blood going to islets is approximately 10% of the 
pancreatic blood (Jansson & Hellerstrom, 1983) indicating that the blood 
flow to the endocrine tissues (expressed as flow per unit weight) is 10 
times greater than that of the exocrine tissues (Bockman, 1992). The islet 
blood flow is regulated by hormonal, nervous and nutrient signals which 
are produced in the islets or in distal tissues (Ballian & Brunicardi, 2007). 
The islets of Langerhans are embedded in a dense capillary network, and 
one to five arterioles per islet supply the endocrine pancreas, these 
arterioles branch into capillaries and form a spherical framework with 
structural similarities to a glomerulus (Jansson et al., 2002; Zanone et al., 
2005), and then these arterioles exit the islets as veins (Ballian & 
Brunicardi, 2007). 
Chapter 1 
General introduction 
 
39 
 
1.11. The role of the blood supply on pancreatic 
function 
 
Pancreatic blood vessels deliver proper gas exchange and nutrients to the 
pancreas. Besides, most secretory stimuli, which are carried by the blood, 
should diffuse rapidly into the endocrine tissues to reach their targets 
(Schaeffer et al., 2011). In addition, the blood takes up the secreted islet 
hormones to deliver them to target tissues and they are also involved in 
secretion of these hormones into the blood stream and in elimination of 
wastes from pancreatic cells (Cabrera et al., 2006; Eberhard et al., 2010). 
The relationship between the pancreatic exocrine and endocrine secretion 
and blood flow has been well documented (Goodhead et al., 1970; Sendur 
& Pawlik, 1994; Schaeffer et al., 2011; Cleaver & Dor, 2012). For example, 
the pancreatic islets are embedded in a very dense microvascular network; 
this network has been shown to play a significant role in endocrine cells 
during secretory episodes (Eberhard et al., 2010). Therefore, the release of 
vasoactive substances most likely play a pivotal role to compensate for the 
deficit of the oxygen level due to the higher metabolic demand (Schaeffer 
et al., 2011,QSDQFUHDWLFLVOHWVERWKHQGRWKHOLDOFHOOVDQGǃ-cells express 
nitric oxide synthase (NOS) (Corbett et al., 1992), and nitric oxide (NO) 
influences the regulation of the islet blood flow and the hormone secretion 
(Salehi et al., 1996). It was shown that administration of glucose doubled 
the islet perfusion to promote the insulin influx into the circulation, as well 
as many abnormalities of islet blood flow regulation have been identified in 
animal models of diabetes mellitus and impaired glucose tolerance, 
indicating that the deregulation of islet perfusion could contribute to islet 
dysfunction (Ballian & Brunicardi, 2007). Although the microvascular 
network in exocrine tissues was shown to be almost two- to three-fold less 
dense than that in endocrine tissues, it was reported that drugs which 
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decreased the pancreatic tissue blood flow were able to inhibit exocrine 
pancreatic secretion, this indicates the importance of the blood flow in 
regulating the pancreatic exocrine functions as well as the endocrine 
functions (Sumi et al., 1991; Schaeffer et al., 2011). 
 
1.12. Insulin 
 
Insulin plays a major role in glucose homeostasis. Human insulin is a 
peptide hormone which has molecular weight of approximately 6,000 
Daltons and contains 51 amino acids. The mature insulin molecule consists 
of two polypeptide chains designated as A and B which are linked by two 
pairs of disulfide bonds (Melloul et al., 2002; Steiner et al., 2009). Insulin 
is stored in the secretory granules with proinsulin which has an additional 
polypeptide (C-peptide) (Figure 1.10). Proinsulin is converted to insulin in 
the Golgi complex via specific proteases (Steiner et al., 2009). The 
pathway in which the insulin is biosynthesised is shown in Figure 1.10. 
Proinsulin is produced from preproinsulin by cleaving the signal peptide 
(green bar) in the endoplasmic reticulum. Proinsulin, similar to 
preproinsulin, contains a connecting domain (the C-domain) (red bar) 
which connects A and B chains (black and blue respectively). Proinsulin 
undergoes folding in the ER, with the formation of three pairs of disulfide 
bridges, which are necessary for stability and bioactivity (Narhi et al., 
1993). Proinsulin is an inactive hormone which reacts weakly with insulin 
receptors. In order to obtain the active hormone (insulin), the C-peptide 
domain in proinsulin needs to be cleaved away by employing the 
proteolytic enzymes in the Golgi apparatus (Figure 1.10). The bioactive 
hormone is stored as Zn2+-stabilised hexamers (6× insulin: 2× Zn2+) in the 
secretory granules. When insulin hexamers are secreted into the 
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circulation, they dissociate to yield insulin monomers which are bioactive 
and bind strongly to the insulin receptors (Weiss, 2009). 
Insulin exerts its effect by binding to insulin receptors. These receptors are 
expressed on many cells including those of the liver, fat and skeletal 
muscles (see review by Fritsche et al., 2008). The primary effect of insulin 
is to regulate the clearance of glucose from the circulation which occurs by 
insulin-induced increase of glucose uptake by skeletal muscle (Gerich et 
al., 1974). In addition, insulin promotes glycogenesis by acting on the liver 
(Aronoff et al., 2004; Fritsche et al., 2008). Insulin also inhibits glucagon 
secretion from D-cells which results in glycogenolysis inhibition (Ohneda et 
al., 1969; Aronoff et al., 2004). Insulin is involved in other actions 
including activation of fat synthesis, simulation of triglyceride storage in fat 
cells, stimulation of the synthesis of the protein in the liver or skeletal 
muscles and inducing cell proliferation and differentiation (Cryer, 1992; 
Fritsche et al., 2008). 
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Figure 1.10: A schematic representation of the conversion of preproinsulin 
to proinsulin and then to insulin and C-peptide by prohormone convertases 
1 and 2 (PC1, PC2) and carboxypeptidase E (CPE). The conversion of 
preproinsulin to folded proinsulin occurs in the endoplasmic reticulum (ER), 
while production of insulin by the cleavage of C-peptide domain occurs in 
the Golgi apparatus via the activity of proteolytic enzymes.  
 
1.13. Glucose-stimulated insulin secretion 
(GSIS) 
 
Numerous nutrients can act as insulin secretagogues, including glucose, 
some amino acid and free fatty acids. However, glucose is the most potent 
secretagogue, since it promotes robust insulin release within a few minutes 
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following its administration, and its stimulatory effect lasts as long as the 
glucose level in the plasma is elevated. The current section will investigate 
briefly the pathways in which glucose stimulates insulin secretion from islet 
ǃ-cells. 
)ROORZLQJDGPLQLVWUDWLRQRIJOXFRVHLQVXOLQVHFUHWLRQIURPSDQFUHDWLFǃ-cell 
is elevated, involving mainly two signalling pathways: the KATP channel-
dependent and KATP channel-independent pathways. It has been reported 
that GSIS is biphasic (Curry et al., 1968). The first peak obtained after 4-8 
min is followed by a nadir in release. Following the nadir in secretion, the 
second phase occurs in which there is a gradual elevation of the rate of the 
insulin release reaching its peak after a further 25-30 min (see reviews by 
Straub & Sharp, 2002; Henquin et al., 2006a,b). 
 
1.13.1. ATP-sensitive potassium channel-dependent 
(KATP) insulin secretion 
 
7KHǃ-cell KATP channels play an essential role in GSIS. In the absence of 
substimulatory glucose concentrations (<8 mM), the membrane potential 
RI WKH ǃ-cell is -60 to -70 mV (Rorsman, 1997). When plasma glucose 
concentration increases above the threshold (2-4 mM) (Henquin et al., 
2006a), glucose enters WKH ǃ-cells via the glucose transporters (GLUTs) 
GLUT2, GLUT1 or GLUT3 (De Vos et al., 1995) (Figure 1.11). Glucose may 
then be phosphorylated to glucose-6-phosphate which is then catabolised 
to pyruvate. The latter is subsequently decarboxylated to acetyl-Coenzyme 
A (Ac-CoA). Ac-CoA then may be metabolised within the mitochondria to 
generate ATP which elevates the ratio of cytosolic ATP/ADP (MacDonald et 
al., 1991; Srivastava & Goren, 2003). High levels of ATP will result in an 
inhibition of KATP channels which increases the intracellular [K
+]. The high 
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level of K+ will result in depolarisation of ǃ-cell membrane potential and 
subsequently opening of the voltage-dependent Ca2+ channels, which 
induce Ca2+ influx, thus triggering insulin granule exocytosis (Smith et al., 
1990) (Figure 1.11). Subsequently, the high intracellular Ca2+ activates the 
voltage-dependent K+ channel, which will result in repolarisation of the 
membrane potential of ǃ-cells, subsequently the insulin secretion may be 
reduced (Smith et al., 1990; Rorsman, 1997) (Figure 1.11).  
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Figure 1.11. A schematic representation of KATP channel-dependent 
signalling. The facilitative glucose transporters 1/2/3 (GLUT1/2/3) 
mediate glucose entry. The metabolism of glucose induces production of 
ATP, following a production of Acetyl-coenzyme A (Ac-CoA). ATP inhibits 
the KATP channel. Closure of which UHVXOWV LQ GHSRODULVDWLRQ RI WKH ǃ-cells 
membrane potential and then opening of the voltage-dependent Ca2+ 
channel, which induces Ca2+ influx. The high level of intracellular Ca2+ 
triggers insulin granule exocytosis. Subsequently, Ca2+ will activate 
voltage-dependent K+ channel which induces repolarisation of the 
PHPEUDQHV SRWHQWLDO RI ǃ-cells and inhibits further insulin release. Some 
P2Y receptors can activate the cAMP pathway, which triggers the insulin 
secretion. Arrows represent positive influences, while dotted arrows 
represent the negative influence. Figure is based on data from Tipparaju et 
al. 2007; Novak, 2008;  Burnstock & Novak, 2012. 
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1.13.2. ATP-sensitive potassium channel-independent 
(KATP) insulin secretion 
 
It has been suggested since 1992 that glucose is able to stimulate insulin 
secretion in both mouse and rat via a second pathway other than KATP 
channel-dependent signalling (Best et al., 1992; Gembal et al., 1992). This 
effect was observed when the KATP channel was clamped open in the 
presence of an activator of KATP channels, diazoxide. It was found that 
glucose was still able to induce an insulin secretion. The mechanisms 
underlying the KATP channel-independent signalling are discussed in detail 
in reviews by Straub & Sharp, 2002; Jitrapakdee et al. 2010.  
In summary, glucose-induced insulin secretion through the KATP channel-
dependent pathways was shown to be involved in the mechanisms 
underlying the first phase of insulin secretion (section 1.13) (see review by 
Straub & Sharp, 2002). Whereas, the second phase of insulin secretion is 
induced by the KATP channel-independent pathways (Taguchi et al., 1995), 
which produces an amplifying signal maintaining a long-lasting second 
phase of insulin release (Gembal et al., 1992). 
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1.14. Aims and objectives 
 
The aims of the current study were to investigate the functional expression 
of the P1 and P2 receptors in porcine isolated pancreatic artery, since the 
roles of these receptors are not well characterised in these arteries. The 
present study focused on the last member of P2Y receptor family, namely 
the P2Y14 receptor, since the role of this receptor in the cardiovascular 
system is novel, and it has not been addressed previously, although, it was 
shown previously that P2Y14 mRNA and protein are present in the heart and 
the blood vessels. Therefore, the primary aim of this study was to examine 
the functional expression of this receptor in porcine pancreatic artery as 
well as identifying the signalling pathways underlying the responses to 
P2Y14 receptor agonists in these arteries. 
The study aimed also to examine the effects of P2Y14 receptor agonists on 
insulin secretion from the pancreas. Therefore, the effects of UDP-glucose 
and MRS2690 on insulin secretion from rat INS-ǃ-cells and from 
rat isolated islets of Langerhans were indentified in the current study, to 
obtain a comprehensive view about the roles of the P2Y14 receptor in the 
pig pancreas, since it is more closely related to that of man. 
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Investigation of the effects of ATP, DE-
meATP, UTP, MRS2768 and ADP on 
vascular tone in porcine isolated 
pancreatic arteries 
 
2.1. Introduction 
 
There are two main families of purine and pyrimidine receptors: ionotropic 
P2X and G protein-coupled P2Y receptors (section 1.4.2). Molecular cloning 
has identified seven mammalian P2X-receptor subunits: P2X1, P2X2, P2X3, 
P2X4, P2X5, P2X6 and P2X7 receptors (Khakh et al., 2001), while eight 
mammalian P2Y receptors have been identified: P2Y1, P2Y2, P2Y4, P2Y6, 
P2Y11, P2Y12, P2Y13 and P2Y14 receptors (Abbracchio et al., 2006). P2X 
receptors are activated by ATP and its stable analogue, DE-meATP 
(Kasakov & Burnstock, 1982; Burnstock, 2006b). P2Y receptors can be 
subdivided on the basis of their endogenous agonists into adenine 
nucleotide-preferring (P2Y1, P2Y11, P2Y12 and P2Y13 receptors) and uracil 
nucleotide or UDP-sugar-preferring (P2Y2, P2Y4, P2Y6 and P2Y14 receptors) 
(section 1.4.2.2) (Kügelgen, 2008). Among the adenine nucleotide group, 
the human P2Y11 receptor is activated by ATP and DE-meATP but it fails to 
respond to ADP (Communi et al., 1997), although the dog orthologue 
responds to both ADP and ATP (Qi et al., 2001; Kennedy et al., 2013). 
P2Y1, P2Y12, and P2Y13 receptors are activated by ADP and, with lower 
potency, by ATP (Léon et al., 1997; Bodor et al., 2003; Marteau et al., 
2003; Waldo & Harden, 2004). Among the uracil nucleotide or UDP-sugar 
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receptors, the P2Y2 receptor is equally activated by ATP and UTP, while the 
P2Y4 receptor is highly selective for UTP over ATP (Nicholas et al., 1996). 
The P2Y6 receptor is activated by UDP and UTP, while the P2Y14 receptor is 
activated by UDP and UDP-sugars (Burnstock, 2006b; Carter et al., 2009).  
Within the pancreatic vasculature, P2X1, P2X2, P2Y1, P2Y2 and P2Y4 
receptors were detected by immunohistochemistry (Coutinho-Silva et al., 
2001; Coutinho-Silva et al., 2003). More than two decades ago, it was 
shown that P2X receptors mediate pancreatic artery vasoconstriction and 
P2Y receptors mediate vasodilatation in response to ATP in perfused rat 
pancreas, this effect was shown by using P2X receptor desensitising agent 
or P2Y receptor antagonist respectively  (Hillaire-Buys et al., 1991), and 
subsequent studies showed an additional involvement of contractile 
receptors sensitive to UTP (named P2U receptors) (Hillaire-Buys et al., 
1999). Purine and pyrimidine receptor sub-classification has advanced 
significantly since that time. A re-evaluation of purine receptors in the 
pancreatic vasculature is clearly warranted. In the current study, I 
characterised pharmacologically P2Y1 and A2A receptor-mediated relaxatory 
responses, in addition to P2X1, P2Y2 and/or P2Y4 receptor-mediated 
contractile responses, of porcine isolated pancreatic artery preparations. 
P2Y2 and/or P2Y4 receptors appear to be expressed mainly on the vascular 
endothelial cells, while P2X1 and A2A receptors appear to be expressed on 
the smooth muscle cells of the pancreatic arteries. 
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2.2. Materials and methods 
 
2.2.1. Tissue preparation 
 
Pancreata from pigs (either sex, age less than 6 months, weight ~50 kg) 
were obtained on ice from a local abattoir (G Wood & Sons Ltd, Mansfield). 
A crude dissection was conducted to isolate the pancreatic artery (the 
dorsal pancreatic artery) which was located in the body of the pancreas 
(Figure 1.9, main). The vessels were dissected out and placed in .UHEV¶-
Henseleit buffer (section 2.2.3) containing 2% (w/v) Ficoll (type 70) and 
refrigerated overnight at 4ºC. The next day, a fine dissection was 
performed, and the arteries were cut into rings of 0.5 cm in length, ~1.5-2 
mm inner diameter and ~0.5 mm thickness, and suspended between two 
supports (wires), in organ baths containing .UHEV¶-Henseleit buffer 
maintained at 37ºC (gassed constantly, 95% O2, 5% CO2). The lower wire 
was inserted through the lumen of the arterial ring and attached to a glass 
rod and placed in the organ bath, with the upper wire which was also 
inserted through the lumen and connected to the transducer for isometric 
recording (Figure 2.1). The whole setup was linked to a Maclab data 
acquisition system (AD Instruments Ltd., Hastings, UK) via an amplifier. 
The endothelium of some arteries was removed by gently rubbing the 
lumen with forceps before attaching the vessels to the setup (Rayment et 
al., 2007b). Successful removal of endothelium was tested using substance 
P (10 nM). Endothelium-denuded arteries relaxed in response to substance 
P to less than 10% of the U46619 (a thromboxane A2 mimetic)-induced 
contraction, while in endothelium-intact arteries the relaxation to 
substance P was 36% ± 8 (n=7). 
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Figure 2.1. Diagrammatic representation of an isometric set up including 
(1) transducer, (2) a thin thread attached to a thin wire (upper support), 
(3) gas tube supplying 95% O2: 5% CO2, (4) blood vessel mounted 
between upper and lower wire supports, (5) glass tissue holder, (6) organ 
bath, (7) .UHEV¶-Henseleit buffer, (8) thin wire (lower support) attached to 
a tissue holder, (9) drain, and (10) base. 
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2.2.2. Responses in porcine isolated pancreatic arteries 
 
Arterial rings were mounted onto wires in tissue baths (20 ml) containing 
warmed (37oC) R[\JHQDWHG.UHEV¶-Henseleit solution and were connected 
via isometric force transducers (ADInstruments, Sydney, Australia) to a PC 
running the computer program LabChart (ADInstruments, Sydney, 
Australia). Rings were put under tension (15 g) and allowed to equilibrate 
for 60 min, before assessing viability with two challenges of 75 mM 
potassium chloride (KCl). The tissues were then allowed to equilibrate for 
60 min, after which U46619 (10-100 nM) was used to contract the tissues 
to 40-80% of the second KCl response. This ensured that if there was a 
vasodilator component to the response, for example, due to activation of 
multiple P2 receptor subtypes, this could be detected. Once an appropriate 
level of U46619 response had been achieved, ATP, DE-meATP, UTP, ADP or 
MRS2768 were applied. Antagonists, inhibitors or desensitisation agents 
[suramin (100 µM), PPADS (10 µM), DE-meATP (1 µM), UTP (1 µM), ATP (1 
µM), NF449 (10 µM), xanthine amine congener (XAC) (10 µM), MRS2578 
(10 µM), DUP 697 (5-bromo-2-(4-fluorophenyl)-3-[4-
(methylsulfonyl)phenyl]-thiophene) (3 µM), MRS2179 (10 µM), SCH58261 
(1 µM)] were applied 10 min prior to the addition of U46619, allowing 
incubation with the tissues for a minimum of 30 min prior to the application 
of agonists. In experiments using dimethyl sulfoxide (DMSO) as the solvent 
(see reagents and drugs section 2.2.3), DMSO 0.1 % (v/v) was added to 
the arteries as vehicle controls. 
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2.2.3. Reagents and drugs 
 
.UHEV¶-Henseleit buffer was composed of the following (mM): NaCl 118, KCl 
4.8, CaCl2.H2O 1.3, NaHCO3 25.0, KH2PO4 1.2, MgSO4.7H2O 1.2 and glucose 
11.1. Suramin, UTP, ATP, DE-meATP, ADP, U46619, XAC, and SCH58261 
were purchased from Sigma (Poole, Dorset, UK), while DUP 697, PPADS, 
MRS2578, MRS2179, MRS2768 and substance P were purchased from 
Tocris Biosciences Ltd. (Bristol, UK). NF449 was purchased from 
Calbiochem-Merck Biosciences (Darmstadt, Germany). U46619 was 
dissolved in ethanol at 10 mM stock concentration. PPADS, suramin, DE-
meATP, ATP, ADP, UTP, NF449, MRS2179, MRS2768 and substance P were 
dissolved in distilled water. DUP 697, XAC, MRS2578 and SCH58261 were 
dissolved in DMSO at 10 mM stock concentration.  
 
2.3. Statistical analysis 
 
The contractions to ATP, Dǃ-meATP and UTP were measured from the 
stabilised U46619-induced response and were expressed in g, while the 
relaxations to ATP and ADP were expressed as a percentage of the 
U46619-induced contraction. Data were expressed as log concentration-
response plots. Values for all figures refer to mean ± S.E.M with 95% 
confidence. Results were compared by two-way analysis of variance 
(ANOVA) or one-ZD\$129$ ZLWK %RQIHUURQL¶V Sost hoc test or unpaired 
6WXGHQW¶Vt-test (Prism, GraphPad, San Diego, CA, USA). Differences were 
considered to be significant when the P value was < 0.05. 7KH³Q´ in the 
results expresses the number of animals. 
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2.4. Results 
 
2.4.1. Effect of purine and pyrimidine nucleotides on 
vascular tone in porcine isolated pancreatic 
arteries 
 
To investigate the effects of purine and pyrimidine receptor agonists on 
porcine pancreatic arteries, DE-meATP (10 nM to 100 µM), ATP (1 µM to 10 
mM), UTP (10 µM to 1 mM), ADP (1 µM to 1 mM) and MRS2768 (100 nM to 
30 µM) were applied after pre-constriction with U46619. The responses to 
ATP and DE-meATP were found to desensitise rapidly. Therefore, they were 
applied at single concentrations (one concentration per tissue segment). 
The responses to UTP, ADP and MRS2768 did not desensitise rapidly, thus 
cumulative concentration-response curves were generated. ATP, DE-
meATP, UTP and MRS2768 induced concentration-dependent contractions 
with a potency order of DE-meATP > MRS2768 > 873  ATP (two-way 
ANOVA; Figure 2.2A), [(mean EC50 value for DE-meATP was 1.6 µM (95% 
confidence interval (CI): 1.05 to 2.53 µM; n=8; it was 0.5 mM (95% 
confidence interval (CI): 0.1 to 1.8 mM; n=7 for ATP; Figure 2.2A). The 
response to ATP was biphasic, since its contraction was followed by a 
relaxation (Figure 2.2B) which was equipotent to the concentration-
dependent relaxation induced by ADP (Figure 2.2A). The Rmax value of DE-
meATP in inducing contraction of pancreatic artery was 9.3 ± 0.2g. The 
efficacy of ATP in inducing contraction was similar to that of DE-meATP, and 
it was greater than those of, of UTP or MRS2768. The relaxations to ADP 
and ATP at the highest concentration of the agonists used (1 mM) were 
similar at 4.5 ± 0.5g (n=10) and 5.5 ± 0.2g (n=7) respectively; there was 
no significant difference between these responses (Figure 2.2A). UTP, 
MRS2768 and DE-meATP (Figure 2.2B) did not elicit vasorelaxation. 
Chapter 2 
Effects of ATP, Dǃ-meATP, UTP & ADP on vascular tone 
 
56 
 
 
 
Figure 2.2. (A) Concentration-dependent contractions of ATP, DE-meATP, 
UTP and MRS2768, a selective P2Y2 receptor agonist, and concentration-
dependent relaxation of ADP and ATP in U46619-preconstricted porcine 
pancreatic arteries (n=7-12). (B) Typical traces showing the biphasic 
response to ATP (contraction followed by relaxation) on the left hand side, 
as well as the monophasic response to DE-meATP (just contraction) on the 
right hand side. 
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2.4.2. Characterisation of responses to ATP and DE-
meATP in U46619-preconstricted porcine isolated 
pancreatic arteries 
 
2.4.2.1. Effect of suramin, PPADS and DE-meATP 
 
Responses to ATP and DE-meATP were characterised using the non-
selective P2 receptor antagonists, suramin (100 µM) and PPADS (10 µM). 
Both suramin and PPADS significantly attenuated the contractions-evoked 
by ATP (1 mM) and DE-meATP (1 µM) (P < 0.01, one-way ANOVA, Figure 
2.3A, B). These concentrations of ATP and DE-meATP were chosen since 
they produced robust, submaximal responses and were close  to the EC50s 
(section 2.4.1). The relaxation to ATP was not affected in the presence of 
suramin or PPADS (Figure 2.3C). Since DE-meATP induces desensitisation 
of P2X1 and P2X3 receptors more readily than ATP because it is broken 
down more slowly than ATP (Kasakov & Burnstock, 1982; Ralevic & 
Burnstock, 1998; Coddou et al., 2011), the responses to ATP and DE-
meATP were studied in the presence of DE-meATP, in which DE-meATP (1 
µM) was added 10 min prior to the addition of U46619 (section 2.2.2). As 
seen in Figure 2.3A, and 2.3B, the contractions to ATP and DE-meATP were 
reduced significantly in the presence of the desensitising agent (P < 0.001, 
one-way ANOVA, Figure 2.3A, B), while the relaxation to ATP was not 
affected (Figure 2.3C), indicating involvement of P2X1 or P2X3 in the 
contractions to ATP and DE-meATP in the porcine pancreatic arteries. 
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Figure 2.3. Effects of suramin (100 µM), PPADS (10 µM) and 
desensitisation by DE-meATP (1 µM) on contractions to (A) ATP (1 mM), (B) 
DE-meATP (1 µM), (C) on the relaxation to ATP in U46619-preconstricted 
porcine pancreatic arteries. PPADS, suramin and DE-meATP reduced the 
contractions of (A) ATP and (B) DE-meATP (**P < 0.01, ***P < 0.001, 
one-way ANOVA with BonIHUURQL¶VSRVWKRF WHVW UHVSRQVHVRI$73RUDE-
meATP vs their responses in the presence of PPADS, suramin or DE-meATP, 
n=6-9). (C) The relaxations to ATP were not significantly different in the 
absence or in the presence of PPADS, suramin or DE-meATP (n=7).  
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2.4.2.2. Effect of NF449, a selective P2X1 receptor antagonist  
 
Contractile response to DE-meATP suggests an expression of P2X1 
receptors in pancreatic arteries (Figure 2.3B). In turn, the involvement of 
P2X1 receptors in the contraction to ATP seems likely because contraction 
was significantly blocked by DE-meATP (Figure 2.3A), since P2X3 receptor 
is not expressed in the VSMCs of the blood vessels (see review by 
Burnstock et al., 2010). The responses to ATP and DE-meATP were 
examined further in the presence of NF449 (10 µM), a P2X1 receptor 
selective antagonist (IC50 value of 1.6 µM in large rat pulmonary arteries) 
(Rettinger et al., 2005; Syed et al., 2010). The contractions to ATP and DE-
meATP were significantly inhibited in the presence of NF449 (P < 0.001, 
XQSDLUHG6WXGHQW¶Vt-test, Figure 2.4). 
 
 
 
 
Chapter 2 
Effects of ATP, Dǃ-meATP, UTP & ADP on vascular tone 
 
60 
 
 
Figure 2.4. Effect of NF449 (10 µM), a selective P2X1 receptor antagonist, 
on contractions to (A) ATP (1 mM), (B) DE-meATP (1 µM) in U46619-
preconstricted porcine pancreatic arteries. NF449 reduced the effects of (A) 
ATP, (B) DE-meATP (***P < 0.001, XQSDLUHG6WXGHQW¶Vt-test, n=10-13). 
 
2.4.2.3. Effect of endothelium removal 
 
The response to ATP was examined after the endothelium had been 
removed. The contraction and the relaxation induced by 1 mM ATP (Figure 
2.5A, B) and the contraction to 1 µM DE-meATP (Figure 2.5C) were not 
significantly different in the absence or presence of the endothelium (P > 
0.05, XQSDLUHG6WXGHQW¶Vt-test). Similarly, removal of the endothelium had 
no effects on the contractions to KCl or U46619; for example, the 
contraction to 75 mM KCl was 9.5 ± 0.5g in endothelium-intact arteries, 
while it was 9 ± 0.5g in endothelium-denuded arteries (n=7-9). The 
contraction to 10-100 nM U46619 was 5.5 ± 0.5g in endothelium-intact 
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arteries, while it was 5.8 ± 0.6g in endothelium-denuded arteries (n=12-
14); there was no significant difference between these responses. On the 
other hand, as can be seen in Figure 2.5A, the contraction to ATP in 
endothelium-denuded pancreatic arteries was reduced slightly (but not 
significantly) relative to its contraction in endothelium-intact arteries 
(Figure 2.5A), indicating involvement of other receptors (P2Y receptors). 
 
 
 
Figure 2.5. Effect of removal of the endothelium on (A) contraction, (B) 
relaxation to ATP (1 mM), (C) contraction to DE-meATP (1 µM) in U46619-
preconstricted porcine pancreatic arteries. (A), (B), (C) The removal of the 
endothelium had no significant effect on the contraction or relaxation of 
ATP or on the contraction to DE-meATP (n=9-11).   
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2.4.2.4. Effect of XAC, an adenosine receptor antagonist 
 
Since P2 receptor antagonists (suramin and PPADS) had no effect on the 
relaxation to ATP, the latter was investigated in the presence of a non-
selective adenosine receptor antagonist. XAC (10 µM) had no effect on the 
contraction evoked by ATP (P > 0.05, XQSDLUHG 6WXGHQW¶V t-test, Figure 
2.6A), while it reduced significantly the relaxation to ATP (P < 0.001, 
XQSDLUHG6WXGHQW¶Vt-test, Figure 2.6B). 
 
Figure 2.6. Effect of XAC (10 µM) on (A) contraction, (B) relaxation to ATP 
(1 mM) in U46619-preconstricted porcine pancreatic arteries. (A) XAC had 
no effect on the contraction to ATP (n=8-10), (B) XAC reduced the 
relaxation to ATP (***P < 0.001, XQSDLUHG6WXGHQW¶Vt-test, n=8-10). 
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2.4.3. Characterisation of response to UTP in U46619-
preconstricted porcine isolated pancreatic arteries 
 
2.4.3.1. Effect of suramin, PPADS, DE-meATP and MRS2578, a 
selective P2Y6 receptor antagonist 
 
The contractions to UTP were examined in the presence of suramin (100 
µM), PPADS (10 µM), DE-meATP (1 µM) and MRS2578 (10 µM). Suramin 
and PPADS significantly reduced the contractions to UTP (P < 0.001, two-
way ANOVA, Figure 2.7); for example, the contraction to 1 mM UTP was 
2.5 ± 0.2g in the absence of suramin, PPADS, while it was 1.8 ± 0.3g, 1.9 
± 0.2g in the presence of suramin, PPADS respectively (P < 0.001, n=9-
12, Figure 2.7). These findings were consistent with those of Shen et al. 
(2004), as 10 µM of suramin and PPADS was able to block the UTP-induced 
increase in peak of [Ca2+] in porcine P2Y2-1321N1 cells. While the UTP 
responses were not affected in the presence of MRS2578 (Figure 2.8A), 
which selectively blocks  P2Y6 receptor with an IC50 of 98 nM at rat P2Y6 
receptor  (Mamedova et al., 2004). In addition, the contraction to UTP was 
unaltered in the presence of P2X receptor desensitising agent, DE-meATP 
(1 µM) (Kasakov & Burnstock, 1982) (Figure 2.8B); for example, the 
contraction to 1 mM UTP was 1.8 ± 0.2g in the absence of MRS2578, while 
it was 2.1 ± 0.2g in the presence of MRS2578 (n=6-7). The contraction to 
1 mM UTP was 2.2 ± 0.2g in the absence of DE-meATP, while it was 2.5 ± 
0.4g in the presence of DE-meATP (n=7); there was no significant 
difference between these responses.  
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Figure 2.7. Effect of suramin (100 µM) and PPADS (10 µM) on contraction 
to UTP in U46619-preconstricted porcine pancreatic arteries. Suramin and 
PPADS significantly reduced the contraction evoked by UTP (***P < 0.001, 
two-way ANOVA, F=14.47, 12.48 respectively; n=9-12).  
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Figure 2.8. Effect of (A) MRS2578 (10 µM), and (B) DE-meATP (1 µM) on 
the contractions to UTP in U46619-preconstricted porcine pancreatic 
arteries. (A), (B) Both MRS2578 and DE-meATP had no significant effect on 
the contraction to UTP (6-7).  
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2.4.3.2. Effect of endothelium removal 
 
To investigate the involvement of the endothelium in the contraction to 
UTP, the response of UTP was studied after the endothelium had been 
removed. The contraction induced by UTP was significantly attenuated in 
the endothelium-denuded arteries (P < 0.001, two-way ANOVA, Figure 
2.9).  
 
Figure 2.9. Effect of removal of the endothelium on the contraction to UTP 
in U46619-preconstricted porcine pancreatic arteries. Removal of 
endothelium reduced significantly the contraction evoked by UTP (***P < 
0.001, two-way ANOVA, F=43; n=10-12).  
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2.4.3.3. Effect of DUP 697, a cyclooxygenase-2 inhibitor 
 
Because the contraction to UTP was largely endothelium-dependent, the 
contraction was studied in the presence of DUP 697, a cyclooxygenase-2 
(COX-2) inhibitor (IC50 value of 10 nM for COX-2), since cyclooxygenase 
facilitates the release of agents which are responsible for endothelium-
dependent contraction (Mombouli & Vanhoutte, 1993; Gierse et al., 1995; 
Wong et al., 2009). DUP 697 (3 µM) diminished the contraction to UTP (P < 
0.001, two-way ANOVA, Figure 2.10) to a similar extent as removal of the 
endothelium (Figure 2.9). While DUP 697 had no effect on the contractions 
to U46619 (the pre-constriction agent) or ATP. The contraction to 1 mM 
ATP was 1.1 ± 0.3g in the absence of DUP 697, while it was 0.9 ± 0.2g in 
the presence of it (n=8-9); there was no significant difference between 
these responses. 
 
Figure 2.10. Effect of DUP 679 (3 µM), a cyclooxygenase-2 inhibitor, on 
the contraction to UTP in U46619-preconstricted porcine pancreatic 
arteries. DUP 679 reduced significantly the contraction evoked by UTP 
(***P < 0.001, two-way ANOVA, F=50.8; n=8-12).  
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2.4.3.4. Desensitisation of UTP-induced contraction in the presence 
of ATP or UTP 
 
Both ATP and UTP separately induced significant attenuation of the 
response to UTP, when the pancreatic arteries were exposed to these 
ligands 30 min prior to the addition of UTP, for example, the response to 
300 µM UTP was 0.7 ± 0.2g in the presence of 1 µM ATP, and it was 0.8 ± 
0.2 in the presence of 1 µM UTP, while the contraction to UTP was 1.2 ± 
0.2 in the absence of these ligands (P < 0.01, n=10-13, Figure 2.11). 
 
 
Figure 2.11. Attenuation of UTP-induced contraction (control) in the 
presence of ATP (1 µM) or UTP (1 µM) in U46619-preconstricted porcine 
pancreatic arteries. Both UTP and ATP significantly attenuated the 
contraction evoked by UTP (**P < 0.01, two-way ANOVA, UTP contraction 
in the absence or in the presence of UTP or ATP, F=18.21, 14.04 
respectively; n=10-13).  
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2.4.4. Characterisation of responses to ADP in U46619-
preconstricted porcine isolated pancreatic 
arteries 
 
2.4.4.1. Effect of MRS2179, a P2Y1 receptor selective antagonist, 
and endothelium removal 
 
The relaxation to ADP in pancreatic arteries was studied in the presence of 
MRS2179 (10 µM), and after the endothelium had been removed. The 
relaxation to ADP was reduced slightly but significantly in the presence of 
MRS2179 (P < 0.01, two-way ANOVA, Figure 2.12A) and in the 
endothelium-denuded arteries (P < 0.001, two-way ANOVA, Figure 2.12B); 
for example, the relaxation to 100 µM ADP was 28 ± 5% in the absence of 
MRS2179 and in endothelium-intact arteries, while it was 16 ± 7% in the 
presence of MRS2179 (P < 0.01, n=8-12), and it was 13 ± 3%  (P < 
0.001, n=10-12) in endothelium-denuded arteries, which indicates the 
involvement of P2Y1 receptors and the endothelium in ADP-mediated 
relaxation of porcine pancreatic arteries. 
 
Figure 2.12. Effect of (A) MRS2179 (10 µM), (B) the removal of the 
endothelium on the relaxation to ADP in U46619-preconstricted porcine 
pancreatic arteries. MRS2179 and removal of endothelium reduced the 
relaxation-evoked by ADP (**P < 0.01, ***P < 0.001, two-way ANOVA, 
F=21.42, F=32.04 respectively; n=10-12). 
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2.4.4.2. Effect of XAC, an adenosine receptor antagonist, and 
SCH58261, a selective adenosine A2A receptor antagonist  
 
The relaxation to ADP was investigated in the presence of XAC (10 µM). 
The relaxation to ADP was largely reduced in the presence of this inhibitor 
which indicates the involvement of adenosine receptors (P < 0.001, two-
way ANOVA, Figure 2.13). To identify the adenosine subtype involved in 
the relaxation to ADP, the response to ADP was investigated in the 
presence of SCH58261, a selective adenosine A2A receptor antagonist with 
Ki of 1.3 nM (Zocchi et al., 1996). This antagonist significantly inhibited the 
relaxation to ADP, to a similar extent as seen with XAC (P < 0.001, two-
way ANOVA, Figure 2.13). This showed that the relaxation to ADP is mainly 
mediated by A2A adenosine receptors. 
 
Figure 2.13. Effect of XAC (10 µM), a non-selective adenosine receptor 
antagonist, and SCH58261 (1 µM), a selective adenosine A2A receptor 
antagonist, on the relaxation to ADP in U46619-preconstricted porcine 
pancreatic arteries. XAC and SCH58261 inhibited significantly the 
relaxation-evoked by ADP (***P < 0.001, two-way ANOVA, F=71.19, 
58.16 respectively; n=9-14).  
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2.4.4.3. Effect of DE-meATP, a P2X receptors desensitisation agent 
 
To find out whether ADP acts at P2X receptors, the relaxation to ADP was 
investigated in the presence of DE-meATP, since the latter induces 
desensitisation of P2X receptors (Kasakov & Burnstock, 1982; Ralevic & 
Burnstock, 1998; Coddou et al., 2011). DE-meATP (1 µM) was applied 10 
min prior to the addition of U46619 (section 2.2.2). As can be seen in 
Figure 2.14, the relaxation to ADP was not significantly altered in the 
presence of the desensitising agent, which rules out the involvement of 
P2X receptors in the relaxation-evoked by ADP. 
 
Figure 2.14. Effect of DE-meATP (1 µM) on the relaxation to ADP in 
U46619-preconstricted porcine pancreatic arteries. DE-meATP had no 
significant effect on the relaxation to ADP (n=14). 
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2.5. Discussion 
 
The current report has provided evidence for the functional expression of 
contractile P2X1, P2Y2 and/or P2Y4 receptors, and vasorelaxant P2Y1 and 
A2A adenosine receptors in porcine isolated pancreatic arteries. These 
receptors are sensitive to the extracellular nucleotides ATP (P2X1), UTP 
(P2Y2 and P2Y4) and ADP/ado (P2Y1 and A2A). The contraction to ATP was 
endothelium-independent, while UTP induced an endothelium-dependent 
contraction which may involve P2Y2 and/or P2Y4 receptors. The relaxation 
to ADP involved the endothelium, P2Y1 receptors and mainly A2A adenosine 
receptors present on the VSMCs. 
 
2.5.1. Characterisation of the response-evoked by ATP 
and DE-meATP in porcine pancreatic arteries 
 
A vasoconstrictor response elicited by ATP has been reported in a number 
of different arteries, including rabbit ear arteries, rat mesenteric arterial 
bed and rat pulmonary vascular bed (Kügelgen et al., 1987; Ralevic & 
Burnstock, 1991a; Rubino & Burnstock, 1996). ATP may also induce 
vasorelaxation depending on the experimental conditions (level of pre-
tone) and relative expression of relevant vasocontractile or vasorelaxant 
receptors (Ralevic & Burnstock 1996; Korchazhkina et al., 1999). In 
porcine pancreatic arteries, ATP induced a biphasic response consisting of a 
contraction followed by a relaxation (Figure 2.2B). In addition, DE-meATP 
elicited a monophasic response consisting of only a contraction in porcine 
pancreatic arteries (Figure 2.2B). Since the contractions to ATP and DE-
meATP were rapidly desensitising, non-cumulative concentration response 
curves were investigated. The contractions to ATP and DE-meATP were 
significantly reduced in the presence of suramin, PPADS, DE-meATP (a 
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desensitiser of P2X1 receptor) and NF449 (a P2X1 selective antagonist) 
(Figure 2.3A, 2.3B and 2.4), which indicates that a large part of the 
contraction to ATP could be attributed to the activation of P2X1 receptors, 
since P2X3 receptor, which is also desensitised in the presence of DE-
meATP, is not likely to be expressed in the VSMCs of the blood vessels (see 
review by Burnstock et al., 2010). Moreover, the contractile effect of DE-
meATP is consistent with the expression of P2X1 receptors in porcine 
pancreatic arteries. In the current study, DE-meATP was shown to be 
approximately 300-fold more potent than ATP in eliciting a 
vasoconstriction, most likely due to its greater stability. This finding was 
consistent with previous reports which showed that DE-meATP was 10-fold 
more potent than ATP in eliciting the contraction of the rat vas deferens, 
and this effect was attributed to the greater stability of DE-meATP, since it 
was shown in that report that DE-meATP was resistant to breakdown by the 
ecto-nucleotidases for 2h, while ATP was metabolised rapidly (Khakh et al., 
1995). 
Since the contractions to ATP and DE-meATP were not significantly changed 
after the endothelium had been removed (Figure 2.5A, C) thus, the 
expression of P2X1 receptors was proposed to be on the vascular smooth 
muscle cells of the pancreatic arteries. This is consistent with the abundant 
expression of P2X1 receptors on VSMCs of most tissues (Kügelgen, 2008). 
On the other hand, the contraction to ATP in endothelium-denuded 
pancreatic arteries was reduced slightly relative to its contraction in 
endothelium-intact arteries (Figure 2.5A). Although this reduction was not 
significant, it is likely that other receptors (P2Y receptors) may be involved. 
These receptors may be expressed, at least partly, on the endothelium, 
and they were responsible for eliciting part of the observed contraction. 
ATP is a potent agonist at P2Y2 receptors which can be expressed on the 
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endothelium (Erlinge & Burnstock, 2008). Likewise, the current study 
showed (as it is discussed later on in this section) that UTP may act at P2Y2 
receptors expressed on the endothelium of the pancreatic arteries to 
induce a contraction, which was also reduced in endothelium-denuded 
vessels. Taken together, it can be concluded that ATP acted at P2X1 
receptors expressed on the VSMCs to induce the major part of the 
observed contraction, as well as acting partly at the endothelial-P2Y2 
receptors to induce the rest of that contraction, which was reduced slightly 
(not significantly) after the endothelium had been removed. Therefore, it is 
also required to examine the contraction to ATP in the presence of a P2Y2 
selective antagonist for that hypothesis to be confirmed. 
ATP-induced vasorelaxation was not affected after the endothelium had 
been removed, or in the presence of suramin or PPADS, which suggests 
that the relaxation to ATP was not due to its action at P2Y1 or P2Y2 
receptors. However, the relaxation to ATP was significantly inhibited in the 
presence of XAC, which suggested an involvement of adenosine receptors 
expressed on VSMCs of the pancreatic arteries. It is likely that this is due 
to the activity of adenosine derived from ATP metabolism by ecto-
nucleotidase-5¶-triphosphate diphosphohydrolase (ENTPDases) enzymes 
followed by the activity of (GPI)-anchored ecto-¶-nucleotidase or APs 
enzymes (section 1.7) (Zimmermann, 2000). Similarly, in rat coronary 
arteries, the relaxation to ATP involved P1 receptors, although there was 
an additional involvement of P2Y receptors (Korchazhkina et al., 1999). 
The relaxation evoked by ATP in mouse thoracic aorta was mainly mediated 
by P2Y2 receptors (Guns et al., 2006). In the current study, further 
investigation of the adenosine receptor subtypes involved in the relaxation 
to ATP is required. Although, it is possible that the adenosine A2A receptor 
is the subtype responsible of the observed relaxation, since the relaxation 
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to ADP in porcine pancreatic arteries (as it is discussed later on in this 
section) was shown to be mediated by this subtype (Figure 2.13). Other 
reports have shown previously a slow relaxation in response to DE-meATP 
in rat mesenteric arteries, subsequent to the contraction (Stanford & 
Mitchell, 1998; Ralevic, 2001, 2002), but this was not observed in the 
present study in porcine pancreatic arteries. 
 
2.5.2. Characterisation of the response-evoked by UTP in 
porcine pancreatic arteries 
 
The vasoconstriction to UTP did not desensitise quickly, therefore, 
cumulative concentration response curves were used to study the effect of 
UTP on pancreatic arteries. This contraction was significantly inhibited in 
the presence of suramin and PPADS (Figure 2.7), and there was a 
significant reduction of the response after the endothelium had been 
removed (Figure 2.9). That would indicate, for the first time, an 
endothelium-dependent vasoconstriction-evoked by UTP, since UTP-
mediated vasoconstrictions, in the previous reports, were mainly mediated 
by P2Y receptors present on the vascular smooth muscle. Moreover, when 
the endothelium of the rat, rabbit and bovine cerebral arteries had been 
removed, the contractions to UTP were not significantly altered (von 
Kugelgen & Starke, 1990; Miyagi et al., 1996; Lopez et al., 2000; Lacza et 
al., 2001; Miyagi et al., 2004). 
UTP is known to be active at P2Y2, P2Y4 receptors and less potently at P2Y6 
receptors (Burnstock & Williams, 2000). The expression of these receptors 
in the endothelium and the smooth muscle of vessels has been reported 
previously (Burnstock, 2007). In the current study, since MRS2578 was not 
able to alter the contraction to UTP (Figure 2.8A), this indicates that the 
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contraction induced by UTP was not due to its action at P2Y6 receptors. 
There are currently no commercially available selective antagonists for 
either P2Y2 or P2Y4 receptors. However, it is believed that UTP acted mainly 
at P2Y4 receptors since the contraction to UTP was significantly inhibited by 
both the removal of the endothelium and in the presence of DUP 697, but 
contraction to ATP (a potent agonist at P2Y2 receptor) did not change 
significantly in endothelium-denuded arteries (section 2.4.2.3) or in the 
presence of DUP 697 (section 2.4.3.3), indicating actions at distinct 
receptors. UTP induced-contraction may also be mediated by P2Y2 
receptors, since MRS2768, which is a selective agonist at P2Y2 receptors 
and displays no affinity for P2Y4 or P2Y6 receptors (Ko et al., 2008), was 
able to evoke a contraction in porcine pancreatic arteries  (Figure 2.2A). 
UTP-induced vasoconstriction has been documented in a number of 
arteries, including rat pulmonary arteries in which the contraction was 
attributed to P2Y2 receptors, and in rabbit basilar arteries in which the 
contraction to UTP was due to its action at P2Y4 receptors (Hartley et al., 
1998; Miyagi & Zhang, 2004). UTP produced an endothelium-dependent 
relaxation in rabbit pulmonary arteries and in rat mesenteric arterial bed, 
but the receptor subtypes were undefined (Ralevic & Burnstock, 1991a; 
Qasabian et al., 1997). In bovine middle cerebral arterial strips, UTP had a 
dual response, it induced a contraction in endothelium-denuded arteries 
but a relaxation in endothelium-intact arteries (Miyagi et al., 1996). The 
absence of endothelium-dependent or -independent relaxation to UTP and 
some other nucleotides in rat renal arteries was reported (Knight et al., 
2003), which is consistent with the current study since there was no 
evidence of a UTP-mediated relaxation in porcine pancreatic arteries. 
Hence, porcine pancreatic arteries appear not to express relaxant P2Y2 
and/or P2Y4 receptors. 
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To investigate the mechanism underlying the contraction mediated by UTP 
in porcine pancreatic arteries, the response to UTP was examined in the 
presence of DUP 697. As seen in Figure 2.10, the endothelium-dependent 
contraction was attenuated in the presence of the selective COX-2 
inhibitor. Endothelial cells can release endothelium-derived contractile 
factors, which may include thromboxane A2, prostaglandin F2D/ 
prostaglandin H2, leukotrienes and endothelin-1. Thromboxane A2 and 
prostaglandin F2D/ prostaglandin H2 are released from the endothelium due 
to the activity of cyclooxygenase (Mombouli & Vanhoutte, 1993; Wong et 
al., 2009). The reduction of the contraction to UTP in the presence of DUP 
697 indicated that thromboxane A2 and prostaglandins, the prominent 
vasoconstrictors arachidonic acid derivatives, can be suspected of 
mediating the UTP-induced contraction. These agents, after being released 
from the endothelium, may act on their receptors on VSMCs to elicit a 
contraction (Wong et al., 2009). Similarly, UTP-induced contraction in rat 
cerebral arteries was associated with an elevation of thromboxane A2 
release (Lacza et al., 2001). To test whether UTP interacts with P2X 
receptors, expressed in porcine pancreatic arteries (section 2.4.2.2), DE-
meATP, which desensitises P2X1 and P2X3 receptors (Kasakov & 
Burnstock, 1982; Ralevic & Burnstock, 1998; Coddou et al., 2011), was 
employed. However, as can be seen in Figure 2.8B, DE-meATP had no 
significant effect on the response to UTP, which ruled out the involvement 
of P2X receptors in the contraction to UTP. 
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2.5.3. Characterisation of the response-evoked by ADP 
in porcine pancreatic arteries 
 
The relaxation to ADP did not desensitise rapidly, therefore, cumulative 
concentration response curves were used to study the effect of ADP on 
pancreatic arteries. The relaxation was significantly attenuated in the 
presence of MRS2179, a selective P2Y1 receptor antagonist (Figure 2.12A). 
In addition, the relaxation to ADP was significantly reduced after the 
endothelium had been removed, by a similar extent as observed in the 
presence of MRS2179 (Figure 2.12B). This may suggest that P2Y1 receptors 
are expressed on the endothelium. Indeed, a number of reports show that 
P2Y1 receptors are expressed on the endothelium and are responsible for 
relaxation of the arteries, including rat thoracic aortic and porcine 
mesenteric arteries (Dol-Gleizes et al., 1999; Alefishat et al., 2010). The 
relaxation to ADP in our study was largely reduced in the presence of XAC 
(an adenosine receptor antagonist) and SCH58261 (a selective adenosine 
A2A receptor antagonist). Adenosine receptors may be expressed on the 
endothelium or the vascular smooth muscle (Schulte & Fredholm, 2003). 
Since XAC and SCH58261 produced a greater reduction in the relaxation to 
ADP than the inhibition induced by removal of the endothelium (Figure 
2.13). This suggested that relaxation to ADP involves A2A adenosine 
receptors expressed, at least in part, on VSMCs. The mechanism by which 
ADP would produce adenosine to act at the adenosine receptors is still to 
be elucidated. The simplest explanation is that ADP may be broken down 
by ENTPDases followed by the activity of (GPI)-anchored ecto-¶-
nucleotidase or APs enzymes (section 1.7) (Zimmermann, 2000). 
Alternatively, as suggested in porcine coronary arteries, ADP mediates a 
relaxation via a mechanism that involves ADP-evoked adenosine release 
and the subsequent activation of A2A receptors (Rayment et al., 2007b). In 
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contrast to the porcine pancreatic vessels, ADP in rat pancreatic arteries 
induced a contraction at a high concentration (1 mM), this contraction was 
similar to that produced by ATP and was much lower than the contraction 
induced by DE-meATP (Chapal & Loubatieres-Mariani, 1983). Further 
investigation is required to determine the involvement of endothelium-
derived relaxing factors or endothelium-derived hyperpolarising factors 
released from the endothelium in the ADP-induced relaxation. To test 
whether ADP binds to P2X receptors expressed in porcine pancreatic 
arteries (section 2.4.2.2), DE-meATP was employed. However, as seen in 
Figure 2.14, DE-meATP had no effect on the response to ADP which ruled 
out the involvement of P2X receptors in the response to ADP in porcine 
pancreatic arteries. 
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2.6. Conclusion 
 
The data presented in this chapter determined the functional expression of 
P2X1 and A2A adenosine receptors expressed on VSMCs, and P2Y2 and/or 
P2Y4 receptors expressed on the vascular endothelial cells of porcine 
pancreatic arteries. Activation of P2X1 receptors by ATP or DE-meATP 
induces a vasoconstriction, and UTP acts at P2Y2 and/or P2Y4 receptors to 
induce a contraction. The slight reduction of the contraction to ATP, 
observed in endothelium-denuded arteries, suggests an involvement of 
P2Y2 receptors in the contraction to ATP. ADP and ATP activate A2A 
adenosine receptors on the VSMCs to induce relaxation, together with an 
action of ADP at P2Y1 receptors expressed on the endothelial cells. 
Pancreatic arteries appear to lack vasorelaxant P2Y2 and/or P2Y4 receptors. 
The data rule out the involvement of P2X receptors in the contraction or 
the relaxation to UTP and ADP respectively. 
 
 
 
 
 
 
 
Chapter 3 
Effects of UDP-glucose, UDP & MRS2690 on vascular tone 
 
81 
 
 
 
 
 
 
 
 
 
 
Chapter Three 
 
 
 
 
 
Chapter 3 
Effects of UDP-glucose, UDP & MRS2690 on vascular tone 
 
82 
 
Investigation of the effects of UDP-
glucose, UDP and MRS2690 on vascular 
tone in porcine isolated pancreatic 
arteries 
 
3.1. Introduction 
 
The P2Y14 receptor is a recently described member of the P2Y receptor 
family, and was identified in 2000 (Chambers et al., 2000). In contrast to 
other P2Y receptors, P2Y14 receptors can be activated by nucleotide sugars 
such as UDP-glucose (Figure 1.5B), in addition to UDP-galactose and UDP-
glucuronic acid which are less potent than UDP-glucose at P2Y14 receptors 
(Abbracchio et al., 2003; Fricks et al., 2008; Harden et al., 2010). P2Y14 
receptors are also activated by UDP (Figure 1.5A) and by MRS2690 (Figure 
1.5C) which is more selective at P2Y14 receptors and was shown to be 7-10 
fold more potent than UDP-glucose, as well as DE-difluoromethylene-UDP 
which is also more potent and selective at P2Y14 receptors (Carter et al., 
2009; Jacobson et al., 2009; Gao et al., 2010). 
PPADS and suramin are non-selective antagonists at most of the P2Y 
receptors, but some P2Y receptors are insensitive to these antagonists 
(Chootip et al., 2005). There is currently no report of antagonist sensitivity 
of P2Y14 receptors for suramin and PPADS. Recently, a novel selective 
antagonist at P2Y14 receptors was identified, namely PPTN (Figure 1.6) 
(Barrett et al., 2013). It was characterised in human embryonic kidney 
cells expressing P2Y14 receptor through its ability to inhibit UDP-glucose-
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stimulated Ca2+ mobilisation (Robichaud et al., 2011). In addition, it 
showed high affinity for the P2Y14 receptor (Ki = 1.9 nM in a chimpanzee 
P2Y14 binding assay) (Robichaud et al., 2011). When it was studied in 
human C6 glioma cells, PPTN showed selectivity for P2Y14 receptors, with 
no agonist or antagonist affinity at other P2Y receptors family (Barrett et 
al., 2013). 
P2Y14 receptor mRNA and protein have a varied expression in the body; 
they have been found in spleen, placenta, lung, heart, adipose tissue, 
gastrointestinal smooth muscle, endothelial cells, and immune cells 
(section 1.4.2.2.1) (Chambers et al., 2000; Scrivens & Dickenson, 2005; 
Umapathy et al., 2010). 
Relatively little is known, however, about the functional expression of the 
P2Y14 receptor in cardiovascular system, best characterised is its role in 
regulation of the immune system, as a number of studies have described 
an involvement of P2Y14 receptors in modulation of the function of human 
neutrophils and T-lymphocytes. Activation of P2Y14 receptors inhibited T-
lymphocyte proliferation and increased secretion of the pro-inflammatory 
cytokine interleukin 8 from airway epithelial cells (Scrivens & Dickenson, 
2005, 2006; Muller et al., 2005). Therefore, the aim of this chapter was to 
investigate the functional expression of P2Y14 receptor-mediated contractile 
response of porcine isolated pancreatic artery preparations. 
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3.2. Materials and methods 
 
3.2.1. Tissue preparation 
 
Pancreata from pigs were obtained on ice from a local abattoir (G Wood & 
Sons Ltd, Mansfield). A crude dissection was conducted to isolate the 
pancreatic arteries (dorsal pancreatic artery) (Figure 1.9, main), followed 
by a fine dissection to obtained rings of 0.5 cm in length, which were 
suspended between two wires LQ.UHEV¶-Henseleit buffer (gassed, 95% O2, 
5% CO2), as described in (section 2.2.1). 
Endothelium denudation (by gentle rubbing) was performed using the 
same protocol described in (section 2.2.1). 
 
3.2.2. Responses in the porcine isolated pancreatic 
artery 
 
Arterial rings were mounted onto wires in tissue baths containing warm 
& R[\JHQDWHG .UHEV¶-Henseleit solution and were connected via 
isometric force transducers (ADInstruments, Sydney, Australia), to a PC 
running the computer program LabChart (ADInstruments, Sydney, 
Australia). Rings were put under tension (15 g) and allowed to equilibrate 
for 60 min before being treated as described in (section 2.2.2). U46619 
(10-100 nM) was used to contract the tissues to 40-80% of the second KCl 
response. Once an appropriate level of U46619 response had been 
achieved, cumulative addition of UDP-glucose, UDP or MRS2690 was 
applied. Antagonists or inhibitors [suramin (100 µM), PPADS (10 µM), PPTN 
(1 µM), DE-meATP (1 µM), ARL67156 (6-N,N-diethyl-D-ǃǄ-
dibromomethyleneATP) (10 µM), MRS2578 (1 µM) or (10 µM) and drug X 
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(1 µM)] were applied 10 min prior to the addition of U46619, allowing 
incubation with the tissues for a minimum of 30 min prior to the application 
of agonists. In some experiments with PPTN, the contraction to UDP-
glucose was constructed at basal tone, in which UDP-glucose was added an 
hour following the second KCl addition in the presence or in the absence of 
PPTN, which was pre-incubated with the tissues for 30 min. 
Desensitisation of the contraction to UDP-glucose in the presence of P2Y14 
receptor ligands was generated by exposing the arteries to UDP (100 µM) 
or UDP-glucose (100 µM) (P2Y14 receptor ligands) 10 min prior to the 
addition of U46619, followed by cumulative addition of UDP-glucose at 
stabilised U46619 level. In experiments using DMSO as the solvent (see 
reagents and drugs section 3.2.4), DMSO 0.1 % (v/v) was added to the 
arteries as vehicle controls. 
 
3.2.3. Immunohistochemical staining 
 
Segments of porcine pancreatic arteries were collected and fixed in 4% 
(w/v) paraformaldehyde overnight at 4oC. Specimens were then washed in 
phosphate-buffered saline (PBS). Slices of vessels were created by freezing 
the tissues with optimal cutting temperature (OCT) mounting solution, then 
cutting to size (14 µm thick) using a microtome. The slices were then 
transferred onto slides and stored at -80oC. 
Whole-mount segments of porcine pancreatic arteries were stained using 
the standard indirect immunofluorescence technique. The tissues were 
permeablised using PBS + 1% (w/v) bovine serum albumin (BSA) + 0.15% 
Triton X-100 at room temperature for 30 min. Non-specific binding was 
blocked with human serum 1:25 in PBS at room temperature for 30 min. 
Chapter 3 
Effects of UDP-glucose, UDP & MRS2690 on vascular tone 
 
86 
 
The slides were incubated overnight at 4ºC with antibody against G 
protein-coupled receptor GPR105/P2Y14, diluted 1:100 in the blocking 
solution, while control slides were incubated overnight with the blocking 
solution. Subsequently, the samples were washed with PBS + 0.1% (w/v) 
bovine serum albumin (BSA), the secondary antibody (anti-rabbit IgG 
FITC) 1:100, diluted in PBS + 0.1% (w/v) BSA, was incubated with the 
samples at 37oC for 30 min followed by further washes. The slides were 
covered using Vector shield mounting solution and glass cover slips. 
Samples were visualised using fluorescence microscopy using an objective 
magnification of x40. 
3.2.4. Western blotting 
 
Segments of porcine pancreatic arteries (PPA), rat heart (RH) and porcine 
heart (PH) were collected and stored in -80oC freezer. They were then 
homogenised with a borosilicate glass homogeniser in lysis buffer (see 
reagents and drugs section 3.2.6), containing protease inhibitor cocktail 
tablets, EDTA-free. After removal of a sample for a protein assay (section 
3.2.5), samples were diluted 1:6 into solubilisation buffer 6×SB: (see 
reagents and drugs section 3.2.6), and were heated at 95°C for 5 min. 
Subsequently, electrophoresis was carried out on 4-20% Tris-Glycine 
(PAGE) Gold Precast Gels (Bio-Rad, Hercules, CA, U.S.A.), 20 µg protein 
per lane was loaded for PPA, 10 µg protein per lane was loaded for RH and 
PH.  
Samples were transferred to nitrocellulose membranes. Next, blots were 
incubated in blocking solution (5% (w/v) powdered milk in Tris-buffered 
saline containing 0.1% (v/v) Tween 20 (Fisher Scientific UK Ltd., 
Loughborough, UK)) for 60 min, at room temperature. Blots were 
incubated overnight at 4°C with primary antibodies against P2Y14 protein 
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(1:500) and against GAPDH (1:10000) diluted in the blocking solution. 
After washing in Tris-buffered saline containing 0.1% (v/v) Tween 20, the 
blots were incubated with an appropriate IRDye® secondary antibody (Li-
Cor Biosciences, Biotechnology, Lincoln, NE, USA). Proteins were visualised 
using the Licor/Odyssey infrared imaging system (Biosciences, 
Biotechnology). 
 
Antibody Cat No. Host MW 
(kDa) 
Sequence 
GAPDH G8795 mouse 37   
anti-P2Y14 
receptor 
(IHC) 
LS-A1486 rabbit  synthetic 20 amino acid 
peptide from C-terminus 
of human P2RY14 
anti-P2Y14 
receptor 
(WB) 
LS-C120603 rabbit 41 amino acids; 146-195 
 
3.2.5. Determination of the protein level 
 
The total level of the protein in porcine pancreatic samples was determined 
using a Lowry test, which is based on measuring the amount of proteins 
with Folin phenol reagent in the presence of alkaline copper conditions 
(Lowry et al., 1951). A stock of bovine serum albumin (BSA) 1 mg/ml was 
made in distilled water, a serial dilution (from 0.05-0.45 mg/ml) was 
prepared from that stock to produce the standard curve. 
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Samples and standard were mixed with Lowry A and Lowry B (section 
3.2.6), followed by 10 min incubation at room temperature. Subsequently, 
Folin phenol reagent, diluted 1:1 in distilled water, was added to the 
samples and standards followed by 45 min incubation in the room 
temperature. After mixing, samples and standards were transferred onto 
96-well plates and the resultant absorbance was determined using spectra 
MAX 340pc plate reader at 750 nm. 
 
3.2.6. Reagents and drugs 
 
Lowry A: 0.4% (w/v) NaoH, 0.2% (w/v) sodium dodecyl sulphate, 2% 
(w/v) Na2CO3. Lowry B: 1% (w/v) CuSO4, 2% (w/v) NaK Tartrate. Human 
serum, UDP and UDP-glucose was purchased from Sigma (Poole, Dorset, 
UK), while MRS2690 and ARL67156 were purchased from Tocris 
Biosciences Ltd. (Bristol, UK). PPTN, a selective high affinity antagonist of 
P2Y14 receptor, was kindly gifted from Merck Frosst Centre for Therapeutic 
Research. Drug X was kindly gifted from Dr. Sue C. Fox, Thrombosis and 
Haemostasis Research Group, School of Medicine, University of 
Nottingham, company name withheld. Lysis buffer (20 mM Tris, 1 mM 
EGTA, 0.1% (v/v) Triton X100, 1 mM NaF, 10 mM beta glycerophosphate, 
pH 7.6). Solubilisation buffer, 6×SB: (24% (w/v) sodium dodecyl sulphate, 
30% (v/v) glycerol, 5% (v/v) beta mercaptoethanol, 2.5% (v/v) 
bromophenol blue, 1.5M Tris HCl, pH 6.8). The antiserum against P2Y14 
receptor protein, used for western blotting study, was purchased from 
Lifespan Biosciences, Inc (cat No. LS-C120603). The mouse monoclonal 
GAPDH antibody was purchased from Sigma (Poole, Dorset, UK) (cat No. 
G8795). The primary antibody (anti-P2Y14 receptor) used for 
immunohistochemical staining study was purchased from Lifespan 
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Biosciences (cat No. LS-A1486). UDP, UDP-glucose, MRS2690, Drug X and 
ARL67156 were dissolved in water, while PPTN were dissolved in DMSO. 
For information about the sources and the solvents of other reagents and 
drugs, see section 2.2.3.   
 
3.3. Statistical analysis 
 
Data were expressed as log concentration-response plots. The contraction 
to all agonists was expressed in g, and measured from the stabilised 
U46619 response. Values for all figures refer to mean ± S.E.M with 95% 
confidence. Results were compared by two-way analysis of variance (Prism 
version 5, GraphPad, San Diego, CA, USA). Differences were considered to 
be significant when the P value was < 0.05. 7KH ³Q´ LQ WKH UHVXOWV
expresses the number of animals. 
 
3.4. Results 
 
3.4.1. Effect of UDP-glucose, UDP and MRS2690 in 
porcine isolated pancreatic arteries 
 
To investigate the possible functional expression of P2Y14 receptors and 
their role in porcine pancreatic arteries, agonists for these receptors were 
applied as cumulative concentrations. MRS2690, a selective P2Y14 receptor 
agonist (10 nM to 30 µM), UDP-glucose (1 µM to 1 mM) and UDP (1 µM to 
1 mM) were added after pre-constriction with U46619. All of the agonists 
induced a concentration-dependent contraction with a rank order of 
potency of MRS2690 > UDP-glucose = UDP. MRS2690 was significantly 
more potent, by approximately 10-fold, than UDP-glucose (P < 0.01, two-
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way ANOVA, Figure 3.1), while UDP-glucose and UDP responses were 
equipotent (Figure 3.1). The contraction to 30 µM MRS2690 was 1.9 ± 
0.4g, while it was 0.97 ± 0.2 and 1.0 ± 0.2 for 30 µM UDP and 30 µM UDP-
glucose respectively (P < 0.01, n=9-12, Figure 3.1). There was no 
significant difference between the contractions to UDP and UDP-glucose. 
 
Figure 3.1. Concentration-dependent contractions evoked by MRS2690, 
UDP and UDP-glucose in U46619-preconstricted porcine pancreatic arteries 
(**P < 0.01, two-way ANOVA, MRS2690 response vs UDP-glucose and UDP 
responses, F=13.74, 16.03; n=9-12). 
 
3.4.2. Effect of PPTN on responses to UDP-glucose and 
MRS2690 in porcine isolated pancreatic arteries 
 
The responses to UDP-glucose and MRS2690 were examined in the 
presence of PPTN (1 µM), a selective high affinity antagonist of P2Y14 
receptors (Robichaud et al., 2011; Barrett et al., 2013). This compound 
significantly reduced the contractions evoked by UDP-glucose and 
MRS2690 in U46619-preconstricted pancreatic arteries (Figure 3.2A, B). 
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PPTN decreased the contractions to 100 µM UDP-glucose and to 10 µM 
MRS2690 by 0.5 ± 0.1g (P < 0.05, n=7) and by 0.7 ± 0.2g (P < 0.01, 
n=9) respectively (Figure 3.2A, B). To find out about the selectivity of 
PPTN at P2Y14 receptors over P2Y2, P2Y4 or P2Y6 receptors, the contraction 
to UTP, which is known to be a ligand at P2Y2, P2Y4 and P2Y6 receptors 
(Burnstock & Williams, 2000), was examined in the presence of PPTN (1 
µM) (the same concentration that induced inhibition of UDP-glucose and 
MRS2690 contractions). As seen in Figure 3.2C, the contraction to UTP was 
not altered in the presence of PPTN, indicating some selectivity of PPTN at 
P2Y14 receptor over some other P2Y receptors in porcine pancreatic 
arteries. Typical traces, showing the effect of MRS2690 in the absence and 
in the presence of PPTN, are shown in Figure 3.3. Similarly, at basal tone 
(section 3.3.2), the concentration-dependent vasoconstriction elicited by 
UDP-glucose was statistically decreased in the presence of PPTN (Figure 
3.4). 
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Figure 3.2. Effect of PPTN (1 µM), a P2Y14 receptor selective antagonist, 
on responses to (A) UDP-glucose, (B) MRS2690, (C) UTP in U46619-
preconstricted porcine pancreatic arteries. (A), (B) PPTN inhibited the 
effects of UDP-glucose and MRS2690 (*P < 0.05, **P < 0.01, two-way 
ANOVA, F=6.56, F=12.85 respectively; n=7-9). (C) PPTN had no effect on 
the response to UTP (n=8-10).  
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Figure 3.3. Typical traces showing the effect of MRS2690 in the absence 
and in the presence of PPTN (1 µM). 
 
 
Figure 3.4. Effect of PPTN (1 µM), a P2Y14 receptor selective antagonist, 
on contraction to UDP-glucose at basal tone in porcine pancreatic arteries. 
PPTN inhibited the contraction induced by UDP-glucose (***P < 0.001, 
two-way ANOVA, F=24.35; n=12). 
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3.4.3. Effect of PPADS and suramin on responses to 
UDP-glucose, UDP and MRS2690 in porcine 
isolated pancreatic arteries 
 
Responses to UDP-glucose, UDP and MRS2690 were characterised using 
the non-selective P2 receptor antagonists PPADS (10 µM) and suramin 
(100 µM) (Rayment et al., 2007a). Both PPADS and suramin significantly 
enhanced the contractions evoked by UDP-glucose and UDP (Figure 3.5A, 
B). The contraction to 100 µM UDP-glucose was enhanced by 1.9 ± 0.2g (P 
< 0.001, n=7) and by 1.7 ± 0.2g (P < 0.001, n=10) in the presence of 
PPADS and suramin respectively (Figure 3.5A). The contraction to 1 mM 
UDP was enhanced by 2 ± 0.3g (P < 0.001, n=8), and by 2.3 ± 0.3g (P < 
0.001, n=10) in the presence of PPADS and suramin respectively (Figure 
3.5B). Suramin and PPADS failed to alter the contraction to MRS2690 
(Figure 3.5C). 
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Figure 3.5. Effect of PPADS (10 µM) and suramin (100 µM) on responses 
to (A) UDP-glucose, (B) UDP, and (C) MRS2690 in U46619-preconstricted 
porcine pancreatic arteries. (A) Suramin and PPADS enhanced the effects 
of UDP-glucose (***P < 0.001, two-way ANOVA, UDP-glucose with suramin 
or PPADS vs UDP-glucose alone, F=19.85, 23.07; n=7-10). (B) Suramin 
and PPADS enhanced the effects of UDP (***P < 0.001, two-way ANOVA, 
UDP with suramin or PPADS vs UDP alone, F=16.83, 45.24; n=8-10). (C) 
Suramin and PPADS had no significant effect on the contraction to 
MRS2690 (n=5-9). 
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3.4.4. Effect of MRS2578 on responses to UDP-glucose, 
UDP and MRS2690 in porcine isolated pancreatic 
arteries 
 
UDP is a ligand at P2Y6 receptors (Mamedova et al., 2004) as well as being 
a ligand at P2Y14 receptors (Carter et al., 2009). Therefore, the effects of 
UDP, UDP-glucose and MRS2690 were examined in the presence of 
MRS2578 (1 µM) and (10 µM), a P2Y6 receptor selective antagonist 
(Mamedova et al., 2004). The contraction evoked by UDP was unaffected 
at lower concentrations but was augmented at higher concentrations of 
UDP (Figure 3.6A). The contraction to 1 mM UDP was enhanced by 0.7 ± 
0.3g (P < 0.001, n=8-16) in the presence of MRS2578 (Figure 3.6A), while 
MRS2578 did not alter the responses to UDP-glucose or MRS2690 (Figure 
3.6B, C).  
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Figure 3.6. Effect of MRS2578 (10 µM) on responses to UDP, UDP-glucose 
and MRS2690 in U46619-preconstricted porcine pancreatic arteries. (A) 
MRS2578 enhanced significantly the contraction evoked by UDP (**P < 
0.01, F= 9.953; n=8-16). (B), (C) MRS2578 failed to alter the contractions 
to UDP-glucose and MRS2690 (n=6-13). 
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3.4.5. Effect of ARL67156 on responses to UDP-
glucose, UDP and MRS2690 in porcine isolated 
pancreatic arteries 
 
Suramin and PPADS can act as ecto-nucleotide pyrophosphatases (eNPPs) 
inhibitors (Grobben et al., 1999; Vollmayer et al., 2003). In addition, they 
act as inhibitors for the ecto-nucleoside-5¶-triphosphate 
diphosphohydrolases (eNTPDases) (Chen et al., 1996; Munkonda et al., 
2007). It has been shown that nucleotide sugars are resistant to hydrolysis 
by the nucleotide-hydrolyzing eNTPDases (Zimmermann, 2000), but they 
could be broken down by eNPPs, as was shown for UDP-glucose 
(Lazarowski et al., 2003b). While, UDP is broken down by eNTPDases 
(section 1.7) (Murphy-Piedmonte et al., 2005; Levesque et al., 2007). 
Since suramin and PPADS were able to potentiate the contractions to UDP-
glucose and UDP, that might raise the possibility that they may act as ecto-
nucleotidase inhibitors (Chen et al., 1996). Therefore, the responses to 
UDP-glucose, UDP and MRS2690 were studied following the exposure to 
ARL67156 (10 µM), which is an ecto-nucleotidase inhibitor with pIC50 of 
4.62 in human blood (Crack et al., 1995; Liu et al., 2004; Levesque et al., 
2007). As shown in Figure 3.8, ARL67156 failed to significantly alter the 
responses to UDP-glucose, UDP and MRS2690.  
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Figure 3.7. Effect of ARL67156 (10 µM), an ecto-nucleotidase inhibitor, 
on responses to (A) UDP-glucose, (B) UDP, (C) MRS2690 in U46619-
preconstricted porcine pancreatic arteries. ARL67156 had no significant 
effect on responses to (A) UDP-glucose (n=5-8), (B) UDP (n=6-14) and 
(C) MRS2690 (n=4-5). 
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3.4.6. Effect of endothelium removal on responses to 
UDP-glucose, UDP and MRS2690 in porcine 
isolated pancreatic arteries 
 
The responses of UDP-glucose, UDP and MRS2690 were studied after the 
endothelium had been removed (section 2.2.1). The contractions induced 
by UDP-glucose, UDP and MRS2690 were significantly attenuated in the 
endothelium-denuded arteries (Figure 3.8). Removal of endothelium 
reduced the contractions to 1 mM UDP-glucose by 1.3 ± 0.2g (P < 0.001, 
n=12, Figure 3.8A), that to 1 mM UDP by 0.5 ± 0.2g (P < 0.001, n=15, 
Figure 3.8B) and that to 30 µM MRS2690 by 0.5 ± 0.2g (P < 0.01, n=5, 
Figure 3.8C). 
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Figure 3.8. Effect of removal of the endothelium on responses to (A) UDP-
glucose, (B) UDP, (C) MRS2690, in U46619-preconstricted porcine 
pancreatic arteries. The removal of endothelium significantly reduced the 
contraction evoked by (A) UDP-glucose, (B) UDP, (C) MRS2690 (**P < 
0.01, ***P < 0.001, two-way ANOVA, F=8.15, 51.24, 9.48; n=5-15).  
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3.4.7. Desensitisation of the contraction to UDP-glucose 
induced by UDP-glucose or UDP 
 
Both UDP-glucose and UDP (P2Y14 receptor ligands), added 10 min prior to 
U46619 addition, separately induced significant attenuation of the response 
to subsequent administration of UDP-glucose. When the pancreatic arteries 
were exposed to these ligands half an hour prior to the addition of UDP-
glucose. The contraction to UDP-glucose was significantly attenuated in the 
presence of prior exposure to UDP-glucose (100 µM) and (1 mM), UDP 
(100 µM) and (1 mM) (Figure 3.9), while the lower concentrations of UDP 
(10 µM) or (1 µM) had no significant effect on the subsequent contraction 
to UDP-glucose (data not shown). The response to 100 µM UDP-glucose 
was decreased by 2.5 ± 0.1g in the presence of 100 µM UDP-glucose, and 
by 2.4 ± 0.1g in the presence of 100 µM UDP (P < 0.001, n=10-13, Figure 
3.9). 
 
Figure 3.9. Effect of UDP-glucose (100 µM) and UDP (100 µM) on the 
contraction to UDP-glucose (the control) in U46619-preconstricted porcine 
pancreatic arteries. Both UDP-glucose and UDP significantly attenuated the 
contraction evoked by UDP-glucose (***P < 0.001, two-way ANOVA, UDP-
glucose contraction in the absence or presence of UDP-glucose or UDP, 
F=63.11, 56.48; n=10-13).  
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3.4.8. Effect of DE-meATP on the contractions to UDP-
glucose and UDP in porcine isolated pancreatic 
arteries 
 
To find out whether UDP-glucose or UDP act at P2X receptors, the 
contractions to UDP-glucose and UDP were investigated in the presence of 
DE-meATP (1 µM). As seen in Figure 3.10, the contractions to UDP-glucose 
or UDP were not altered in the presence of the desensitising agent, which 
rule out the involvement of P2X receptors in the contraction to P2Y14 
ligands. 
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Figure 3.10. Effect of DE-meATP (1 µM), a P2X receptors desensitising 
agent, on contraction to (A) UDP-glucose and (B) UDP in U46619-
preconstricted porcine pancreatic arteries. DE-meATP had no significant 
effect on the responses to (A) UDP-glucose (n=8-10) or (B) UDP (n=10-
16). 
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3.4.9. Investigation of the expression of P2Y14 
receptors in porcine pancreatic arteries 
 
The expression of P2Y14 receptor was investigated in porcine pancreatic 
arteries using western blotting in the presence of a rabbit polyclonal 
antiserum against C-terminal tail of the P2Y14 receptor (green bars). This 
was performed in the presence of mouse GAPDH monoclonal antibody (red 
bars), which determines the total amount of the protein in the sample, and 
showed an immunoreactive band at around 37 kDa. The P2Y14 receptor 
mRNA has been identified previously in the rat heart (Musa et al., 2009), 
and thus it has been used as a positive control in the current study. 
In the absence of the P2Y14 primary antibody, no bands were evident 
(Figure 3.11A), similarly, no bands were evident following pre-incubation 
with the neutralizing antigen (Lifespan Biosciences, Inc, cat No. LS-
C120603) (data not shown). While two immunoreactive bands were 
obtained in the presence of the P2Y14 antibody, one around 59 kDa with 
second band at around 41 kDa in rat heart (RH) and porcine heart (PH), 
which are used as positive controls in the current study (Figure 3.11B). 
These findings were consistent with other reports which showed the 
presence of P2Y14 receptors in HEK-293 cells and liver hepatocellular cells 
(HepG2) with an immunoreactive band of approximately 41 kDa (Lifespan 
Biosciences, cat No. LS-C120603), and in human brain membranes and 
human P2Y14 receptor-transfected HEK-293 cells with multiple 
immunoreactive bands of around 40-65 kDa (Moore et al., 2003; 
.U]HPLĔVNLet al., 2008). In contrast, the previous immunoreactive bands 
were also apparent in undifferentiated HL-60, in differentiated SH-SY-5Y 
(neuronal cells) and in mouse thoracic aorta (Moore et al., 2003; Fricks et 
al., 2009; Kauffenstein et al., 2010) (Figure 3.12), which were reported not 
to express P2Y14 mRNA, and used as negative controls in my study. The 
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previous observations suggested some lack of specificity of the P2Y14 
receptor antibody, used in the current study. In porcine pancreatic arteries 
(PPA), two immunoreactive bands were also apparent at 59 kDa and 41 
kDa, indicating the expression of P2Y14 receptor in my arteries. 
 
Figure 3.11. The P2Y14 protein expression detected using western blotting, 
in the absence (A) or in the presence (B) of P2Y14 antiserum (green bars). 
(A), (B) The total protein was determined using GAPDH antibody (red 
bars). Two immunoreactive bands were evident in rat heart (RH) (10 
µg/lane), in porcine heart (PH) (10 µg/lane) and in porcine pancreatic 
arteries (PPA) (20 µg/lane) at around 59 and 41 kDa. The band sizes of the 
molecular weight markers from top to bottom are 75, 50, 36 kDa 
respectively. Blots are representative of staining from six separate 
experiments. 
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Figure 3.12. The P2Y14 protein expression detected using western blotting, 
in presence of P2Y14 antiserum (green bars). The total protein was 
determined using GAPDH antibody (red bars). Samples were loaded at 10 
µg/lane. An immunoreactive band was evident in HEK-293 cells (HEK), 
mouse brain (MB), mouse thoracic aorta (MTA), rat brain (RB), 
undifferentiated HL-60 cells and differentiated SH-SY-5Y at 41 kDa. The 
band sizes of the molecular weight markers from top to bottom are 50, 36 
kDa respectively. Blots are representative of staining from three separate 
experiments. 
 
 
 
 
Chapter 3 
Effects of UDP-glucose, UDP & MRS2690 on vascular tone 
 
108 
 
3.4.10. P2Y14-like receptor immunostaining in porcine 
isolated pancreatic arteries 
 
Since removal of the endothelium significantly attenuated the contraction 
evoked by P2Y14 receptor agonists (by almost half), the expression of P2Y14 
receptors in porcine pancreatic arteries was investigated using 
immunohistochemistry. An intense P2Y14-like receptor immunoreactivity 
was observed in the endothelial cells of the pancreatic arteries (Figure 
3.13A, C). Staining was evident, but was less intense, in the smooth 
muscle of the pancreatic arteries (Figure 3.13A, C). In the absence of anti 
GPR105/P2Y14 receptors, no staining was obtained (Figure 3.13D). 
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Figure 3.13. P2Y14±like receptor immunoreactivity in porcine pancreatic 
arteries. (A), (B) Cross-sections of the arteries showing staining in the 
presence of (A) P2Y14 receptor antiserum, (B) 1% (w/v) toluidine blue, in 
smooth muscle (SM) and endothelial cells (EC). (C), (D) Longitudinal 
sections of the arteries showing immunostaining in the presence (C) and 
absence (D) of P2Y14 receptor antiserum in smooth muscle (SM) and 
HQGRWKHOLDO FHOOV (& 6FDOH EDU    ǋP ,PDJHV DUH UHSUHVHQWDWLYH RI
staining from three separate experiments. 
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3.4.11. Effect of GPR17 receptor antagonist on the 
contraction to UDP-glucose in porcine isolated 
pancreatic arteries 
 
Recently, a new G protein-coupled receptor, GPR17 was identified as a 
P2Y-like receptor, which is activated by UDP-glucose, UDP and cysteinyl 
leukotriene, and is primarily coupled to Gi protein leading to an inhibition of 
cAMP (Fumagalli et al., 2011). This receptor was mainly found in neurons 
and it plays a significant role in some physiological and pathological 
processes, including brain injury, spinal cord injury (Zhang et al., 2013), 
but little is known about its influence in the cardiovascular system. To 
investigate the possible functional expression of GPR17 receptor in 
pancreatic arteries (Fumagalli et al., 2011), the contraction to UDP-glucose 
was studied in the presence of Drug X (1 µM), an antagonist of the purine 
binding site on GPR17 receptor. Drug X failed to inhibit the contraction to 
UDP-glucose (Figure 3.14), indicating that GPR17 receptor is not involved 
in the contraction to UDP-glucose. 
 
Figure 3.14. Effect of Drug X (1 µM), an antagonist of the purine binding 
site on GPR17 receptor, on contraction to UDP-glucose in U46619-
preconstricted porcine pancreatic arteries. Drug X had no significant effect 
on the response to UDP-glucose (n=5). 
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3.5. Discussion 
 
The current study presents evidence for the functional expression of 
contractile P2Y14 receptors, sensitive to the endogenous nucleotides, UDP-
glucose and UDP, in arteries of pig pancreas. Evidence from the 
immunostaining along with the results obtained in endothelium-denuded 
arteries strongly suggested that the expression of P2Y14 receptors is mainly 
on the endothelium of the porcine pancreatic arteries. 
 
3.5.1. Functional expression of P2Y14 receptor in porcine 
pancreatic arteries 
 
The contractile studies (Figure 3.1) together with the immunoblotting 
studies (Figure 3.11) suggested the expression of the P2Y14 receptor in 
porcine pancreatic arteries. The contractions to UDP-glucose and UDP were 
almost equipotent, whereas the contraction to MRS2690, a selective P2Y14 
receptor agonist, was approximately 10-fold more potent than those of 
UDP-glucose and UDP at the P2Y14 receptor (Figure 3.1). This is consistent 
with previous reports which suggested a 7-10 fold greater potency of 
MRS2690 over UDP-glucose (Jacobson et al., 2009; Gao et al., 2010). In 
the current study, 056DFWLYLW\ZDVREVHUYHGDW0DW0, 
MRS2690 has been reported to be inactive at P2Y2 receptors, indicating 
that the contraction observed in the presence of MRS2690 is mediated by 
acting at P2Y14 receptor in pancreatic arteries (Ko et al., 2009). 
PPTN is a non-nucleotide, high affinity competitive antagonist at P2Y14 
receptors. When it was assessed in HEK-293 cells using a calcium 
mobilisation assay, PPTN inhibited UDP-glucose mediated signalling 
(Robichaud et al., 2011). In addition, PPTN showed no effect on other P2Y 
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receptors at concentrations up to 10 µM (Barrett et al., 2013). In the 
current study, when the responses to P2Y14 receptor agonists were 
examined in the presence of this antagonist, PPTN blocked the contractions 
induced by UDP-glucose and MRS2690 which was consistent with the 
involvement of P2Y14 receptors in pancreatic arteries (Figure 3.2A, B). The 
selectivity of PPTN for P2Y14 receptor over P2Y2, P2Y4 and P2Y6 receptors 
has been assessed in porcine pancreatic arteries, by examining the 
contraction induced by UTP (an agonist for P2Y2, P2Y4 and P2Y6 receptors, 
Burnstock & Williams, 2000) in the presence of PPTN. The data suggested 
some selectivity of PPTN at P2Y14 receptor because the response to UTP in 
the presence of PPTN was different from that of UDP-glucose (Figure 
3.2C),. UDP showed a high selectivity at P2Y14 receptors in the previous 
reports (Carter et al., 2009), besides, in the current study UDP induced a 
contraction of porcine pancreatic arteries (Figure 3.1), which can be 
mediated by P2Y14 receptor.. Therefore, further studies are still required to 
investigate the effect of PPTN on the contraction induced by UDP in  
pancreatic arteries to confirm whether it is mediated by action at P2Y14 
receptors. Unfortunately, due to the limited availability of PPTN, these 
experiments were not performed.  
 
3.5.2. Investigation of the effect of non-selective P2 
receptor antagonists on the contraction to P2Y14 
receptor agonists 
 
The responses to P2Y14 receptor agonists were examined in the presence of 
the non-selective P2 receptor antagonists, suramin and PPADS, as there is 
no information available on the sensitivity of P2Y14 receptor to suramin and 
PPADS. The non-selective antagonists induced an increase in the 
contractions to UDP and UDP-glucose (Figure 3.5A, B). However, they 
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failed to alter the response to MRS2690 (Figure 3.5C). The lack of effect of 
suramin and PPADS, as inhibitors of the contractions-evoked by UDP-
glucose and UDP, appears to rule out an involvement of P2Y2 and/or P2Y4 
receptors. Since it has been shown, in the current study, that they blocked 
the responses to UTP in porcine pancreatic arteries (section 2.4.3.1) and 
other tissues, including porcine coronary arteries and porcine ear arteries 
(Rayment et al., 2007a). It has been reported that UDP-glucose and UDP 
can be broken down by eNPPs and eNTPDases respectively, resulting in 
decreased nucleotide activities (Murphy-Piedmonte et al., 2005; 
Kauffenstein et al., 2010; O'Keeffe et al., 2010). Some reports indicate 
that both suramin and PPADS act as inhibitors for eNPPs as well as for 
eNTPDases (Chen et al., 1996; Grobben et al., 1999; Vollmayer et al., 
2003; Munkonda et al., 2007). Therefore, one explanation of the 
enhancement to the contractions to UDP-glucose and UDP, occurred in the 
presence of suramin and PPADS is that when the responses to UDP and 
UDP-glucose were tested in the presence of suramin and PPADS, the 
vasoconstrictions induced by these agonists were enhanced due to the 
enhancement with their availability (Figure 3.5A, B). Whereas, there was 
no change to the response to MRS2690 in the presence of suramin and 
PPADS (Figure 3.5C), since the MRS2690 could be more stable and it is not 
affected by ecto-nucleotidase enzymes.  
To test this hypothesis, the responses to UDP-glucose, UDP and MRS2690, 
were examined in the presence of ARL67156. In contrast, ARL67156 failed 
to alter the responses to all of these agonists (Figure 3.7). However, 
ARL67156 at concentrations used in the literature 50-100 µM has been 
shown to be a weak inhibitor of some human and mouse ecto-nucleotidase 
isoforms (NTPDase1, NTPDase3 and NPP1) (Levesque et al., 2007). In the 
current study, the concentration used for ARL67156 was 10 µM. Therefore, 
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insufficient blockade of ecto-nucleotidases by 10 µM may explain the lack 
of effect of ARL67156 on the contractions to P2Y14 receptor agonists. We 
could not investigate the effects of higher concentrations due to cost 
considerations. Therefore, investigating the contractions to P2Y14 receptor 
agonists in the presence of higher concentrations of ARL67156 is required. 
It would be also useful to use ǃǄ-meATP as an ecto-nucleotidases inhibitor, 
since it was shown in the report of Joseph et al. (2004) that it acts as 
eNPPs inhibitor as well as eNTPDases inhibitor, which was also found to 
significantly inhibit the hydrolysis of UDP-glucose in 1321N1 cell line (Kreda 
et al., 2008). 
Alternatively, the enhancement of the responses to UDP and UDP-glucose 
may involve other P2Y receptor subtypes. UDP and UDP-glucose are not 
selective agonists at P2Y14 receptors. UDP-glucose was found to be a weak 
full agonist, with an EC50 of 10 ǋM, at P2Y2 receptors and its effect could be 
antagonised by suramin and PPADS (Shen et al., 2004; Ko et al., 2009). 
Additionally, UDP was reported to be a ligand at P2Y6 receptors, which may 
be present on the endothelial cells and account for relaxation to UDP 
observed in some arteries, such as mouse thoracic aorta (Guns et al., 
2005; Bar et al., 2008). Similarly, endothelial P2Y2 receptor was reported 
to induce a vasorelaxation in human vascular endothelial cells and in 
mouse thoracic aorta mediated by ATP and UTP (Guns et al., 2006; Raqeeb 
et al., 2011). In my preparations, UDP-glucose and UDP induced 
contractions which were significantly increased in the presence of suramin, 
PPADS and MRS2578 (in the case of UDP) (Figure 3.5A, 3.5B, 3.6A). It is 
possible that UDP-glucose acted at P2Y14 receptors to induce a contraction, 
as well as acting partly at P2Y2 receptors on endothelial cells to induce a 
relaxation. Meanwhile, UDP acted at P2Y14 receptors to induce a 
contraction, as well as acting partly at P2Y6 receptors on endothelial cells to 
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induce a relaxation. The relaxation induced by UDP and UDP-glucose was 
blocked by suramin, PPADS and MRS2578 (in the case of UDP), and 
accordingly that would increase the contractile response to UDP and UDP-
glucose. MRS2690 is a selective agonist at P2Y14 receptors (Jacobson et al., 
2009), and consequently its response was not altered in the presence of 
these antagonists. Indeed, it is not fully clear why these antagonists 
enhanced the effects of P2Y14 receptor agonists. However, it is apparent 
that suramin and PPADS had different effects on UTP responses (section 
2.4.3.1) versus responses of MRS2690, UDP and UDP-glucose indicating 
actions at distinct receptors. 
 
3.5.3. Effect of the removal of the endothelium, and the 
involvement of P2X or GPR17 receptors 
 
Contractile responses to UDP-glucose, UDP and MRS2690 were significantly 
inhibited after the endothelium was removed (Figure 3.8). In addition, 
immunostaining showed that the expression of P2Y14-like receptors is 
mainly on the endothelium of the pancreatic arteries, with slight expression 
on the smooth muscle (Figure 3.13). This indicated an involvement of 
endothelial P2Y14 receptor-mediated contraction in pancreatic arteries. 
Similarly, the protein for P2Y14 receptor has been reported to be expressed 
in the endothelial cells of the porcine coronary artery, the portion and 
mRNA were also evidenced in human lung microvascular endothelial cells, 
and mRNA for P2Y14 receptor was shown in pulmonary artery vasa vasorum 
endothelial cells (Umapathy et al., 2010; Abbas et al., 2011; Lyubchenko 
et al., 2011). While mRNA expression for P2Y14 receptor was barely 
detectable in mouse thoracic aorta and in human coronary artery 
endothelial cells (Kauffenstein et al., 2010; Ding et al., 2011). In contrast, 
rat aortic smooth muscle cells showed robust expression of mRNA for the 
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receptor, as observed in freshly isolated and cultured cells (Govindan et al., 
2010). 
It has been reported that pyrimidine nucleotides might interact with P2X 
receptors, which would influence their responses (Froldi et al., 1997; Froldi 
et al., 2001; Mo et al., 2013). To test whether UDP-glucose or UDP bind to 
P2X receptors expressed in porcine pancreatic arteries (section 2.4.2.2), 
DE-meATP, which desensitises P2X1 and P2X3 receptors (Kasakov & 
Burnstock, 1982), was employed. However, as seen in Figure 3.10, DE-
meATP had no effect on the responses to UDP-glucose or UDP, which ruled 
out the involvement of P2X receptors in the responses to UDP-glucose and 
UDP. P2Y-like GPR17 receptor is reported to play a significant role in the 
central nervous system (Fumagalli et al., 2011). A recent study showed 
that inhibition of the activity of GPR17 receptor is effective for the 
modulation of bronchoconstriction in humans with bronchial asthma 
(Maekawa et al., 2010). In addition, this receptor can be activated by UDP-
glucose and UDP (Fumagalli et al., 2011). Therefore, a study was 
conducted to identify whether GPR17 receptor plays a role in the 
contraction to UDP-glucose in porcine pancreatic arteries. The data in 
Figure 3.14 indicated that GPR17 receptor is not involved in the 
contraction-mediated by UDP-glucose, which indicated that the contraction 
to UDP and UDP-glucose were solely mediated by acting at P2Y14 receptor. 
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3.6. Conclusion 
 
The data presented in this chapter described novel vasocontractile actions 
of UDP-glucose, UDP and MRS2690 which are mediated by the P2Y14 
receptor in porcine isolated pancreatic arteries. The functional expression 
of P2Y14 receptor was shown, by the contractile studies and by 
immunostaining for P2Y14 receptors, to be mainly on the endothelium, with 
slight expression on the smooth muscle of the pancreatic arteries. The data 
rule out the involvement of P2X receptors or P2Y-like GPR17 receptors in 
the responses to UDP or UDP-glucose, which indicate that P2Y14 receptor is 
the most influential receptor regarding the contraction obtained in 
responses to UDP, UDP-glucose or MRS2690. Since alterations in blood flow 
can influence physiological and pathological functions of the pancreas, a 
drug which decreases the activity of P2Y14 receptor as a vasoconstrictor of 
porcine pancreatic arteries, such as PPTN, may serve as a potential 
therapeutic approach for the treatment of some pancreatic diseases. 
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Investigation of the signalling pathways 
underlying the responses to UDP-
glucose, UDP and MRS2690 in porcine 
isolated pancreatic arteries 
 
4.1. Introduction 
 
P2Y14 receptor activation involves Gi protein-mediated signalling, leading to 
an inhibition of adenylyl cyclase activity (hence decreases in cAMP level) 
and, accordingly, it is pertussis toxin-sensitive (Jacobson et al., 2009). Gi 
protein-derived GǃǄ-GLPHUV FDQ LQLWLDWH SKRVSKROLSDVH &ǃ signalling 
pathways, which lead to the stimulation of diacylglycerol and inositol 1,4,5-
trisphosphate and subsequent activation of RhoA/ROCK signalling, protein 
kinase C (PKC) and myosin light chain kinase (MLCK) (Amano et al., 1996; 
Hartshorne & Gorecka, 2011; Sesma et al., 2012).  
It has been indicated in previous reports that P2Y14 receptors were involved 
in the regulation of intracellular Ca2+ (Skelton et al., 2003). This effect was 
also shown by further studies which demonstrated the ability of UDP-
glucose and UDP to increase the intracellular calcium in RBL-2H3 mast 
cells, as well as showing the ability of UDP-glucose to induced a rapid and 
concentration-dependent Ca2+ elevation in epithelial cell lines, A549 and 
BEAS-2B (Muller et al., 2005; Gao et al., 2010). The effects of UDP-glucose 
and UDP on Ca2+ elevation in the previous cells was abolished following 
pre-treatment with PTX, which catalyses ADP-ribosylation of the Di 
subunits, resulting in inactivation of Gi protein. The inhibition in the effect 
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of UDP-glucose following pre-treatment with PTX confirmed an involvement 
of P2Y14 receptor coupled to Gi proteins (Muller et al., 2005; Gao et al., 
2010). 
Activation of Gi protein coupled receptors may also involve an activation of 
mitogen-activated protein kinases (MAPK), thus, when the effect of UDP-
glucose on (ERK1/2) was tested in HEK-293 cells, UDP-glucose evoked a 
concentration-dependent elevation in phosphorylated ERK (Fricks et al., 
2009; Harden et al., 2010). The ability of UDP-glucose to induce elevation 
in phosphorylated ERK1/2 in HEK-293 cell line was abolished when the cells 
were pre-incubated with pertussis toxin indicating signalling through Gi 
proteins (Fricks et al., 2009; Harden et al., 2010). Although many attempts 
have been carried out to investigate the signalling pathways involving the 
P2Y14 receptor activation, there is still a lack of knowledge in that respect 
in the cardiovascular system. Therefore, the aim of this chapter is to 
investigate the signalling pathways underlying the contraction evoked by 
UDP-glucose, MRS2690 and UDP through activating P2Y14 receptors in 
porcine isolated pancreatic arteries. 
 
4.2. Materials and methods 
 
4.2.1. Tissue preparation 
 
Pancreata from pigs were obtained on ice from a local abattoir (G Wood & 
Sons Ltd, Mansfield). A crude dissection was conducted to isolate the 
pancreatic arteries (dorsal pancreatic artery) (Figure 1.9, main), followed 
by a fine dissection to obtained rings of 0.5 cm in length, which were 
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suspended between two wires LQ.UHEV¶-Henseleit buffer (gassed, 95% O2, 
5% CO2), as described in section 2.2.1. 
Endothelium denudation (by gentle rubbing) was conducted using the same 
protocol described in section 2.2.1. 
 
4.2.2. Responses in the porcine isolated pancreatic 
artery 
 
Arterial rings were mounted onto wires in tissue baths containing warm 
& R[\JHQDWHG .UHEV¶-Henseleit solution and were connected via 
isometric force transducers (ADInstruments, Sydney, Australia) to a PC 
running the computer program LabChart (ADInstruments, Sydney, 
Australia). Rings were put under tension (15 g) and allowed to equilibrate 
for 60 min before being treated as described in section 2.2.2. Then U46619 
(10-100 nM) was used to contract the tissues to 40-80% of the second KCl 
response. Once an appropriate level of U46619 response had been 
achieved, cumulative addition of UDP-glucose, UDP or MRS2690 were 
applied. Antagonists or inhibitors [nordihydroguiaretic acid (NDGA) (10 
µM), nifedipine (10 µM), thapsigargin (100 nM), zafirlukast (10 µM), BQ788 
(N-cis-2,6-dimethylpiperidinocarbonyl-L-gmethylleucyl-D-1-
methoxycarboyl-D-norleucine) (1 µM), PD98059 (2-(2-amino-3-
methoxyphenyl)-4H-1-be­nzopyran-4-one) (10 µM), DUP 697 (3 µM), 
BQ123 (cyc(DTrp-DAsp-Pro-D-Val-Leu)) (1 µM), Y-27632 (trans-4-[(1R)-1-
aminoethyl]-N-4-pyridinyl-cyclohexane carboxamide) (10 µM), (5 µM)]  
were applied 10 min prior to the addition of U46619, allowing incubation 
with the tissues for a minimum of 30 min prior to the application of the 
agonists. An exception to the pre-constriction with U46619, were 
experiments with L-655,240 (1-[(4-Chlorophenyl)methyl]-5-fluoro-ĮĮ-
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trimethyl-1H-indole-2-propanoic acid) (1 µM), in which arteries were pre-
constricted with endothelin-1 (1±10 nM). In experiments using DMSO as 
the solvent (see reagents and drugs section 4.2.6), DMSO 0.1 % (v/v) was 
added to the arteries as vehicle controls. 
 
4.2.3. Effect of forskolin on subsequent UDP-glucose or 
UTP responses 
 
Tissues were exposed to U46619 (10-100 nM) and relaxed with forskolin (1 
µM, to induce an elevation of cAMP level), or with sodium nitroprusside 
(SNP) (100 µM, to induce an elevation of cyclic guanosine-¶-
monophosphate (cGMP) level), back to the baseline. Cumulative 
concentration-response curves were then constructed for UDP-glucose (1 
µM±1 mM) or UTP (10 µM±1 mM). Responses to UDP-glucose or UTP 
obtained under these conditions were compared to the control responses in 
which drugs were added at basal tone without exposing to either U46619 
or forskolin. The tissues were allowed to recover for 20 min before 
concentration-response curves to UDP-glucose or UTP were constructed. 
 
4.2.4. Western blotting 
 
Segments of porcine pancreatic arteries were set up in the organ baths (20 
ml) and tensioned to 15 g, then left for approximately 60 min to reach a 
new baseline of resting tension. Then tissues were incubated with 100 µM 
UDP-glucose for 30, 60, 120, 180, 240 and 300 s for MLC, isoform 2 
phosphorylation study and for 30, 60, 120 and 300 s for ERK1/2, JNK and 
p38 phosphorylation studies. Segments were rapidly removed from the 
organ baths and immediately frozen on dry ice. Control tissues were not 
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exposed to any compound (basal conditions). Segments were then 
homogenised with a borosilicate glass homogeniser in lysis buffer (section 
3.2.5), containing protease inhibitor cocktail tablets, EDTA-free. After 
removal of a sample for a protein assay (section 3.2.5), samples were 
diluted 1:6 into solubilisation buffer 6×SB: (section 3.2.6), and were 
heated at 95°C for 5 min. Subsequently, electrophoresis was carried out on 
4-20% Tris-Glycine (PAGE) Gold Precast Gels (Bio-Rad, Hercules, CA, 
U.S.A.), 15 µg protein per lane was loaded for MLC2 study, 10 µg protein 
was loaded for JNK and p38 studies, while 0.5 µg protein per lane was 
loaded for ERK1/2 study.  
Samples were transferred to nitrocellulose membranes. Next, blots were 
incubated in blocking solution (5% (w/v) powdered milk in Tris-buffered 
saline containing 0.1% (v/v) Tween 20 (Fisher Scientific UK Ltd., 
Loughborough, UK)) for 60 min, at room temperature. Blots were 
incubated overnight at 4°C with primary antibodies against phosphorylated 
MLC2 (1:500) and total MLC2 (1:1000) or against phosphorylated p38 
MAPK (1:1000) and total p38 MAPK (1:1000) or against phosphorylated 
SAPK/JNK (1:1000) and total SAPK/JNK (1:1000) or against 
phosphorylated ERK1/2 (1:1000) and total ERK1/2 (1:1000) diluted in the 
blocking solution. After washing in Tris-buffered saline containing 0.1% 
(v/v) Tween 20, the blots were incubated with an appropriate IRDye® 
secondary antibody (Li-Cor Biosciences, Biotechnology, Lincoln, NE, USA). 
Proteins were visualised using the Licor/Odyssey infrared imaging system 
(Biosciences, Biotechnology). Bands were analyzed by densitometry using 
the Odyssey application software, and expressed as phosphorylated MLC2 
or ERK1/2 normalised to total MLC2 or ERK1/2 respectively. 
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Antibody Cat No. Host MW Sequence 
PMLC 3674 rabbit 18 threonine 18/serine 19 
MLC 3672 mouse 18 threonine 18/serine 19 
PERK1/2 4370 rabbit 44/42 threonine 202/Tyrosine 204, 
threonine 185/tyrosine 187 
ERK1/2 9102 mouse 44/42 threonine 202/Tyrosine 204, 
threonine 185/tyrosine 187 
 
 
4.2.5. cAMP measurement in porcine pancreatic arteries 
 
Pancreatic artery rings were stimulated with 75 mM KCl and then 
challenged with UDP-glucose (1 mM), MRS2690 (1 µM), UTP (1 mM) or 
distilled water (control group), preceded by U46619 (10-100 nM) plus 
forskolin (1 µM). When the contractions to UDP-glucose or MRS2690 
reached a plateau (~3 min after addition of agonists), the segments were 
quickly removed from the tissue baths, and immediately frozen on dry ice 
and stored in vials at -80oC, for later use. For cAMP measurement, the 
tissue samples were homogenised in 5% (w/v) trichloroacetic acid (TCA) in 
distilled water with a borosilicate glass homogeniser, and then centrifuged 
for 10 min at 1500 g. TCA was extracted from the supernatant samples 
using water-saturated ether at room temperature, and then evaporated for 
5 min at 70oC to remove the residual ether from the aqueous fractions. 
Samples were diluted (1:2) in ether-extracted 5% (w/v) TCA. cAMP 
concentration was measured using a competitive enzyme immunoassay kit 
(EIA kit) (see reagents and drugs section 4.2.6). The working range of the 
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cAMP assay was 0.1±1000 pmol/ml. cAMP concentration was expressed as 
a percentage of forskolin-induced cAMP elevation. 
 
4.2.6. Reagents and drugs 
 
NDGA, nifedipine, thapsigargin, SNP, zafirlukast, Tween 20, UK14304 (5-
Bromo-6-(2-imidazolin-2-ylamino)quinoxaline), BQ788, UDP-glucose and 
UDP were purchased from Sigma (Poole, Dorset, UK), while DUP 697, 
MRS2578, PD98059, L-655,240, endothelin-1, BQ123, pertussis toxin, Y-
27632 and forskolin were purchased from Tocris Biosciences Ltd. (Bristol, 
UK). Primary antibodies for western blotting were purchased from Cell 
Signalling Technology (Danvers, MA, USA) for phosphorylated MLC2 
antibody (cat No. 3674), for total MLC2 antibody (cat No. 3672), for 
phosphorylated p44/42 MAPK (ERK1/2) (cat No. 4370), for total p44/42 
MAPK (ERK1/2) (cat No. 9102), for phosphorylated p38 MAPK (cat No. 
9216), for total p38 MAPK (cat No. 8690), for phosphorylated SAPK/JNK 
(cat No. 9255) and for total SAPK/JNK (cat No. 9258). Cyclic AMP EIA kit 
(cat No. 581001) was purchased from Cayman Chemical Company, (Ann 
Arbor, MI). DUP 697, BQ788, L-655,240, nifedipine, thapsigargin, 
zafirlukast, UK14304, PD98059 and forskolin were dissolved in DMSO. All 
other drugs were dissolved in distilled water. For information about the 
sources and the solvents of other reagents and drugs, see section 2.2.3 
and 3.2.5. 
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4.3. Statistical analysis 
 
Data were expressed as log concentration-response plots. The contraction 
to all agonists was expressed in g, and measured from the stabilised 
U46619 response. Values for all figures refer to mean ± S.E.M with 95% 
confidence. Results were compared by two-ZD\ $129$ RU 6WXGHQW¶V
unpaired t-test (Prism, GraphPad, San Diego, CA, USA). Differences were 
considered to be significant when the P value was < 0.05. 7KH³Q´ LQWKH
results expresses the number of animals. 
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4.4. Results 
 
4.4.1. Effect of DUP 697 on responses to UDP-glucose, 
UDP and MRS2690 in porcine isolated pancreatic 
arteries 
 
Because the contractions to P2Y14 receptor agonists were mainly 
endothelium-dependent (section 3.4.6), the effect of DUP 697, a 
cyclooxygenase-2 inhibitor, on the contraction to P2Y14 receptor agonists 
was investigated, since COX-2 facilitates the release of some agents which 
are responsible for the endothelium-dependent contraction (Mombouli & 
Vanhoutte, 1993; Wong et al., 2009). DUP 697 (3 µM) diminished the 
contractions to UDP-glucose, UDP and MRS2690 to a similar extent as 
removal of the endothelium (Figure 3.8), while DUP 697 did not alter the 
contraction to U46619 (the pre-constriction agent) or the contraction to 
ATP (section 2.4.3.3). DUP 697 reduced the contraction to 1 mM UDP-
glucose by 1 ± 0.2g (P < 0.001, n=11), that to 1 mM UDP by 0.55 ± 0.2g 
(P < 0.001, n=15) and that to 30 µM MRS2690 by 0.5 ± 0.4g (P < 0.01, 
n=4), (Figure 4.1). 
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Figure 4.1. Effect of DUP 697 (3 µM) on responses to (A) UDP-glucose, 
(B) UDP, (C) MRS2690 in U46619-preconstricted porcine pancreatic 
arteries. DUP 697 inhibited the contractions-evoked by (A) UDP-glucose, 
(B) UDP, (C) MRS2690 (**P < 0.01, ***P < 0.001, two-way ANOVA, 
F=7.85, 35.31, 4.95 respectively; n=4-15). 
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4.4.2. The role of endothelium-derived contractile 
factors in the response to UDP-glucose in porcine 
isolated pancreatic arteries 
 
The following experiments were carried out using mainly UDP-glucose or 
UDP due to the cost considerations involved with use of MRS2690. The 
possible involvement of thromboxane A2, leukotrienes, endothelin-1 and 
prostaglandins, which can be released from endothelial cells (Mombouli & 
Vanhoutte, 1993; Kurahashi et al., 2003; Wong et al., 2009), in 
endothelially-mediated contraction to UDP-glucose was investigated. The 
contraction to UDP-glucose was not altered in the presence of NDGA (10 
µM), a lipoxygenase inhibitor (Figure 4.2A) or zafirlukast (10 µM), a 
selective cysteinyl leukotriene type 1 receptor antagonist (Figure 4.2B). 
The contraction to UDP-glucose was reduced in the presence of BQ123 (1 
µM), a selective endothelin ETA receptor antagonist (Ki value is 1.4 nM at 
ETA receptor (Sakamoto et al., 1993)); for example, the response to 100 
µM UDP-glucose was attenuated by 0.2g (P < 0.05, n=14) in the presence 
of BQ123 (Figure 4.2C), which was only effective in the arteries with intact 
endothelium (Figure 4.2D). The contraction to UDP-glucose was unaltered 
in the presence of BQ788 (1 µM), a selective endothelin ETB receptor 
antagonist (IC50 of 1.2 nM for inhibition of endothelin-1 in human girardi 
heart cells (Okada et al., 2002)) (Figure 4.2E). UDP-glucose induced-
contraction was reduced in the presence of L-655,240 (1 µM), a selective 
thromboxane A2/prostaglandin receptor antagonist (IC50 of 7 nM for 
inhibition of endothelin-1 in human platelet aggregation) (Hall et al., 1987; 
Wong et al., 2009); for example, the response to 1 mM UDP-glucose was 
inhibited by 0.6 ± 0.1g (P < 0.001, n=9) in the presence of L-655,240 
(Figure 4.2F). These data indicated that UDP-glucose mediated-contraction 
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occurs mainly via thromboxane and prostaglandins, with a lesser 
involvement of endothelin-1. 
 
Figure 4.2. The contraction evoked by UDP-glucose in the presence of (A) 
NDGA (10 µM), (B) zafirlukast (10 µM), (C) BQ123 (1 µM), (D) in 
endothelium-denuded arteries in the presence or absence of BQ123 (1 µM) 
(E) BQ788 (1 µM) in U46619-preconstricted porcine pancreatic arteries, (F) 
L-655,240 (1 µM) in endothelin-1-preconstricted porcine pancreatic 
arteries. (A), (B), (E) NDGA, zafirlukast and BQ788 did not alter the 
responses to UDP-glucose (n=7-10). (C), (F) BQ123 and L-655,240 
inhibited the responses evoked by UDP-glucose (*P < 0.05, ***P < 0.001, 
two-way ANOVA, F=4.97, 19.03 respectively; n=9-14). (D) BQ123 had no 
effect on the contraction evoked by UDP-glucose in endothelium-denuded 
pancreatic arteries. 
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4.4.3. Effect of BQ123 and BQ788 on contraction to 
endothelin-1 in porcine isolated pancreatic 
arteries 
 
Since the contraction to UDP-glucose was decreased in the presence of a 
selective ETA receptor antagonist (Figure 4.2C), that may suggest the 
involvement of endogenous endothelin-1, released as a consequence of 
P2Y14 receptor activation via UDP-glucose. Endothelin-1 may act at 
endothelin ETA receptor in porcine pancreatic arteries to induce a 
contraction. To investigate this further, the contraction to exogenous 
endothelin-1 (0.1±10 nM) was studied in U46619-preconstricted pancreatic 
arteries. As seen in Figure 4.3, endothelin-1 induced a vasoconstriction 
which was inhibited in the presence of BQ123 (P < 0.0001, two-way 
ANOVA), while it was not affected in the presence of BQ788. These findings 
were in agreement with the data in Figure 4.2C, E which indicated the 
involvement of endothelin ETA receptor only in the contraction evoked by 
UDP-glucose, without an involvement of endothelin ETB receptor. 
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Figure 4.3. Effects of BQ123 (1 µM) and BQ788 (1 µM) on contraction to 
endothelin-1 in U46619-preconstricted porcine pancreatic arteries. BQ123 
decreased significantly the contraction to endothelin-1 (***P < 0.001, F= 
51.77; n=4-6), while BQ788 had no effect on the contraction to 
endothelin-1. 
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4.4.4. Effect of pre-constriction with U46619, and 
relaxation with forskolin or incubation with 
pertussis toxin on the response to UDP-glucose in 
porcine isolated pancreatic arteries 
 
Agonist-promoted activation of Gi and subsequent inhibition of adenylyl 
cyclase is one of the signalling responses of P2Y14 receptors. Therefore, the 
response to UDP-glucose was tested after the exposure to U46619 and 
subsequent relaxation by forskolin (back to the baseline), involving an 
elevation of intracellular cyclic AMP. UDP-glucose induced a greater 
contraction compared with the control, in which UDP-glucose was applied 
at basal tone, without the tissues being exposed to U46619 or forskolin 
(Figure 4.4A). The contraction to 1 mM UDP-glucose was enhanced by 2.7 
± 0.2g (P < 0.001, n=11) after exposure to U46619 and forskolin (Figure 
4.4A). In agreement with the data obtained in endothelium-denuded 
pancreatic arteries (section 3.4.6). When the endothelium has been 
removed, exposing the tissue to U46619 and subsequently to forskolin 
enhanced the contraction to UDP-glucose relative to the control (UDP-
glucose was applied at basal tone). However, this elevation was 
significantly less than that in endothelium-intact pancreatic arteries; 
Removal of endothelium reduced the contractions to 1 mM UDP-glucose by 
1 ± 0.3g (P < 0.01, n=15). 
In contrast, when responses to UTP, an agonist at P2Y2 and P2Y4 receptors 
(Gq/11 protein coupled receptors) were investigated in the presence and 
absence of U46619 and forskolin, there was no change within its 
contractions (Figure 4.4B). In addition, the response to UDP-glucose was 
not altered after the arteries were pre-contracted with U46619 and relaxed 
with SNP (100 µM), which elevates intracellular cyclic GMP (Figure 4.5) 
(Roberts et al., 1999), which ruled out the involvement of cGMP in the 
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contraction to UDP-glucose. Typical traces showing the effect of UDP-
glucose on basal tone (inset) and after the tissues had been contracted by 
U46619 and then relaxed back with forskolin (main) are shown in Figure 
4.4C. 
Since P2Y14 receptor is a Gi protein-coupled receptor (Jacobson et al., 
2009), the contraction to P2Y14 receptor agonist (UDP-glucose) was 
examined following overnight incubation of pancreatic arteries with 
pertussis toxin (100 ng/ml or 1 µg/ml), which inhibits Di subunit of Gi 
protein. The study was conducted in the presence of UK14304 (30 µM) 
which is an adrenergic D2 agonist, and it was used in the current study as a 
positive control. By contrast, overnight incubation with PTX had no effect 
on the contractions to UK14304 or UDP-glucose (Figure 4.6).  
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Figure 4.4. Effect of pre-constriction with U46619 followed by relaxation 
with forskolin (1 µM) on the responses to (A) UDP-glucose, (B) UTP in 
porcine pancreatic arteries. (A) Exposing the tissues to U46619 followed by 
forskolin significantly enhanced the contraction evoked by UDP-glucose 
(***P < 0.001, two-way ANOVA, F=54.34; n=8-13). (B) Exposing the 
tissues to U46619 followed by forskolin failed to alter the response to UTP. 
(C) Typical traces showing the effect of UDP-glucose on basal tone (inset) 
and after the tissues were pre-constricted with U46619 and then relaxed 
with forskolin (main). 
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Figure 4.5. Effect of pre-constriction with U46619 followed by relaxation 
with SNP (100 µM) on the response to UDP-glucose in porcine pancreatic 
arteries. Exposing the tissues to U46619 followed by SNP had no significant 
effect on the contraction evoked by UDP-glucose (n=6).  
 
 
 
Figure 4.6. Effect of pertussis toxin (PTX; 1 µg/ml) on contraction 
responses to (A) UK14304 (30 µM), (B) UDP-glucose in U46619-
preconstricted porcine pancreatic arteries. (A), (B) overnight incubation 
with PTX had no effect on the contractions to UK14304 or UDP-glucose 
(n=5-9). 
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4.4.5. Effect of UTP, UDP-glucose and MRS2690 on the 
cAMP level in porcine isolated pancreatic arteries 
 
On the basis that cAMP is involved in the contraction to UDP-glucose 
(section 4.4.4), the cellular levels of this second messenger were measured 
in pancreatic arterial rings. We investigated the effects of UDP-glucose, 
MRS2690 and UTP (as a negative control, since it is coupled to Gq/11 
protein) on cAMP level in the presence of U46619 plus forskolin (to mimic 
the raised tone condition of the pharmacology experiments). UDP-glucose 
(1 mM) and MRS2690 (10 µM) induced a significant decrease within the 
level of cAMP relative to the control, in which the tissues were exposed just 
to U46619 and forskolin; UDP-glucose (1 mM) decreased the level of cAMP 
by 0.19 ± 0.06 pmol\mg tissue, while MRS2690 (10 µM) decreased it by 
0.13 ± 0.02 pmol\mg tissue (*P < 0.05, n=4, Figure 4.7). By contrast, UTP 
had no significant effect on cAMP level (Figure 4.7). 
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Figure 4.7. Effect of UDP-glucose (UDP-G) (1 mM), MRS2690 (10 µM)and 
UTP (1 mM) on the cAMP concentrations in porcine pancreatic arteries 
exposed to U46619 (10-100 nM) followed by forskolin (1 µM). UTP had no 
significant effect on cAMP levels, while UDP-glucose and MRS2690 reduced 
significantly the cAMP level (*P < 0.05, 6WXGHQW¶VXQSDLUHGt-test, the 
responses to UTP or UDP-glucose or MRS2690 vs their respective controls, 
n=4). Basal cyclic AMP level represents the level of cAMP in the absence of 
forskolin. Distilled water was added to the arteries as vehicle controls. 
 
4.4.6. Effect of inhibition of calcium release and calcium 
entry on the responses to UDP-glucose and UDP 
in porcine isolated pancreatic arteries 
 
Binding of agonists to the P2Y14 receptor leads to increased Ca
2+ 
mobilisation in some cells, including A549, BEAS-2B and RBL-2H3 cell lines. 
This elevation could result from triggering PLCǃ signalling pathways 
following activation Gi protein-derived GǃǄ-dimers of P2Y14 receptor. 
Activation of PLCǃ signalling pathways results in an elevation of the level of 
IP3 and DAG, which induce an elevation of the level of intracellular Ca
2+ 
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(Skelton et al., 2003; Gao et al., 2010; Verin et al., 2011). To test this 
mechanism in porcine pancreatic arteries, responses to UDP-glucose and 
UDP were examined in the presence and absence of nifedipine (1 µM), a L-
type voltage-gated calcium channel blocker, and thapsigargin (100 nM), a 
potent inhibitor of sarco-endoplasmic reticulum Ca2+-ATPases which leads 
to depletion of intracellular calcium. Both of these inhibitors reduced 
significantly the contraction- evoked by UDP-glucose; for example, the 
contraction to 1 mM UDP-glucose was reduced by 1 ± 0.1g (P < 0.001, 
n=15) in the presence of nifedipine, and by 0.6 ± 0.2g (P < 0.05, n=15) in 
the presence of thapsigargin (Figure 4.8). Similarly, they attenuated the 
contraction to UDP; for example, contraction to 100 µM UDP was inhibited 
by 0.6 ± 0.2g (P < 0.001, n=9) in the presence of nifedipine, and by 0.4 ± 
0.1g (P < 0.001, n=9) in the presence of thapsigargin. Typical traces 
showing the effect of UDP-glucose in the absence and in the presence of 
nifedipine are shown in Figure 4.8C. 
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Figure 4.8. Effect of (A) nifedipine (1 µM) and (B) thapsigargin (100 nM) 
on the response to UDP-glucose in U46619-preconstricted porcine 
pancreatic arteries. Both inhibitors, nifedipine and thapsigargin, inhibited 
the contraction evoked by UDP-glucose (*P < 0.05, ***P < 0.001, two-
way ANOVA, F=32.5, 5.84; n= 9-15). (C) Typical traces showing the 
responses of UDP-glucose in the absence and in the presence of nifedipine. 
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4.4.7. Effect of inhibition of the Rho-kinase pathway on 
the responses to UDP-glucose, UDP and MRS2690 
in porcine isolated pancreatic arteries 
 
Activation of P2Y14 receptors may cause stimulation of RhoA/ROCK 
signalling (Sesma et al., 2012). To test the possible involvement of this 
pathway, experiments were conducted to study the contractions to UDP-
glucose, UDP and MRS2690 in the presence of Y-27632 (5 10 µM), a 
selective inhibitor of the Rho-associated protein kinase (Ki value is 0.14 ǋ0
for ROCK) (Uehata et al., 1997; Narumiya et al., 2000). Y-27632 
significantly inhibited the contraction evoked by UDP-glucose, UDP and 
MRS2690. For instance, the response to 1 mM UDP-glucose was reduced by 
1.3 ± 0.2g (P < 0.001, n=9, Figure 4.9A), that to 300 µM UDP by 0.7 ± 
0.1g (P < 0.001, n=15, Figure 4.9B) and that to 30 µM MRS2690 by 1 ± 
0.4g (P < 0.001, n=9, Figure 4.9C).  
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Figure 4.9. Effect of Y-27632 (5 µM), a selective inhibitor of the Rho-
associated protein kinase on responses to (A) UDP-glucose, (B) UDP, (C) 
MRS2690 in U46619-preconstricted porcine pancreatic arteries. Y-27632 
reduced significantly the contractions to (A) UDP-glucose, (B) UDP (C) 
MRS2690 (***P < 0.001, two-way ANOVA, F=42.68, 53.07, 10.32; n=9-
15).  
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4.4.8. Effect of UDP-glucose on the level of MLC 
phosphorylation in porcine isolated pancreatic 
arteries 
 
The response to UDP-glucose was associated with an elevation of the level 
of MLC2 phosphorylation at 18 kDa, which was consistent with the 
expected band size reported previously (Cell Signalling Technology, cat No. 
3674). The elevation of the level of phosphorylated MLC2 occurred within 
30-60 s of treatment with 100 µM UDP-glucose, and returned to the basal 
level of phosphorylated MLC within 120-300s, (Figure 4.10), which 
suggested an involvement of MLC activation in the signalling pathways 
underlying the response to P2Y14 receptor agonist. The ability of UDP-
glucose (100 µM) or MRS2690 (10 µM) to elevate the MLC phosphorylation 
(within 30 s of treatment) was decreased by 0.22 ± 0.03 normalised 
intensity (NI) (the ratio of phospho protein to total protein) and 0.12 ± 
0.03 NI respectively (*P < 0.05, n=3, Figure 4.11) in the presence of PPTN 
(1 µM), which indicated that the ability of UDP-glucose or MRS2690 to 
elevate MLC phosphorylation in porcine pancreatic arteries is mediated by 
the activation of P2Y14 receptors. 
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Figure 4.10. Effect of UDP-glucose (100 µM) on MLC phosphorylation in 
porcine pancreatic arteries. UDP-glucose induced changes in MLC 
phosphorylation in a time-dependent manner, the level of MLC 
phosphorylation was elevated within 30-60 s (*P < 0.05, one-way ANOVA 
ZLWK %RQIHUURQL¶V SRVW KRF WHVW, n=4). Representative immunoblots of a 
time course of UDP-glucose-induced change within the level of 
phosphorylated MLC2 from four separate experiments.  
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\Figure 4.11. PPTN (1 µM) abolished the ability of UDP-glucose (100 µM) 
and MRS2690 (10 µM) to elevate the level of phosphorylated MLC within 30 
s of treatment (*P < 0.05, one-ZD\$129$ZLWK%RQIHUURQL¶VSRVWKRFWHVW, 
n=3). Representative immunoblots of MLC2 phosphorylation from three 
separate experiments in the absence or presence of PPTN.  
 
4.4.9. Effect of UDP-glucose and UDP on extracellular 
signal-regulated kinase ERK1/2 phosphorylation 
 
It is previously reported that MAP kinase signalling pathways are 
stimulated via activation of receptors that couple to Gi protein (Harden et 
al., 2010). This effect occurs following triggering PLCǃ signalling pathways 
following activation GǃǄ subunits of P2Y14 receptor. Activation of PLCǃ 
signalling pathways results in an elevation of the level of DAG, which 
activates PKC, the latter is associated with phosphorylation of ERK in many 
cell types (Langan et al., 1994; Marquardt et al., 1994; Zhao et al., 2005). 
That was also shown after activation of P2Y14 receptors in HEK-293 cells via 
UDP-glucose or UDP (Carter et al., 2009). To investigate the involvement 
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of ERK1/2 in the responses to UDP-glucose or UDP in pancreatic arteries, 
PD98059 (10 µM), a MEK inhibitor with an IC50 of 4 µM (Alessi et al., 
1995), was employed. PD98059 was not able to alter the contractions to 
UDP-glucose or UDP (n=9-16) (Figure 4.12A, B). On the other hand, when 
the level of phosphorylated ERK1/2 was determined by western blotting 
using 0.5 µg protein per lane (section 4.2.4), the response to UDP-glucose 
(100 µM) was associated with an increase with the level of phosphorylated 
ERK1/2 at 44, 42 kDa respectively. These were consistent with the 
expected bands size reported previously (Cell Signalling Technology, cat 
No. 4370). The elevation in the level of phosphorylated ERK1/2 was 
apparent within 60 s of the treatment, and peaked within 300 s (*P < 
0.05, **P < 0.01, 6WXGHQW¶VXQSDLUHGt-test, n=6) (Figure 4.12C), before it 
returned back to the basal level of phosphorylated ERK1/2 within 10 min 
(data not shown). In contrast, UDP-glucose was not able to elevate 
phosphorylated JNK or p38 level up to 5 min of treatment with 100 µM 
UDP-glucose (data not shown). 
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Figure 4.12. Effect of PD98059 (10 µM) on the contractions to (A) UDP-
glucose, (B) UDP in U46619-preconstricted porcine pancreatic arteries. 
PD98059 had no significant effect on the responses to UDP-glucose or UDP 
(n=9-16). (C) UDP-glucose (100 µM) induced elevation with the level of 
ERK1/2 phosphorylation in a time-dependent manner. The level of ERK1/2 
phosphorylation was apparent at 60 s and peaked within 300 s (*P < 0.05, 
**P < 0.01, one-ZD\ $129$ ZLWK %RQIHUURQL¶V SRVW KRF WHVW, n=6). 
Representative immunoblots of ERK1/2 phosphorylation from six separate 
experiments. 
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4.5. Discussion  
 
The current study describes the signalling pathways underlying the 
responses to P2Y14 receptor agonists in arteries of pig pancreas. The 
contractile response was mediated largely by the endothelium with an 
involvement of endothelin-1, thromboxane A2 and PGF2D/PGH2. Evidence 
from the contractile studies and the cAMP immunoassay indicates that 
P2Y14 receptor couples to Gi protein, and hence the activation of this 
receptor can lead to an inhibition of the level of adenylyl cyclase. While 
immunoblotting study for MLC2 and ERK1/2 indicates the downstream 
involvement of phosphorylated MLC2 and ERK1/2.  
 
4.5.1. The involvement of Endothelium-derived 
contractile factors (EDCFs) in the 
vasoconstriction-evoked by UDP-glucose 
 
To investigate the mechanism underlying the contraction to P2Y14 receptor 
agonists in pancreatic arteries, responses to UDP-glucose, UDP and 
MRS2690 were examined in the presence of DUP 697. As seen in Figure 
4.1, the endothelium-dependent contractions were significantly attenuated 
in the presence of the selective COX-2 inhibitor. Endothelial cells can 
release endothelium-derived contractile factors in addition to endothelium-
derived relaxing factors. EDCFs may include thromboxane A2, PGF2D/PGH2, 
leukotrienes and endothelin-1. thromboxane A2 and PGF2D/PGH2 are 
released from the endothelium due to the activity of cyclooxygenase 
(Mombouli & Vanhoutte, 1993; Wong et al., 2009). To characterise the 
EDCFs involved in the contraction to UDP-glucose, experiments were 
conducted to study the responses to UDP-glucose in the presence of NDGA, 
zafirlukast, BQ123, BQ788 and L-655,240. The results showed that only 
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BQ123 and L-655,240 were able to decrease significantly the contraction 
evoked by UDP-glucose, which indicated an involvement of thromboxane 
A2, prostaglandins and endothelin-1 (mainly via ETA receptor). These 
agents, after being released from the endothelium, may act on their 
receptors on the vascular smooth muscle cells to elicit a contraction (Wong 
et al., 2009). Since L-655,240 is a selective thromboxane A2/prostaglandin 
receptor antagonist (Wong et al., 2009), the contraction of U46619 may be 
inhibited in the presence of that antagonist, as I found also in the current 
study, since U46619 was unable to induce a contraction to the pancreatic 
arteries, with concentrations up to 10 µM. Therefore, U46619, as a pre-
constriction agent, was substituted by endothelin-1, since endothelin-1 
induces contraction via acting at endothelin receptors expressed on the 
VSMCs, which are distinct from thromboxane receptors. In turn, a control 
(in the absence of L-655,240) of concentration-dependent contraction of 
UDP-glucose in endothelin-1-preconstricted arteries was generated (Figure 
4.2F). 
To confirm the involvement of endothelin receptors in the contraction to 
UDP-glucose, since BQ123 induced little inhibition of the contraction to 
UDP-glucose (Figure 4.2C), the contraction to exogenous endothelin-1 was 
investigated in U46619-preconstricted pancreatic arteries. Endothelin-1-
evoked contraction was significantly inhibited in the presence of BQ123 
(Figure 4.3), while BQ788 had no effect on the endothelin-1-evoked 
contraction (Figure 4.3), which was in accordance with the results obtained 
in the presence of UDP-glucose. Taken together, these findings indicated 
an involvement of ETA receptors in the contraction to exogenous 
endothelin-1, as well as to the endogenous endothelin-1, released as a 
result of P2Y14 receptor activation by UDP-glucose. The results obtained in 
(Figure 4.2D) showed that BQ123 had no effect on the contraction to UDP-
Chapter 4 
Signalling pathways underlying P2Y14 receptor agonists 
 
150 
 
glucose in endothelium-denuded arteries which indicates that the 
contribution of endothelin in the UDP-glucose-evoked contraction is solely 
endothelium-dependent. 
The involvement of extracellular calcium influx and calcium released from 
sarcoplasmic reticulum as a part of the response to P2Y14 receptor 
activation has been reported previously (Verin et al., 2011). In addition, 
calcium-induced release of calcium from SR and influx of external Ca2+ in 
response to some activated receptors have been also reported (Fabiato, 
1983; Li et al., 2003). In porcine pancreatic arteries, contractions to UDP-
glucose (Figure 4.8A, B) and UDP (section 4.4.6) were significantly 
decreased in the presence of nifedipine or thapsigargin. This indicated an 
involvement of elevated intracellular Ca2+ level, mainly via Ca2+ influx from 
extracellular milieu, in the contraction to UDP and UDP-glucose in porcine 
pancreatic arteries. In contrast, activation of P2Y14 receptors in A549 and 
BEAS-2B cells regulated mobilisation of Ca2+ from intracellular stores rather 
than from extracellular milieu, since the ability of UDP-glucose to elevate 
Ca2+ level in these cells was not influenced by the absence of external Ca2+ 
(Muller et al., 2005). The dependency on the extracellular calcium could be 
also determined by examining the contractions to UDP-glucose or MRS2690 
following removal of the extracellular calcium ions using a calcium-free 
Krebs¶ buffer, and then observing any change within these contractions 
following reintroduction of calcium to the bathing solution. 
Collectively, our results suggest that when UDP-glucose, UDP and 
MRS2690 activate P2Y14 receptors, which are expressed mainly on the 
endothelium, the intracellular Ca2+ levels may be elevated. This may then 
activate COX-2 and the release of the endothelin (Luscher et al., 1992; 
Vanhoutte et al., 2005; Wong et al., 2009). COX-2 facilitates the 
Chapter 4 
Signalling pathways underlying P2Y14 receptor agonists 
 
151 
 
production of the contractile agents; thromboxane A2 and prostaglandins, 
which bind to thromboxane receptors (TP) on the vascular smooth muscle 
cells to induce a contraction. Whereas, endothelin binds to endothelin ETA 
receptors on the vascular smooth muscle cells, which contributes to that 
contraction. The ability of the nucleotides to stimulate the biosynthesis and 
release of prostanoids has been reported previously (Bruner & Murphy, 
1990; Bowden et al., 1995). In addition, it was shown in isolated rat 
middle cerebral arteries that the vasoconstriction-evoked by UTP was 
mediated by thromboxane A2 release, since the contraction to UTP was 
significantly attenuated in the presence of a thromboxane receptor 
antagonist (Lacza et al., 2001), which was in agreement with the current 
findings. 
Thromboxane receptors and endothelin ETA receptors are Gq/11 protein-
coupled receptors (Wilson et al., 2005). Thus, activation of these receptors 
leads to an activation of PLC, the latter hydrolyses plasma membrane 
phosphatidylinositol 4,5-bisphosphate into IP3 and DAG, that will result in 
activation of PKC and calcium release from endoplasmic reticulum 
(Falkenburger et al., 2013). Consequently, P2Y14 receptor activation can 
indirectly initiate Gq/11 signalling pathway via a downstream regulation of 
the level of endothelin, thromboxane and prostaglandins. This finding was 
in agreement with the report of Skelton et al. (2003), where they found 
that PTX was only able to block part of the response-evoked by UDP-
glucose activates P2Y14 receptors, while the rest of the response was 
attributed to an activation of Gq/11 signalling pathways. Activation of 
intracellular Ca2+ release following the stimulation of Gq/11 protein-coupled 
receptors by endothelin, thromboxane and prostaglandins may serve to 
amplify the signalling induced by P2Y14 receptor agonists, resulting in 
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greater elevation in the level of intracellular Ca2+ following activation of 
P2Y14 receptors. 
 
4.5.2. The involvement of cAMP, ERK1/2, MLC and RhoA 
in the vasoconstriction to P2Y14 receptor agonists 
 
It is well established that P2Y14 receptor is coupled to Gi protein, leading to 
an inhibition of forskolin-stimulated adenylyl cyclase activity, and hence 
inhibition of the cyclic AMP level. Accordingly, P2Y14 receptor is pertussis 
toxin-sensitive (Jacobson et al., 2009). It is notoriously difficult to 
successfully block Gi protein-coupled receptors with PTX in isolated blood 
vessels, as it was advised by Dr. Vincent Wilson and his group (The 
University of Nottingham, School of Life Sciences), and as I have also 
found in my preliminary studies. PTX (0.1±2 µg/ml) incubated with the 
tissues overnight, in .UHEV¶-Henseleit buffer or in DulbeFFR¶V PRGLILHG
(DJOH¶V PHGLXP, with 5% FCS (fetal calf serum) or without it, failed to 
block the responses to either UDP-glucose or UK14304, an agonist of D2 
adrenoceptors, classical Gi protein-coupled receptors (Figure 4.6) (Bylund 
et al., 1994). This showed that our attempts to inhibit the responses to Gi 
protein-coupled receptors agonists (UDP-glucose or UK14304) with PTX 
was unsuccessful. However, in tissues which had been pre-constricted with 
U46619 and relaxed with forskolin (to elevate the cAMP levels), subsequent 
addition of UDP-glucose produced a significantly greater contraction 
compared with the control (UDP-glucose added at basal tone) (Figure 
4.4A). The contraction to UTP (P2Y2, P2Y4 and P2Y6 agonist, Gq/11 protein-
coupled receptor), applied after pre-constriction with U46619 and 
relaxation with forskolin, was not different from its respective control (UTP 
added at basal tone) (Figure 4.4B). This was consistent with P2Y14 receptor 
coupled to Gi proteins, since other P2Y receptors, namely P2Y1, P2Y2, P2Y4, 
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P2Y6 receptors, are generally Gq/11 protein-coupled receptors. The 
significant decrease within the contraction of UDP-glucose occurred in 
endothelium-denuded pancreatic arteries (section 4.4.4), confirmed the 
findings in the Chapter 3, since it was indicated that P2Y14 receptor was 
mainly present on the endothelial cells of the porcine pancreatic arteries. 
On the other hand, relaxation with SNP (to elevate cGMP levels) after pre-
constriction with U46619 had no significant effect on the contractile 
response to UDP-glucose (Figure 4.5), which indicates that cGMP elevation 
is not a part of the signalling pathways involved in the contraction evoked 
by UDP-glucose. 
These findings together with the data obtained from cAMP assay (Figure 
4.7), which showed the ability of UDP-glucose (1 mM) and MRS2690 (10 
µM), but not UTP (1 mM), to diminish the cAMP level, indicated that the 
enhanced contraction to UDP-glucose seen in Figure 4.4A is mainly 
dependent on the agonist's ability to lower the cAMP levels. In Figure 4.7, 
UDP-glucose (1 mM) decreased cAMP level by 0.19 ± 0.06 pmol\mg tissue, 
which was slightly greater than the reduction induced by MRS2690 (10 µM) 
(0.13 ± 0.02 pmol\mg tissue). It was shown using pharmacological 
experiment that MRS2690 was more potent than UDP-glucose (section 
3.4.1), in the current experiment the concentration used for MRS2690 was 
100-fold lower than that of UDP-glucose, which may justify the greater 
inhibition occurred in the presence of UDP-glucose.  . Further experiments 
seem vital to investigate the effect of UDP, a P2Y14 receptor agonist (Carter 
et al., 2009) on the cAMP level. In addition to examining the effects of 
P2Y14 receptor agonists (UDP-glucose, MRS2690 and UDP) on cAMP level in 
the presence of PPTN to confirm that the decrease within the level of cAMP 
in the presence of UDP-glucose, MRS2690 and UDP occurs mainly through 
acting at P2Y14 receptors.  
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A number of studies have considered the signalling mechanisms underlying 
the response of P2Y14 receptor agonists (Harden et al., 2010; Sesma et al., 
2012). Recent reports claimed that UDP-glucose promotes concentration-
dependent activation of RhoA in isolated human neutrophils (Sesma et al., 
2012). This action was examined in porcine pancreatic arteries where 
contractions to UDP-glucose, UDP and MRS2690 were investigated in the 
presence of Y-27632. This compound inhibited the contraction evoked by 
these agonists (Figure 4.9A, B, C), which indicated an involvement of RhoA 
in the response to P2Y14 receptor agonists. The level of activated RhoA 
could be determined using immunoblotting technique, in which it can be 
examined in a time-dependent manner, as the report of Sesma et al. 
(2012) showed that RhoA/ROCK signalling was activated within 1 min in 
the presence of 100 µM UDP-glucose in isolated human neutrophils. 
Therefore, further experiments could be performed to quantify the level of 
activated RhoA resulting from P2Y14 receptors activation in porcine 
pancreatic arteries. 
Activation of RhoA can lead to an inhibition of myosin light-chain 
phosphatase (MLCP), and thus phosphorylation of MLC and subsequently 
contraction of the blood vessels in a calcium-independent manner (Amano 
et al., 1996; Hartshorne & Gorecka, 2011). Accordingly, when UDP-glucose 
was incubated with the tissues, the level of phosphorylated MLC2 was 
elevated within 30±60 s of incubation (Figure 4.10). This observation was 
confirmed by employing PPTN which was able to abolish the ability of UDP-
glucose or MRS2690 to elevate the MLC2 phosphorylation (Figure 4.11). 
This finding was consistent with the involvement of MLC2 phosphorylation 
in the signalling pathways involved in P2Y14 receptor activation. Moreover, 
these data were in accordance with the ability of UDP-glucose and 
MRS2690 to diminish the level of cAMP, since it was reported that an 
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increase in the level of cAMP in blood vessels leads to an inhibition of 
myosin light chain kinase, which is responsible for the phosphorylation of 
the MLC and subsequently inducing a contraction of the smooth muscles 
(Raina et al., 2009). 
It has been reported that activation of P2Y14 receptors via UDP-glucose or 
UDP in some cells, including HEK-293 or differentiated human 
promyelocytic leukemia cells (HL-60) leads to stimulation of 
phosphorylated ERK1/2 (Carter et al., 2009; Fricks et al., 2009; Harden et 
al., 2010). In the current study, the involvement of MAP kinase pathways 
in the contractions to UDP-glucose and UDP was examined by employing 
the MEK inhibitor, PD98059. The latter had no effect on the contractions-
evoked by UDP-glucose or UDP. Likewise, when the level of phosphorylated 
ERK1/2 was quantified using immunoblotting study, following loading 10 µg 
protein per lane, there was no difference between the samples (treated or 
untreated samples) (data not shown). However, when the blots were 
analysed in more detail, I found that the level of ERK1/2 in untreated 
samples (the basal level of ERK1/2) was too high already, which may be 
because of some factors in the .UHEV¶-Henseleit buffer (used throughout 
the experiment), which activate ERK1/2. The previous observation may be 
the reason behind the high level of the activated ERK1/2 obtained. To 
overcome that issue, 0.5 µg of the samples (treated and untreated) were 
loaded per lane (section 4.2.4), which allowed obtaining low level of the 
basal ERK1/2 phosphorylation. As can be seen in Figure 4.12C, the 
response to UDP-glucose was associated with an increase within the level 
of ERK1/2 phosphorylation, which was apparent within 60 s of the 
treatment, and peaked within 300 s, before it returned back to the basal 
level of phosphorylated ERK1/2 within 600 s. On the other hand, UDP-
glucose-induced phosphorylated ERK1/2, in HEK-293 cells, did not peak 
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until at least 15 min of incubation, and was retained for approximately 30 
min (Fricks et al., 2009; Harden et al., 2010).  
Thus, the lack of effect of PD98059 on the contractions to UDP-glucose or 
UDP may be because of the elevated levels of activated ERK1/2 in the 
tissues, that kept in the .UHEV¶-Henseleit buffer throughout the 
experiments. Furthermore, in agreement with other reports of HEK-293 
and differentiated HL-60 cells, UDP-glucose was not able to elevate the 
levels of phosphorylated JNK or p38 in porcine pancreatic arteries too 
(Fricks et al., 2009). Further experimentation seems vital to investigate the 
contraction to UDP-glucose or UDP in the presence of higher concentrations 
of PD98059, to find out whether PD98059 might be able to decrease the 
responses to UDP-glucose or UDP and overcome the high level of the 
phosphorylated ERK1/2 within the solution. In the current study, PD98059 
was used at 10 µM, while other report suggested to use it within 10-50 µM 
(Roberts, 2001).  
The contraction evoked by 100 µM UDP-glucose plateaued within 60-180 s 
(Figure 4.8C), in addition, 100 µM UDP-glucose induced an elevation with 
the level of phosphorylated MLC2 which peaked within 30-60 s (Figure 
4.10). This indicates an involvement of the phosphorylated MLC2 in the 
signalling pathways of UDP-glucose-induced contraction. In contrast, UDP-
glucose 100 µM elevated ERK1/2 phosphorylation, but this elevation was 
not significant until a later time of 300 s, while UDP-glucose failed to 
enhance significantly the level of phosphorylated ERK1/2 at lower time 
points (Figure 4.12C), where UDP-glucose induced its contraction. This is 
indicating that phosphorylated ERK1/2 may be not a major part of the 
signalling pathways involved in UDP-glucose-induced contraction. However, 
ERK signalling can function in the VSMC since it is associated with the cell 
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growth and differentiation (Howe et al., 2002; Roy et al., 2002), with 
phenotypic modulation in VSMC and regulating of contractile responses 
(Moses et al., 2001; Schauwienold et al., 2003). Therefore, further 
experiments could be conducted to investigate the functions of 
phosphorylated ERK1/2 in the smooth muscle of the pancreatic arteries. It 
is also important to examine the ability of UDP-glucose and MRS2690 to 
elevate the level of phosphorylated ERK1/2 in the presence of PPTN, to 
investigate whether this effect was mediated by the actions at P2Y14 
receptors, since other receptors could be involved in that effect namely, 
P2Y2 receptor. In the current study, these experiments were not performed 
due to the limited availability of PPTN. 
In summary, when P2Y14 receptor (expressed mainly on the endothelium of 
the porcine pancreatic arteries) is activated by its agonists, this leads to 
dissociation of GiD subunit from GǃǄ subunits and the receptor. Free GiD 
subunits interact with adenylyl cyclase leading to an inhibition of the level 
of cAMP. The latter effect induces a calcium-independent contraction of the 
porcine pancreatic arteries through an elevation of the level of MLCK which 
phosphorylates MLC. Gi protein-derived GǃǄsubunits trigger PLCǃ signalling 
pathways, resulting in an elevation of the level of IP3 and DAG. IP3 induces 
an elevation of the level of intracellular Ca2+. The high level of Ca2+ may 
activate the release of endothelin, thromboxane and PGF2D/PGH2, which 
then bind to their receptors, endothelin receptors and TP respectively. 
Endothelin receptors and TP receptors are Gq/11 protein-coupled receptors 
which involves an activation of PLC and hence a further elevation of the 
levels of IP3 and DAG. Elevation of the level of IP3 may increase the release 
of Ca2+ from ER, which will result in further increase within the level of 
intracellular Ca2+. DAG induces an activation of PKC and Rho/ROCK. PKC 
activation is associated with phosphorylation of ERK in many cell types 
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(Langan et al., 1994; Marquardt et al., 1994; Zhao et al., 2005). In 
addition, PKC together with Rho/ROCK signalling inhibit MLCP, increases 
Ca2+ sensitivity and promotes phosphorylation of MLC and contraction 
(Zhao et al., 2005). The high level of Ca2+, following binding to calmodulin, 
may activate MLCK, which leads to a phosphorylation of MLC, resulting in 
initiating the crossbridge between the actin and myosin leading to inducing 
a contraction of the porcine pancreatic arteries. 
 
4.6. Conclusion 
 
This chapter has demonstrated the signalling pathways underlying the 
responses to UDP-glucose, MRS2690 or UDP activating P2Y14 receptor in 
porcine isolated pancreatic arteries. P2Y14 receptor agonists induce 
vasoconstriction with an involvement of endothelin-1, thromboxane A2 and 
prostaglandins, released from the endothelium, and then act at their 
respective receptors on the smooth muscles of the pancreatic arteries. In 
addition, P2Y14 receptor activation by UDP-glucose involves an activation of 
Rho/ROCK signalling pathways, and the subsequent phosphorylation of 
MLC2, as well as the phosphorylation of ERK1/2. The ability of UDP-glucose 
and MRS2690 to inhibit cAMP levels indicates that P2Y14 receptor is 
involved in Gi protein-coupled receptor mediated signalling. This study has 
provided evidence supporting the functional expression of P2Y14 receptor 
and the signalling pathways involving in the contraction to the receptor 
agonists in porcine isolated pancreatic arteries. 
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Investigation of the effects of UDP-
glucose and MRS2690 on insulin 
secreted from the rat INS-1 823/13 ǃ-
cell line and rat isolated islets of 
Langerhans 
 
5.1. Introduction 
 
The activities of both endocrine and exocrine cells are regulated by 
parasympathetic and sympathetic nerves, as well as by hormones, 
autocrine and paracrine mediators. The pancreatic ǃ-cell behaves as a fuel 
sensor that maintains blood glucose concentration within a narrow range 
by secreting insulin. The modulation of glucose stimulated insulin secretion 
occurs by various pathways (section 1.13). The purinergic system has been 
described for a long time as a significant pathway involved in the regulation 
of GSIS (Rodriguez Candela et al., 1963; Loubatieres-Mariani et al., 1979; 
Chapal & Loubatieres-Mariani 1981; Burnstock & Novak, 2013). Previously, 
studies using immunohistochemistry have shown the expression of P2X1, 
P2X4, P2X7, P2Y1, P2Y2 and P2Y4 receptor subtypes in rat pancreas 
(Coutinho-Silva et al., 2001; Coutinho-Silva et al., 2003). In addition P2Y2 
receptor expression was shown in human pancreas, as well as P2Y11 and 
P2Y12 receptors which were found in the human pancreatic islets (Stam et 
al., 1996; Lugo-Garcia et al., 2008). Recently, reports showed the 
expression of P2Y1, P2Y2, P2Y4, P2Y6 and P2Y12 receptors in the INS-ǃ-cell 
line, both at the mRNA and protein levels (Lugo-Garcia et al., 2007). 
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5HJDUGLQJWKHHIIHFWRIQXFOHRWLGHVRQLQVXOLQUHOHDVHIURPǃ-cells, ATP was 
the first nucleotide studied in 1963, and it induced an increase in insulin 
release in both rabbit pancreas and in isolated rat and hamster pancreas 
(Rodrigue-Candela et al., 1963; Loubatieres et al., 1972; Feldman & 
Jackson, 1974; Loubatieres-Mariani  et al., 1976). The ability of ATP to 
induce an elevation in the insulin release is mediated by two different types 
of receptors: P2X and P2Y receptors (Petit et al., 1998). The mechanism by 
which ATP induces insulin secretion via P2X or P2Y receptors involves 
[Ca2+] elevation (Squires et al., 1994; Jacques-Silva et al., 2010). Other P2 
receptor agRQLVWVKDYHDOVRWKHDELOLW\ WRUHJXODWH LQVXOLQUHOHDVH IURPǃ-
cells, including DE-meATP which mimics the effect of ATP on insulin release, 
suggesting the involvement of P2X1 or P2X3 receptors (Petit et al., 1987). 
P2Y receptors may mediate ELSKDVLFLQVXOLQVHFUHWLRQIURPǃ-cells. UDPǃS, 
a selective P2Y6 agonist, induced concentration-dependent stimulation of 
insulin and glucagon secretion in isolated mouse pancreatic islets and 
purified ǃ-cells during short-term incubation (1h), while the activation of 
P2Y6 receptors, via UDPǃS, during a longer period of 24h, enhanced insulin 
release only, especially at high glucose levels at 20 mM. This effect was 
abolished in the presence of MRS2578, a selective antagonist of P2Y6 
receptor (Parandeh et al., 2008). UTP had no effect on insulin release in 
isolated mouse pancreatic islets and purified ǃ-cells, but it increased insulin 
secretion in INS-1 cell line very weakly, indicating the involvement of P2Y2 
or P2Y4 receptors in insulin secretion is not likely to be of major 
physiological importance (Verspohl et al., 2002; Parandeh et al., 2008). 
Studies on both intact mouse pancreatic islets aQG LVRODWHG ǃ-cells using 
quantitative real-time PCR revealed an expression of P2Y1 and P2Y13 
receptors. The role of these receptors has been investigated using ADP, a 
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ligand of the P2Y1 and P2Y13 receptors. ADP had a dual effect on mouse 
pancreatic islets: promoting insulin secretion via P2Y1 receptors and 
inhibiting the secretion via P2Y13 receptors (Amisten et al., 2010). This was 
shown by using the selective P2Y1 antagonist, MRS2179, and the selective 
P2Y13 antagonist, MRS2211, where the effects mediated by ADP at the 
respective receptors were confirmed (Amisten et al., 2010). Regarding 
effects mediated by adenosine receptors on GSIS, several studies 
suggested that  A1 and A2B  receptors  mediate inhibition of insulin 
secretion (see review by Rusing et al., 2006; Burnstock & Novak, 2013). 
A2A receptors mediated augmentation of GSIS in mouse pancreatic arteries 
(Ohtani et al., 2013), which indicated that activation of P1 and P2 
receptors can exert synchronised effects on insulin secretion which 
contributes to the regulation of glucose homeostasis. 
There is increasing evidence to suggest that UDP-glucose can act as 
extracellular signalling molecules via cell surface P2Y14 receptors (Xu et al., 
2012; Meister et al., 2013). However, no report has indicated the direct 
effect of activation of P2Y14 receptor on insulin or any other hormones 
released from the islet of Langerhans. Therefore, the aim of this chapter is 
to investigate the functional expression of P2Y14 receptors in both rat INS-1 
823/13 ǃ-cell line and freshly isolated rat islet of Langerhans. 
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5.2. Materials and methods 
 
5.2.1. Insulin secretion studies 
 
Insulin secretion can be studied using several models, it can be studied in 
vivo or from perfused pancreas, isolated islets, ǃ-cell line (monolayers or 
pseudoislets) (Howell & Taylor, 1968; Park et al., 1999; Hohmeier et al., 
2000; Guo-Parke et al., 2012; Lee et al., 2013). Among these models, the 
use of freshly isolated exocrine-free islets of Langerhans in this study has 
some advantages: the effects of treatments on insulin release directly 
exhibit variations in islet cell activities. In addition, the isolated islets 
architecture is maintained, as well as the elimination of the influences of 
exocrine and acinar tissues, blood and immune system which would 
normally interfere with the islet responses to the agents. However, since 
this method utilises the collagenase enzyme (section 5.2.1.3) to digest the 
pancreas and liberates the islets, one limitation would be the potential 
damage to cell surface proteins during the isolation procedure which may 
affect the functions of the islets. In addition, proteolytic enzymes (e.g. 
protease, phospholipase) are released from the exocrine tissues during the 
tissue dissociation (autodigestion) which may hydrolyse the proteins and 
reduce the islet yields (Wolters et al., 1989). This loss can be overcome by 
culturing the islets to allow recovery (Gingerich et al., 1979; Marchetti et 
al., 1995). In addition, it has also been suggested that addition of a high 
concentration (10%) of bovine serum albumin (BSA) to the digestion 
medium may be beneficial, as it suppresses the release of proteolytic 
enzymes from the exocrine tissues in the pancreas during the collagenase 
digestion, which would result in an increase of the islet yield (Wolters et 
al., 1989; van Suylichem et al., 1992).  
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The other model used in this chapter to study the insulin secretion is the 
rat ǃ-cell line. The SDQFUHDWLFǃ-cell line has some advantages, including as 
an DEXQGDQWVRXUFHRIǃ-cells, in addition, the study could be performed in 
the absence of other cell types. Moreover, these cells display a lot of 
essential characteristics of the pancreaWLFǃ-cells, including the high level of 
insulin contents and the responsiveness to glucose (Asfari et al., 1992). 
Nevertheless, it is been reported that the magnitude of the insulin 
response of these cell lines is less than that detected in freshly isolated rat 
islets (Asfari et al., 1992)+RZHYHUDPRQJǃ-cell line derivatives, the INS-
1 823/13 ǃ-cell line has been shown to be one of the highly responsive 
clones and was able to secrete relatively large amounts of insulin in 
response to glucose concentrations in a physiological range (Hohmeier et 
al., 2000). In addition, the amount of insulin released from this cell line 
compares well with the response exhibited by freshly isolated rat islets 
(Zawalich & Zawalich 1996; Hohmeier et al., 2000). 
 
5.2.1.1. INS-ǃ-cell secretion studies 
 
Cell culture, The rat INS-  ǃ-cells were grown in T75 flasks at 
37°C and 95% O2, 5% CO2 in a humidified atmosphere. The cells were 
passaged every 5 days by using 1 ml 0.05% (w/v) trypsin-EDTA. The 
culture medium was RPMI-1640 with 11.1 mM glucose supplemented with 
5% (v/v) fetal calf serum, 2 mM glutamine, 10 mM HEPES, 1 mM sodium 
S\UXYDWH  ǋ0 -mercaptoethanol, with 100 U/ml penicillin and 0.1 
mg/ml streptomycin. Cells from passage 86-91 were used for all 
experiments. 
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Secretion assays, INS-1 823/13 ǃ-cells were seeded in 24-well plates at 
a density of ~1 × 105 cells/well in 1 ml culture medium, and were grown to 
100% confluence before assay. At 18 h before secretion experiments, the 
standard tissue culture medium containing 11.1 mM glucose was switched 
to fresh RPMI-1640 media with 5 mM glucose. Cells were washed in 1 ml 
Krebs-Ringer bicarbonate HEPES buffer (KRBH) (section 5.2.3), followed by 
1 h incubation in 1 ml of the same buffer. Subsequently, the cells were 
incubated for 1 h at 37oC in 0.5 ml of the incubation buffer with two 
different concentrations of glucose: basal glucose (2 mM) and maximal 
stimulatory glucose (20 mM), with or without UDP-glucose (100 µM, 1mM) 
or MRS2690 (10 µM), which was tested in the absence and presence of 
PPTN (1 µM), a P2Y14 receptor selective antagonist. For determination of 
secreted insulin during glucose stimulation of INS-1 823/13 ǃ-cells, 
samples were diluted (1:2) in assay buffer then analyzed using rat insulin 
radioimmunoassay (RIA) kit with 125I-labelled insulin (section 5.2.3). The 
total amount of the protein per well was determined using the protocol in 
section 3.2.5, followed by determination of the amount of insulin secreted 
per well. The data were presented as a percentage of basal glucose (2 mM) 
induced insulin secretion. 
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5.2.1.2. Rat isolated islets of Langerhans 
 
Islet Isolation, As the islets are dispersed throughout the pancreas, they 
first need to be isolated from the surrounding exocrine tissue. A two-step 
method was used to isolate the islets, utilising collagenase enzyme to 
digest the pancreas and to liberate the islets. Collagenase enzymes are 
usually applied by injection via the pancreatic bile duct or by chopping of 
the pancreas into small pieces followed by an incubation of the pancreatic 
tissues with collagenase at 37oC (van Suylichem et al., 1992). This 
procedure will specifically hydrolyse the collagen fibres which connect the 
endocrine and exocrine tissues together. Separation of the exocrine tissue 
from islets is then achieved by picking the islets or by density gradient 
purification techniques (Noguchi et al., 2012). 
 
5.2.1.3. Isolation of rat islets of Langerhans (performed by Dr. 
S.L.F. Chan) 
 
The method that we utilised for the isolation of rat islets described below is 
based upon the protocols described by Howell & Taylor (1968); Chan et al. 
(2001) and Anderson et al. (2013) which used bicarbonate-buffered 
physiological saline solution (Gey & Gey, 1936) (G&G) (section 5.2.3) 
supplemented with glucose 4 mM. 
Male Wistar rats 200-250g in weight were obtained from Charles River 
(England, UK), and were used in this study. After stunning, they were killed 
by cervical dislocation. Rats were killed using the Code of Practice for the 
Humane Killing of Animals under Schedule 1 of the Animals (Scientific 
Procedures) Act 1986. The pancreas was isolated and separated from the 
spleen, fat and other tissues (intestine, lymph nodes, large blood vessels). 
The pancreas was distended with G&G bicarbonate-buffered medium using 
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a syringe fitted with a needle (a total volume of 7-l0 ml). Excess fat and 
blood vessels, which were clearly visible, were then dissected. 
Subsequently, the pancreas was placed in a small beaker and chopped 
vigorously as finely as possible with scissors to obtain uniformly small 
pieces (~1 mm3 pieces). The pieces were then transferred to a 15 ml 
centrifuge tube and were spun down gently (2000 rpm, 3 s) and the 
supernatant was pipetted off completely. The segments were then poured 
into a 25 ml conical flask and 10 ml of a solution of collagenase P (0.5 
mg/ml) in bicarbonate buffer was applied. The flask was vigorously shaken 
(~200 shakes/minute) for 5-6 min at 37oC using Griffin flask shaker (Griffin 
and George Ltd., UK) until a fine, smooth digest, free of exocrine 
fragments was obtained. The incubation time was checked by the size and 
appearance of the fragments in the flask. The reaction was ended by 
pouring the solution into a 20 ml conical flask, and adding the bicarbonate 
buffer followed by spinning down gently. Islets and fragments of exocrine 
tissue separated out at the bottom of the tube and the supernatant was 
poured off. The fragments were resuspended in a further 10 ml of G&G 
buffer. Exocrine-free islets were manually isolated from the digest using 
finely drawn-out Pasteur pipettes under a dissecting binocular SZ4045 
microscope (Olympus, Essex, UK). The total time taken from the death of 
the animal to the isolation of islets, ready for incubation, was 45-60 min. 
Yields of 150-300 islets were obtained from a single rat pancreas. 
 
5.2.1.4. Islet static incubation studies 
 
The buffer used for these experiments was G&G bicarbonate-buffered 
saline with 1 mg/ml BSA. The following protocol describes the use of 96-
well plates for the islHWV VWXGLHV  ǋO EXIIHU DW WKH UHTXLUHG JOXFRVH
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concentrations and reagents) were first added to the wells. Batches of 3 
islets were carefully added to each well using a finely drawn-out Pasteur 
pipette. The islets were incubated at 37oC for 1 h. At the end of the 
incubation period, the 96-well plate was agitated to allow mixing and then 
transferred on ice for 5 min to stop further insulin secretion. Samples of 
the incubation media were then taken from each well and were analysed 
using rat insulin radioimmunoassay (RIA) kit with 125I-labelled insulin 
(section 5.2.3) or samples were stored at -20oC for later use. The data 
were presented as ng of insulin secreted/islet/hour. The working range of 
the insulin assay was from 0.156-5 ng/ml. 
 
5.2.1.5. Radioimmunoassay (RIA) 
 
RIA is a very sensitive, competition-based assay which is utilised to 
quantify the antigens (e.g. insulin) using specific antibodies (e.g. anti-
insulin) to form an antigen-antibody complex. To perform a RIA, a known 
quantity of an antigen is made radioactive, by labelling it with gamma-
radioactive isotopes of iodine (Iodine-125 (125I)). This radiolabelled antigen 
is then mixed with a known amount of antibody for that antigen, and as a 
result, a complex of antigen-antibody would be constructed. A sample with 
unknown quantity of that same antigen (non-radiolabelled) is added. This 
causes the unlabelled (or "cold") antigen from the unknown sample to 
compete with the radiolabelled antigen ("hot") for antibody binding sites. 
As the concentration of "cold" antigen is increased, more of it binds to the 
antibody, displacing the radiolabelled variant, and reducing the ratio of 
antibody-bound radiolabelled antigen to free radiolabelled antigen. At the 
end of the reaction, a separation step is performed to isolate antigen-
DQWLERG\FRPSOH[IURPXQERXQGUHDJHQWV³KRW´DQG³FROG´DQWLJHQ7KXV
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level of radioactivity of antigen-antibody complex will be inversely 
SURSRUWLRQDOWRWKHFRQFHQWUDWLRQRI³FROG´DQWLJHQUsing standard samples 
RINQRZQDPRXQWVRI³FROG´DQWLJHQDbinding curve can then be generated 
ZKHUH FRQFHQWUDWLRQ RI WKH ³FROG´ DQWLJHQ [-axis) is plotted against 
radioactivity (y-axis). That will allow the amount of antigen to be estimated 
by the amount of radioactivity in the antigen-antibody complex. 
 
5.2.1.6. Insulin RIA 
 
 
All solutions used in the experiment were made using insulin assay buffer 
(IAB) (section 5.3.3). The primary antibody was raised in guinea-pig 
against highly purified rat insulin. Purified rat insulin was used as a 
standard and at a stock of 10 ng/ml concentration. The standard curve of 
insulin standards of concentration range (0.156-5 ng/ml) was constructed 
by two-fold serial dilution of the 10 ng/ml standard in IAB. The assay also 
contained non-specific binding and total radioactivity controls. 
$OOVDPSOHVDQGVWDQGDUGVZHUHDVVD\HGLQGXSOLFDWHZKHUHǋOVDPSOHV
RUVWDQGDUGVZHUHLQFXEDWHGZLWKǋORIJXLQHDSLJDQWL-rat insulin serum 
DQG  ǋO RI 125I-insulin tracer. Subsequently, the samples and the 
standards were incubated overnight at 4oC. The next day, the primary 
antibody was separated from solution using 0.5 ml of the precipitating 
reagent, followed by mixing and incubating of the tubes at 4oC for 20 min. 
The role of precipitating reagent is to precipitate the secondary-primary 
antibody complex, which would otherwise normally need an additional 
overnight incubation period to get precipitated (Peterson & Swerdloff, 
1979). The samples were then centrifuged at 3000 rpm (Eppendorf 
Centrifuge 5810R) for 20 min at 4oC and the supernatant was then 
carefully aspirated off, making sure not to disturb the pellets. The amount 
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of radiation being emitted by the pellets was counted using a Packard 
Cobra II ஝-counter (Perkin-Elmer, MA, USA). The insulin content within 
each sample was automatically determined, as ng of insulin/ml, by 
interpolation of the RIA standard curve by the Packard Cobra II ஝-counter. 
 
5.2.2. Western blotting 
 
Segments of porcine heart (PH) and rat brain (RB) were collected and 
homogenised with a borosilicate glass homogeniser in lysis buffer (see 
reagents and drugs section 3.2.6), containing protease inhibitor cocktail 
tablets, EDTA-free. INS-1 823/13 cells and rat isolated islets were collected 
in lysis buffer. After removal of a sample for a protein assay (section 
3.2.5), samples were diluted 1:6 into solubilisation buffer 6×SB: (see 
reagents and drugs section 3.2.6), and were heated at 95°C for 5 min. 
Subsequently, electrophoresis was carried out on 4-20% Tris-Glycine 
(PAGE) Gold Precast Gels (Bio-Rad, Hercules, CA, U.S.A.), 10 µg protein 
per lane was loaded for all of these samples.  
Samples were transferred to nitrocellulose membranes. Next, blots were 
incubated in blocking solution (5% (w/v) powdered milk in Tris-buffered 
saline containing 0.1% (v/v) Tween 20 (Fisher Scientific UK Ltd., 
Loughborough, UK)) for 60 min, at room temperature. Blots were 
incubated overnight at 4°C with primary antibodies against P2Y14 protein 
(1:500) and against GAPDH (1:10000), diluted in the blocking solution. 
After washing in Tris-buffered saline containing 0.1% (v/v) Tween 20, the 
blots were incubated with an appropriate IRDye® secondary antibody (Li-
Cor Biosciences, Biotechnology, Lincoln, NE, USA). Proteins were visualised 
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using the Licor/Odyssey infrared imaging system (Biosciences, 
Biotechnology). 
 
5.2.3. Reagents and drugs and cell culture media 
 
1x G & G bicarbonate-buffered saline was composed of the following (mM): 
NaCl 111, NaHCO3 25.2, KCl 5, MgCl2.6H2O 1, MgSO4.7H2O 0.3, Na2HPO4 
0.4, KH2PO4 0.3 and CaCl2 1. This was gassed for 10 min with 95% O2, 5% 
CO2 prior to the experiment to oxygenate the buffer and adjust the pH of 
the buffer to 7.4. During the experiment, the buffer was periodically re-
gassed to maintain the pH at 7.4. KRBH was composed of the following 
(mM): NaCl 135, KCL 3.6, NaH2PO4 5, MgCl2 0.5, CaCl2 1.5, HEPES 10, and 
1 mg/ml BSA pH 7.4. Precipitating reagent and IAB were part of the rat 
insulin RIA Kit (cat No. #RI-13K) which was purchased from LINCO 
Research (St. Charles, MI, USA). BSA was purchased from Wilfred Smith, 
Edgeware, U.K. For information about the sources and the solvents of other 
reagents and drugs, see section 3.2.6. 
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5.3. Statistical analysis 
 
 
The mean of insulin secretion rate was determined for each group (both 
control and test groups). Outliers were removed based on objective 
judgement to reduce variation (standard error of the mean > 2 SDs). For 
rat INS-ǃ-cells experiments, the mean of insulin secretion rates 
within the experiment were then standardised against the 2 mM glucose 
control group, as the mean of insulin secretion rates were expressed as a 
percentage of insulin released in the presence of the 2 mM glucose control 
(which was always 100%). Variation was expressed as the mean ± SEM. 
Non-parametric Kruskal-Wallis test was used followed by non-parametric 
Mann-Whitney unpaired test (Prism, GraphPad, San Diego, CA, USA). The 
non-parametric tests were used since the values were standardised to a 
control. Therefore, normal distribution of data cannot be assumed. For all 
experiments, P value < 0.05 was considered significant. 
With regards to the secretion experiments with rat isolated islets, variation 
was expressed as the mean ± SEM. One-way analysis of variance (ANOVA) 
was used followed by 6WXGHQW¶V XQSDLUHG t-test (Prism, GraphPad, San 
Diego, CA, USA). For all experiments, P value < 0.05 was considered 
significant. 
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5.4. Results 
 
5.4.1. Effect of P2Y14 receptor activation on insulin 
released from rat INS-1 823/13 ǃ-cells 
 
To determine the effect of P2Y14 receptor activation on the insulin released 
IURP ǃ-cell, INS-1 823/13 ǃ-cells were grown in appropriate medium 
(section 5.2.1.1) until they were 100% confluent. On the day of the 
experiment the cells were treated with two different concentrations of 
glucose: one is a basal (2 mM) and the other is the maximal stimulatory 
concentration (20 mM) of glucose. As seen in Figure 5.1, the insulin 
secretion was stimulated five-fold as glucose concentration was increased 
from 2-20 mM (P < 0.01, n=9). This level of elevation was similar to the 
range described by Hohmeier et al. (2000), Yang et al. (2004), Winzell et 
al. (2006) and Youl et al. (2010).  
In the presence of UDP-glucose (100 µM, 1 mM) or MRS2690 (10 µM), the 
level of insulin secreted from INS-ǃ-cells was significantly attenuated  (P 
< 0.05, n=4-9) (Figure 5.1). In contrast, MRS2690 was unable to alter the 
amount of insulin secreted from INS-1 823/13 ǃ-cells in the presence of 
PPTN, a selective high affinity antagonist of P2Y14 receptor (Figure 5.1), 
indicating that its effect was mediated by acting at P2Y14 receptor. In the 
presence of basal glucose concentration (2 mM), PPTN itself was able to 
elevate significantly the level of insulin secreted from INS-1 823/13 ǃ-cells 
(P < 0.05, n=4-9). In contrast, it had no significant effect on the insulin 
secretion in the presence of stimulatory glucose concentration (20 mM) 
(Figure 5.1). 
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Figure 5.1. The effect of P2Y14 receptor agonists, UDP-glucose (100 µM, 1 
mM) or MRS2690 (10 µM), in the presence or absence of PPTN (1 µM) on 
insulin released from rat INS-ǃ-cells. Cells were incubated with 
low (2 mM) or high (20 mM) concentrations of glucose. Data were 
presented as a percentage of basal insulin secretion. (*P < 0.05, **P ޒ 
0.01, non-parametric Mann-Whitney unpaired test, n=4-9). 
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5.4.2. Effect of UDP-glucose on GSIS in rat isolated 
islets of Langerhans 
 
Islets were incubated at 3 mM, 10 mM and 20 mM glucose in order to 
assess for islet viability and glucose responsiveness. These concentrations 
represent basal, intermediate and maximal levels of GSIS (Figure 5.2). The 
insulin secretion was stimulated by two-fold as glucose concentration was 
increased from 3-10 mM, while the stimulation was three-fold as the 
glucose concentration was increased to 20 mM (Figure 5.2). These findings 
were similar to reports by Chan et al. (2001) and Anderson et al. (2013) in 
which the stimulation of insulin secreted by rat isolated islets was four-fold 
when the glucose concentration was increased from 4-20 mM. 
To determine the effect of P2Y14 receptors activation on the insulin released 
from the islet of Langerhans, islets were incubated with UDP-glucose (100 
µM or 1 mM) in the presence of glucose 10 mM. As seen in Figure 5.2, in 
the presence of UDP-glucose (100 µM or 1 mM), the insulin secreted from 
the islets were significantly attenuated to the basal level relative to the 
amount of insulin secreted at 10 mM glucose (P < 0.05, n=5) (Figure 5.2), 
indicating the ability of the P2Y14 receptor ligand to regulate the insulin 
secretion by rat isolated islets. 
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Figure 5.2. UDP-glucose inhibited GSIS in rat isolated islets of 
Langerhans. Islets were incubated at the indicated glucose concentrations 
for 1 h at 37oC. The treatments (P2Y14 receptor ligand, UDP-glucose 100 
µM or 1 mM) were performed in the presence of glucose 10 mM. Data were 
presented as changes in quantity of insulin released from the islet cells per 
hour. UDP-glucose at both concentrations significantly attenuated the 
insulin secreted from the islets (*P < 0.05, one-way ANOVA with 
%RQIHUURQL¶VSRVWKRFWHVW, n=5).  
 
 
 
 
 
Chapter 5 
Effects of UDP-glucose, MRS2690 on insulin secretion 
 
177 
 
5.4.3. Investigation of the expression of P2Y14 receptor 
in rat isolated islets of Langerhans and in rat INS-
1 823/13 ǃ-cells 
 
The expression of P2Y14 receptor was investigated using a rabbit polyclonal 
antiserum against C-terminal tail of the P2Y14 receptor (green bars), while 
the total amount of the protein in each sample was determined in the 
presence of mouse GAPDH monoclonal antibody (red bars).. GAPDH 
monoclonal antibody showed an immunoreactive band at around 37 kDa, 
while P2Y14 receptor antibody showed an immunoreactive band at around 
41 kDa. As seen in Figure 5.3, P2Y14 protein was expressed in rat brain 
(RB), used as a positive control, since P2Y14 receptor protein is widely 
expressed throughout the rat and human brain (Moore et al., 2003). In 
addition, P2Y14 protein was also present in porcine heart (PH), which was 
also used as a positive control in the current study (section 3.4.9). 
An immunoreactive band was obtained in the presence of the P2Y14 
antibody at around 41 kDa in rat brain and in porcine heart (Figure 5.3). 
These findings were consistent with other reports which showed the 
presence of P2Y14 receptors in HEK-293 cells and liver hepatocellular cells 
(HepG2) with an immunoreactive band of approximately 41 kDa (Lifespan 
Biosciences, cat No. LS-C120603), and in human brain membranes and 
human P2Y14 receptor-transfected HEK-293 cells with multiple 
immunoreactive bands of around 40-65 kDa (Moore et al., 2003; 
.U]HPLĔVNLet al., 2008). Similarly, an immunoreactive band with the same 
size (41 kDa) was observed in rat islet (RI), rat INS-1 823/13 cells 
indicating the presence of P2Y14 receptor in these cells. The band size 
observed in this section (41 kDa) was in accordance with that observed in 
rat heart and porcine pancreatic arteries in section 3.4.9. 
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Figure 5.3. P2Y14 protein expression detected by western blotting, in the 
presence of P2Y14 antiserum (green bars). The total protein was 
determined using GAPDH antibody (red bars). An immunoreactive band 
was evident in rat brain (RB) (10 µg/lane), rat islet (RI) (10 µg/lane), rat 
INS-1 823/13 (10 µg/lane) and porcine heart (PH) (10 µg/lane) at around 
41 kDa. The band sizes of the molecular weight marker from top to bottom 
are 50, 36, 25 kDa respectively. Blots are representative of staining from 
three separate experiments. 
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5.5. Discussion 
 
The role of purine and pyrimidine receptors in modulation of insulin 
secretion has been described for a long time (Loubatieres-Mariani et al., 
1979; Chapal & Loubatieres-Mariani 1981; Burnstock & Novak, 2013). The 
expression of P2Y1, P2Y2, P2Y4, P2X1, P2X4 and P2X7 receptors was 
detected by immunohistochemical studies in the rat and mouse pancreas 
(Coutinho-Silva et al., 2001; Coutinho-Silva et al., 2003). In the current 
study, the expression of P2Y14 receptor protein in rat INS-1 823/13 ǃ-cell 
line and in rat isolated islets was determined using a specific antiserum 
against P2Y14 protein. Samples taken from rat brain and porcine heart were 
used as positive controls, since the expression of P2Y14 receptors in rat 
brain was shown elsewhere (Moore et al., 2003.U]HPLĔVNLet al., 2008). 
The expression of P2Y14 protein in porcine heart was demonstrated in the 
current study in section 3.4.9. GSIS from rat INS-1 823/13 ǃ-cell line, in 
the presence of 20 mM glucose, was significantly deceased following 
activation of P2Y14 receptor with its selective agonists, UDP-glucose or 
MRS2690. While these agonists were not able to alter the insulin released 
from these cells under basal conditions (in the presence of 2 mM glucose) 
(Figure 5.1). In Figure 5.1, 10 µM MRS2690 decreased the insulin secretion 
to the same extent as 100 µM and 1 mM UDP-glucose although the 
concentration used for MRS2690 was 10-100-fold less than that of UDP-
glucose, which suggests some greater potency of MRS2690 over UDP-
glucose in the current experiment. The attenuation induced by the 
activation of P2Y14 receptors by MRS2690 in rat INS-1 823/13 ǃ-cell line 
was abolished in the presence of PPTN, a selective antagonist at P2Y14 
receptors (Figure 5.1), which indicated that the ability of MRS2690 to 
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GHFUHDVHWKHOHYHORILQVXOLQUHOHDVHGIURPǃ-cells occurred through acting 
at P2Y14 receptors. 
Moreover, PPTN itself was able to elevate the basal insulin secretion from 
rat INS-1 823/13 ǃ-cells (Figure 5.1). This suggests that there may be a 
constitutive release of UDP-glucose occurring by rat INS-1 823/13 ǃ-cells. 
This release may attenuate the insulin secretion rate. The tonic inhibition of 
insulin release was then blocked in the presence of P2Y14 receptor 
antagonist. Constitutive release of UDP-glucose from various cell lines 
including Calu-3 airway epithelial, COS-7, CHO-K1, and C6 glioma cells has 
been reported elsewhere (Lazarowski et al., 2003b). Similarly PPTN 
induced concentration-dependent elevation of the basal forskolin-
stimulated cAMP accumulation in C6 glioma expressed P2Y14 receptor, with 
EC50 of 3-10 nM, while it exhibited no effect in wild-type cells. The previous 
findings were justified by the idea that the effect of PPTN on cAMP levels 
(in the absence of added agonist) occurs due to the blockade of the effect 
of UDP-glucose, released from these cells into the medium (Barrett et al., 
2013). Alternatively, PPTN could act as an inverse agonist since P2Y14 
receptor may be constitutively active that is, its activity does not depend 
on binding of ligand (Kenakin, 2004). 
A large number of reports have indicated the ability of purine and 
pyrimidine nucleotides to regulate the level of insulin secreted from 
pancreatic islets (Loubatieres-Mariani et al., 1979; Fernandez-Alvarez et 
al., 2001; Parandeh et al., 2008; Meister et al., 2013). In general, the role 
of purine and pyrimidine nucleotides as modulators of insulin secretion 
involves stimulation of insulin secretion (see reviews by Burnstock & Novak 
2012, Novak, 2008). In contrast, few reports described the ability of some 
nucleotides to inhibit the insulin secretion by pancreatic islets. One such is 
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the report of Amisten et al. (2010) where ADP was able to decrease the 
level of insulin secreted from mouse pancreatic islets following activation of 
P2Y13 receptors, and this effect was blocked by a competitive antagonist at 
P2Y13 receptor. In the current study, following activation of P2Y14 receptors 
in isolated rat islets by the selective ligand, UDP-glucose, the level of 
insulin secreted from the cells was significantly decreased in the presence 
of glucose 10 mM (Figure 5.2), which showed the ability of UDP-glucose to 
inhibit the insulin released from freshly isolated rat islets. Similarly, P2Y14 
receptor was described to play a significant role in glucose homeostasis in 
the report of Xu et al. (2012), which was shown via using a GPR105 
knocked-out model. Alternatively, it is recommended to investigate the 
concentration-response curves for multiple concentrations of UDP-glucose 
and MRS2690 which would allow calculation of the pharmacological values 
for these agonists, including EC50, Rmax. By calculating these values, a 
comparison between their efficacies and potencies would be conducted. In 
addition, this would be useful for characterisation the effects of MRS2690 
and UDP-glucose in the presence of PPTN. It is also recommended to 
determine whether there is a constitutive release of UDP-glucose in rat 
isolated islets, which could be addressed by examining the effect of PPTN in 
the absence of exogenous UDP-glucose. If PPTN is able to elevate the basal 
insulin secretion from rat isolated islets that may suggest a physiological 
role of this receptor in rat islets. Alternatively, the level of UDP-glucose can 
be measured at basal, intermediate and maximal levels of glucose. This 
measurement will determine whether there is any constitutive release of 
UDP-glucose in rat islets. The level of UDP-glucose can be assayed based 
on the protocol used by Lazarowski et al. (2003b); UDP-glucose 
pyrophosphorylase catalysed the conversion of UDP-glucose to [32P]UTP in 
the presence of [32P]pyrophosphate. Subsequently, HPLC separates 
Chapter 5 
Effects of UDP-glucose, MRS2690 on insulin secretion 
 
182 
 
[32P]UTP from [32P]PPi, then the determination of [32P]UTP would allow an 
accurate quantification of the extracellular UDP-glucose concentrations 
(Lazarowski et al., 2003b). 
The ability of P2Y14 receptor agonists to lower the level of insulin released 
from INS-1 823/13 ǃ-cell line and from isolated rat islets is consistent with 
their coupling to Gi/o protein, since the ability of cAMP to increase the GSIS 
IURP SDQFUHDWLF ǃ-cells is well-established (see review by Furman et al., 
2010). The mechanism by which cAMP modulates insulin release has been 
studied in several reports, including the review of Furman et al. 2010. 
Some reports suggested that cAMP/PKA inhibits ǃ-cell KATP channels, 
resulting in depolarisation of the ǃ-cell membrane potential, and hence 
Ca2+ influx, resulting in insulin granule exocytosis (Brisson & Malaisse 
1973; Suga et al., 1997; Kang et al., 2006). Other studies showed that the 
ability of cAMP/PKA to promote insulin release involves a mechanism at a 
site distal to the elevation of intracellular Ca2+, with increased effectiveness 
of the KATP channel-independent action of glucose (section 1.10.2) (Yajima 
et al., 1999). The ability of P2Y14 receptor agonists to lower cAMP level was 
shown earlier in section 4.4.5, which is consistent with their ability to 
GHFUHDVHWKHOHYHORILQVXOLQUHOHDVHGIURPSDQFUHDWLFǃ-cells in the current 
study. Further studies are essential to investigate the effect of UDP-glucose 
or MRS2690 on cAMP level in rat INS-1 823/13 ǃ-cell line or in isolated rat 
islets, which can be addressed by a direct measurement of cellular cAMP 
levels in these cells (using the protocol in section 4.2.6) in the presence of 
UDP-glucose or MRS2690 in the absence or presence of PPTN. In addition, 
the effect of P2Y14 receptor activation in rat INS-1 823/13 ǃ-cell line or in 
isolated rat islets, needs to be investigated in the presence of PTX (Gi 
inhibitor), to confirm the involvement of P2Y14 receptor coupling to Gi 
protein in the UDP-glucose and MRS2690 mediated inhibition of the insulin 
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secretion. Other signalling pathways might be also involved in the P2Y14 
receptors mediated inhibition of insulin secretion. 
Further studies are required to investigate the effect of UDP on insulin 
secretion from INS-1 823/13 ǃ-cell line and from isolated rat islets, since 
UDP was reported to be a potent agonist at P2Y14 receptors (Carter et al., 
2009; Harden et al., 2010). Additionally, UDP also acts as an agonist at 
P2Y6 receptors (Mamedova et al., 2004). The data presented by Parandeh 
et al. (2008) and Ohtani et al. (2008) showed that UDP induced a dose-
dependent stimulation of insulin in isolated mouse pancreatic islets at lower 
concentrations up to 10 µM, which was mediated by P2Y6 receptors, while 
UDP at higher concentration (100 µM) decreased the insulin release from 
isolated mouse pancreatic islets, which was suggested to be mediated via 
acting at other receptors. Therefore, investigation of the effect of UDP on 
insulin release from rat INS-1 823/13 ǃ-cell line and from isolated rat 
islets, with a range of concentrations, seems essential. This determines 
whether UDP would induce insulin secretion elevation or inhibition 
mediated by P2Y6 or P2Y14 receptors respectively. In addition, investigation 
of the effect of P2Y14 receptor activation on insulin secretion by human 
islets would indicate whether species differences exist in the role of P2Y14 
receptor controlling the insulin secretion. Moreover, if PPTN is able to 
abolish the inhibitory effect evoked by UDP-glucose on insulin release from 
human islets that may suggest a therapeutic value of PPTN for patients 
with impaired glucose tolerance or type 2 diabetes. In addition, as part of 
characterisation of the role of P2Y14 receptor in the pancreas, the effects of 
P2Y14 receptor agonists on other hormones secreted from the pancreas 
including glucagon should be examined, to identify completely the role of 
this receptor in the endocrine pancreas, and that might suggest a 
physiological role of P2Y14 receptor in the pancreas. Additionally, it is 
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necessary to examine the effect of UDP-glucose on the exocrine secretion 
to get a comprehensive view about the role of P2Y14 receptors in the 
pancreas. 
 
5.6. Conclusion 
 
The data presented in this chapter provides evidence for the functional 
expression of P2Y14 receptors in rat isolated islets and in rat INS-1 823/13 
ǃ±cell line. The expression of P2Y14 protein in rat isolated islets and in rat 
INS-1 823/13 ǃ-cell line was shown by western blotting. Activation of P2Y14 
receptors by the selective agonists, UDP-glucose and MRS2690 induced an 
inhibition of the glucose-stimulated insulin release from rat isolated islets 
and from rat INS-1 823/13 ǃ±cell line. The mechanism by which P2Y14 
receptors induced the attenuation of the insulLQUHOHDVHGIURPǃ-cells is still 
to be elucidated. However, it is believed that cAMP inhibition by P2Y14 
receptor agonists (section 4.4.5) is at least part of the signalling pathways 
underlying P2Y14 receptor-induced inhibition of the insulin release, although 
other signalling may be involved. When P2Y14 receptors were antagonised 
by 3371056IDLOHGWRGHFUHDVHWKHLQVXOLQVHFUHWHGIURPǃ-cells. In 
addition, PPTN was able to elevate basal insulin secreted from INS-1 
823/13 ǃ-cells, suggesting that P2Y14 receptor may play a role as an 
autocrine regulator of insulin secretion and may serve as a target for 
treatment of diabetes mellitus. Modulation of the effect of P2Y14 receptors 
on insulin released from islets of Langerhans may be of importance in 
patients with impaired glucose tolerance or with insulin resistance.  
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General discussion 
 
This study investigated the functional expression of P2X1, P2Y1, P2Y2 
and/or P2Y4, P2Y14 and A2A adenosine receptors in porcine isolated 
pancreatic arteries (Chapter 2,3,4), as well as characterisation of P2Y14 
receptors in rat INS-  ǃ-cells and in rat isolated islets of 
Langerhans, including examining the effects of UDP-glucose and MRS2690 
on insulin secretion (Chapter 5). The study focused primarily on the 
functional expression of P2Y14 receptors and the signalling pathways 
underlying the vasoconstriction-evoked by P2Y14 receptor agonists in 
porcine pancreatic arteries. There is currently a lack of information about 
the role of P2Y14 receptors in the cardiovascular system, although both 
P2Y14 mRNA and protein are present in the heart and blood vessels (Musa 
et al., 2009; Umapathy et al., 2010; Abbas et al., 2011). 
 
6.1. Characterisation of P1 and P2 receptors in 
porcine pancreatic arteries 
 
The expression of P2X1, P2X2, P2Y1 and P2Y2 receptors has been detected 
by immunohistochemistry earlier in rat pancreatic vasculature (Coutinho-
Silva et al., 2001; Coutinho-Silva et al., 2003). Although a few reports 
investigated the functional expression of P1 and P2 receptors in rat 
pancreatic arteries, there is no report investigating P1 and P2 receptors in 
porcine pancreatic arteries. In the current study, P1 and P2 receptors and 
their signalling are described in arteries of the pig pancreas. The 
expression of P1 and P2 receptors on the VSMCs or ECs of the porcine 
pancreatic arteries, which has been observed in the current study, is shown 
in figure 6.1. 
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Figure 6.1. A schematic representation of P2X1, P2Y1, P2Y2, P2Y4, P2Y14 
and A2A adenosine receptors expressed on the endothelial cells (ECs) or 
vascular smooth muscle cells (VSMCs) of the porcine pancreatic arteries, 
together with their selective agonists and antagonists. ATP and ADP are 
broken down by ecto-nucleoside-5¶-triphosphate diphosphohydrolases 
(eNTPDases) to AMP, which is broken down to adenosine (Ado) by the 
activity of GPI-anchored alkaline phosphatases (APs). Arrows represent 
positive influences, while dotted arrows represent the negative influence. 
 
Porcine pancreatic arteries express some P1 and P2 relaxatory receptors, 
since ADP and ATP induced vasorelaxation in these arteries (Chapter 2). 
The relaxation to ADP was shown to be mainly mediated by A2A receptors, 
as that relaxation was inhibited in the presence of SCH58261, a selective 
adenosine A2A receptor antagonist, and XAC, an adenosine receptor 
antagonist. The expression of A2A receptors was shown to be on the VSMCs 
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of the pancreatic arteries, since the removal of the endothelium had less 
effect on the ADP-induced relaxation than that of SCH58261 or XAC. 
Similarly, the expression of A2A receptors was shown to be on the VSMCs of 
rat smooth muscle cells and porcine coronary arteries (Schulte & Fredholm, 
2003; Rayment et al., 2007b). ATP also induced a relaxation in porcine 
pancreatic arteries following its contraction, and this relaxation was also 
evoked by adenosine receptors expressed on the VSMCs of the pancreatic 
arteries, without an involvement of the endothelium, since the relaxation 
was significantly inhibited in the presence of XAC, but not in endothelium-
denuded arteries. The adenosine receptor subtypes involved in the 
relaxation to ATP were not identified in the current study, due to the time 
limit. Nevertheless, the findings obtained with ADP identify relaxatory 
adenosine A2A receptors on the VSMCs of the pancreatic arteries, and these 
may be the subtype responsible for the relaxation to ATP, since the 
relaxations to ADP and ATP were significantly inhibited in the presence of 
XAC (10 µM), but this relaxation was not abolished in endothelium-
denuded arteries. The relaxation to ADP was also inhibited in the presence 
of a selective adenosine A2A receptor antagonist, SCH58261 (1 µM) to the 
same extent observed in the presence of XAC. However, further studies are 
still needed to identify the adenosine receptor subtype involved in ATP-
induced relaxation in porcine pancreatic arteries, which could be addressed 
using SCH58261. 
 
6.2. Characterisation of P2Y14 receptor in 
porcine pancreatic arteries 
 
The contractions to P2Y14 receptor agonists were investigated following 
raising the vascular tone with U46619. The main reason for pre-
constricting with U46619 was to allow investigation of a possible 
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vasodilator component to the response. Additionally, the presence of a 
vasoconstrictor such as U46619 represents the physiological state since the 
vascular tone, which is defined as the degree of vessel constriction relative 
to their maximally dilated state under basal tone conditions in vivo, is 
controlled by a number of mechanisms (Kur & Newman, 2013). These 
mechanisms include extrinsic or intrinsic innervation by the autonomic 
nervous system, and the local release of vasoactive agents from vascular 
cells (Hamel, 2006). In the current study, the contractions to P2Y14 
receptor agonists were also observed on basal tone, although the 
amplitude of that contraction was less than that in the presence of U46619, 
but that contraction was significantly attenuated in the presence of PPTN 
(section 3.4.3). Moreover, in the arteries which were pre-constricted with 
endothelin-1 (instead of U46619) (section 4.4.2), the contraction to UDP-
glucose was apparent with a similar amplitude seen in the presence of 
U46619. Taken together, the previous observations indicate that the 
contractions to P2Y14 receptor agonists are not restricted to contractions 
evoked by U46619, which is consistent with the functionally expressed 
P2Y14 receptor in the arteries of the pig pancreas. 
In Chapter 3, the functional expression of P2Y14 receptor has been shown 
by using the selective agonists (UDP-glucose and MRS2690) at this 
receptor. The rank order of potencies of MRS2690 (10-fold) > UDP-glucose 
in eliciting vasoconstrictions in the pancreatic arteries was consistent with 
that reported previously in the literature, which showed that MRS2690 was 
7-10-fold more potent than UDP-glucose (Jacobson et al., 2009; Gao et al., 
2010), suggesting the involvement of P2Y14 receptor in pancreatic arteries. 
Moreover, the inhibition of the contractions to UDP-glucose and MRS2690 
which occurred in the presence of PPTN, a selective antagonist at P2Y14 
receptors (Robichaud et al., 2011; Barrett et al., 2013) indicated that the 
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contractions to UDP-glucose and MRS2690 occurred via actions at P2Y14 
receptors expressed in porcine pancreatic arteries. It is still required to 
investigate the concentration-response curves of UDP-glucose or MRS2690 
in the presence of multiple concentrations of PPTN to allow us to create 
Schild plots, and determine slope, which would indicate whether PPTN is a 
competitive antagonist at P2Y14 receptor in porcine pancreatic arteries. In 
addition, the IC50 value for PPTN needs to be determined, which would 
indicate the potency of that antagonist in the inhibition of the contractions 
to P2Y14 receptor agonists. These experiments were not performed here 
due to the limited availability of PPTN. 
A number of selective antagonists at P2Y14 receptor have been developed 
as naphthoic acid derivatives by Gauthier et al. (2011). However, some of 
these antagonists were either non-competitive or bound with high affinity 
to serum albumin. PPTN was identified as a naphthoic acid derivative which 
bound with high affinity to P2Y14 receptor but exhibited less human serum 
albumin binding (Robichaud et al., 2011). Moreover, a prodrug derivative 
of PPTN (an ester of carboxylic acid) was also prepared which enhanced its 
bioavailability (Robichaud et al., 2011). In the current study, PPTN showed 
some selectivity at the P2Y14 receptor over P2Y2, P2Y4 and P2Y6 receptors 
in porcine pancreatic arteries (Chapter 3). In addition, Barrett et al. (2013) 
showed that PPTN at concentrations as high as 1 µM exhibited no effect on 
the ability of agonists to activate their respective P2Y receptors in cell lines. 
It can be anticipated from the previous observations that PPTN may exhibit 
selectivity at P2Y14 receptor over other P2Y receptors. Although, it is still 
recommended to investigate the specificity of PPTN in in vivo studies, 
which may be of important for any clinical use in future. Subsequently, I 
believe that PPTN is a promising compound which may be used to develop 
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a drug with specificity at P2Y14 receptors and with high bioavailability. This 
compound may be used for managing cardiovascular disease. 
 
6.3. Characterisation of P2Y14 receptor in rat ǃ-
cells; therapeutic approach of PPTN 
 
The expression of purine and pyrimidine receptors in rat and mouse 
pancreas has been shown previously using immunohistochemical studies 
(Coutinho-Silva et al., 2001; Coutinho-Silva et al., 2003). However, the 
involvement of P2Y14 receptor in endocrine or exocrine tissues has not been 
addressed previously. The P2Y14 receptor could play an important role in 
these tissues, as its endogenous ligand (UDP-glucose) was shown to be 
released constitutively from different types of cells (but not endocrine or 
exocrine cells). Therefore, in Chapter 5, the effects of P2Y14 receptor 
activation on insulin secretion were investigated. MRS2690 and UDP-
glucose were able to inhibit glucose-induced insulin secretion, back to the 
basal level, in INS-ǃ-cells. In addition, UDP-glucose attenuated 
the level of insulin secreted from rat isolated islets. The ability of MRS2690 
to inhibit the insulin secretion from INS-ǃ-cell line was abolished 
in the presence of PPTN. The findings in the current study are consistent 
with the ability of P2Y14 receptor agonists to decrease the level of insulin 
secreted from these cells. However, it is still necessary to examine the 
ability of UDP-glucose and MRS2690 to inhibit the secretion of insulin  from 
rat isolated islets in the presence of PPTN, to confirm that inhibition is 
mediated by an action at P2Y14 receptors. Moreover, PPTN itself was able to 
increase the level of insulin secreted from the rat INS-ǃ-cell line 
in the presence of basal glucose concentration, which may suggest a 
constitutive release of UDP-glucose from this cell. To confirm the 
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constitutive release of UDP-glucose occurred in rat INS-  ǃ-cell 
line, the basal level of UDP-glucose can be measured in this cell based on 
the protocol used by Lazarowski et al. (2003b), as described in Chapter 5. 
Although the exact mechanisms remain to be established, an increase in 
pancreatic endocrine cell activity during hormone secretion corresponds 
with an increase in blood flow, to meet metabolic demand (Schaeffer et al., 
2011). Thus, alterations in blood flow can influence pancreatic function, as 
a reduction in pancreatic blood flow has been observed in acute and 
chronic pancreatitis and some other pancreatic diseases such as diabetes 
mellitus and impaired glucose tolerance (Satoh et al., 2000; Ballian & 
Brunicardi, 2007; Nguyen et al., 2010), implicating pancreatic tissue 
perfusion as an important factor in pathogenesis of pancreatic diseases and 
symptoms. There is increasing evidence for the role of purinergic signalling 
in the pathophysiology of the pancreas, as well as the involvement of 
purine and pyrimidine receptors in hormone secretion (see reviews by 
Burnstock & Knight 2004; Burnstock & Novak, 2012). Drugs designed to 
target specific component of the purinergic system may be of relevance to 
the management of pancreatic disorders including pancreatitis, cystic 
fibrosis, pancreatic cancer and diabetes.  
In the current study, it has been shown that activation of P2Y14 receptor by 
UDP-glucose in porcine pancreatic arteries induced a vasoconstriction, and 
hence that would result in decrease in blood flow to the pancreatic cells. 
The effect of UDP-glucose was abolished in the presence of PPTN. 
Moreover, UDP-glucose has been shown to be released constitutively from 
different type of cells, with levels ranging within 1-20 nM (Arase et al., 
2009). The level of the extracellular UDP-glucose may reach effective levels 
ranging within 10 nM- 1 mM during damage and/or injury to cells or when 
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the cells are subjected to mechanical forces (e.g., shear, cell swelling, 
hydrostatic pressure) (Lazarowski et al., 2003b; Arase et al., 2009). 
Furthermore, the level of intracellular UDP-glucose may be regulated by 
the glucose level, as the level of UDP-glucose would be elevated following 
an increase in the level of glucose, since glucose is converted to glucose-1-
phosphate before being converted to glycogen by the activity of glycogen 
synthase (Seoane et al., 1996). Glucose-1-phosphate is the precursor for 
UDP-glucose synthesis (Chapter 1), which suggests a relationship between 
the glucose level and the production of UDP-glucose. Therefore, it can be 
proposed that when the level of UDP-glucose is elevated (during some 
disorders, such as diabetes), that would induce a decrease in blood flow to 
the pancreas, which may result in a decrease of the hormone secreted 
from the islets, including the secretion of the insulin. In Chapter 5, UDP-
glucose had also a direct inhibitory effect on insulin secretion IURPǃ-cells, 
an effect which was abolished in the presence of PPTN. Consequently, that 
would raise the therapeutic value of PPTN, since the usage of PPTN would 
abolish the tonic inhibitory activity induced by endogenous UDP-glucose, 
which may result in an attenuation of the complications accompanied with 
some diseases including diabetes. It is recommended to measure the level 
of UDP-glucose in tissue cultured with increasing glucose concentrations, to 
indentify the relationship between the level of UDP-glucose and different 
concentrations of glucose.  
 It is still required to examine the effect of UDP-glucose on the blood flow 
in small porcine pancreatic arteries, using the wire myograph system, since 
it is well known that smaller arteries are more involved in the control of 
blood flow than larger arteries (Rutishauser, 1994). Thus, if we can control 
the blood flow in smaller pancreatic arteries, in the presence of PPTN, this 
would have a greater impact on patients with exocrine/endocrine 
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pancreatic dysfunctions than that in larger arteries. Alternatively, the blood 
flow to the exocrine/endocrine pancreatic cells can be determined (in vivo) 
in the pancreas (such as rodent) by using nonradioactive microspheres, 
injected into the left ventricle, according to the protocol of Lifson et al. 
(1980). This approach involves locating and counting microscopically the 
spheres in fixed and stained portions of the pancreas, following the animal 
sacrifice (Lifson et al., 1980). By applying this approach the flow rate per 
bead can be determined in the presence of various compounds (including 
UDP-glucose in the presence and absence of PPTN) or in animal models of 
diabetes. 
 
6.4. Functional expression of P2Y14 receptor in 
other vessels; validation of the specificity 
of the P2Y14 receptor antibody used in the 
study 
 
Pharmacological studies demonstrated the functional expression of the 
P2Y14 receptor in porcine coronary arteries, which was shown to be 
expressed on the VSMCs and the ECs (Abbas et al., 2011). Activation of 
P2Y14 receptor by its selective agonists, UDP-glucose and MRS2690, 
induced concentration-dependent contractions in coronary arteries (Abbas 
et al., 2011). The previous observations were in agreement with the 
findings in the current studies. Similarly, Umapathy et al. (2010) showed 
that activation of P2Y14 receptors with UDP-glucose induced inhibition in 
the forskolin-induced cAMP production, with an involvement of ERK1/2, in 
human lung microvascular endothelial cells. These findings were also in 
accordance with my findings in the current study. Moreover, the expression 
of P2Y14 mRNA and protein was shown using RT-PCR, western blot, and 
immunofluorescence studies in these cells (Umapathy et al., 2010) as well 
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as in pulmonary artery vasa vasorum endothelial cells (Lyubchenko et al., 
2011). On the other hand, contractile P2Y14 receptor was not present in 
endothelium-denuded rat intrapulmonary arteries, as UDP-glucose had no 
effect on these arteries (Mitchell et al., 2012). In addition, the absence of 
P2Y14 mRNA, demonstrated by using RT-PCR studies, has been 
documented in human coronary artery endothelial cells and in mouse 
thoracic aorta (Kauffenstein et al., 2010; Ding et al., 2011). Taken 
together, the expression of contractile P2Y14 receptor is not limited to the 
porcine pancreatic arteries, although some arteries lack the contractile 
P2Y14 receptor. Therefore, it is recommended to investigate the functional 
expression of the contractile P2Y14 receptor in various arteries, and if the 
role of this receptor is shown to be widespread, then it can be a novel 
target for the treatment of cardiovascular diseases. 
In Chapter three and five, the expression of P2Y14 receptor protein was 
shown by using western blotting, which indicated the presence of this 
receptor in porcine pancreatic arteries, rat INS-1 823/13 ǃ-cell line and in 
isolated rat islet of Langerhans. Although the immunoreactive bands were 
completely eliminated in the absence of the P2Y14 primary antibody (Figure 
3.11) or following pre-incubation with the neutralizing antigen (section 
3.4.9), attempts to validate the specificity of this antibody, by performing 
the same assay on undifferentiated HL-60 cells and on mouse thoracic 
aorta as negative controls, since they were shown to not express P2Y14 
mRNA (Fricks et al., 2009; Kauffenstein et al., 2010) were unsuccessful. In 
the current study, P2Y14 receptor immunoreactive bands were observed in 
these tissues (Chapter 3). This observation suggested that there may be 
another cellular antigen identified by this antibody. In fact, there are a 
growing number of GPCRs which have been described as having poorly 
validated detection reagents. Some of these receptors are dopamine 
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receptors, D DQG ǃ-adrenoceptors as well as P2Y6 receptors (Yu et al., 
2013). Therefore, P2Y14 receptor might be added to these collections of 
GPCRs, which may have deficient antibodies. Nevertheless, it is still 
required to look for rigorous controls to allow us to validate the specificity 
of P2Y14 antibodies. Alternatively, the generation of GPCR-specific 
nanobodies (functional antibodies devoid of heavy chains) may become a 
useful approach to obtain specific GPCR antibodies (Harmsen et al., 2007). 
 
6.5. Future directions in identifying the role of 
P2Y14 receptor  
 
Inflammation has been implicated as a key initial trigger for type 2 
diabetes, and as P2Y14 receptor participates in inflammation reactions (Xu 
et al., 2012)7KXVWKHHIIHFWRI3371RQWKHLQVXOLQVHFUHWLRQIURPLVOHWǃ-
cells needs to be examined appropriate in in vivo animal models of type 2 
diabetes, and then if PPTN were able to abolish the inhibitory effect of 
endogenous UDP-glucose on insulin secretion, that may suggest the use of 
PPTN as a lead compound for the design of drugs which can be used as a 
potential treatment for patients with type 2 diabetes. That may confirm the 
possible therapeutic benefit of this antagonist in prevention of the decrease 
of the insulin secretion, induced by elevated level of endogenous UDP-
glucose, since it was discussed earlier that the level of UDP-glucose may be 
elevated during diabetes, as the level of blood sugar is increased.  
In the current study, the physiological role of P2Y14 receptor has not been 
investigated. Therefore, it is necessary to identify the role of this receptor 
in cardiovascular physiology to find out whether P2Y14 receptor plays a 
major role in blood pressure regulation. Since the P2Y14 receptor knockout 
mice is available (Bassil et al., 2009), as well as P2Y14 specific siRNA (Gao 
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et al., 2010), these effects could be addressed. However, P2Y14 receptor 
knockout mice showed only an improvement in insulin sensitivity by 
inhibiting macrophage recruitment and tissue inflammation (Xu et al., 
2012), as well as exhibiting a marked resistance to tissue injury induced by 
infra red in utero (Kook et al., 2013). In addition, UDP-glucose did not 
induce contractions in the stomach of P2Y14 receptor knockout mice (Bassil 
et al., 2009). Thus, it would seem from these reports that P2Y14 receptor 
does not have a major role in blood pressure regulation. Further studies of 
this kind are still of relevance to investigate the effect of P2Y14 receptors 
and its role in blood pressure regulation, since compensatory mechanisms 
may occur after receptor knockout. 
 
In summary, this project characterised the P2Y14 receptor in the pancreas, 
and identified a novel vasocontractile role of P2Y14 receptor in porcine 
pancreatic arteries, antagonised by PPTN. This study confirmed that P2Y14 
receptor is coupled to Gi protein, which was consistent with previous 
reports. P2Y14 receptor evoked an inhibitory effect on the insulin secreted 
from the pancreas (Chapter 5), this effect was abolished by PPTN. This 
would give a hint that PPTN may be used as a lead for compounds that 
may be used in the management of some pancreatic disorders. It is hoped 
that the information presented in this thesis will aid future investigations in 
the cardiovascular field to obtain a more complete understanding of the 
roles of purine and pyrimidine receptors in cardiovascular diseases. 
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